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Mycobacterium tuberculosis, the etiological agent of tuberculosis, remains the leading 
cause of mortality from a single infectious organism. The persistence of this human 
pathogen is associated with its distinctive lipid rich cell wall structure that is highly 
impermeable to hydrophilic drugs. This highly complex and unique structure is crucial 
for the growth, viability and virulence of M. tuberculosis, thus representing an attractive 
target for vaccine and drug development. In this study, we have demonstrated that 
enzymes involved in Corynebacterium glutamicum cell wall assembly and precursor 
formation build complicated multi-protein complexes. Specifically, we have identified 24 
putative interactions in vivo between 12 proteins responsible for AG biosynthesis. 
Additionally, we have demonstrated that AftB arabinosyltransferase have a dual 
functionality and plays a role in both AG and LAM biosynthesis in M. smegmatis. We 
have also demonstrated that Emb arabinosyltransferase, the target of ethambutol, 
possesses !(1"5) activity in C. glutamicum. Finally, we examined the overexpression 
and biophysical characterisation of membrane AftA solubilised in a stryrene maleic acid 
polymer, demonstrating that detergent free extraction of membrane proteins from 
corynebacteria is possible. These findings provide a useful recourse for understanding the 
biosynthesis and function of the vital cell wall (lipo)polysaccharides of 
Corynebacterineae, as well as providing new therapeutic targets for drug design against 
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X-gal    5-bromo-4-chloro-3-indolyl-!-D- galactopyranoside 
°C    degrees centigrade  
v/v    volume/volume  
w/v    weight per volume  
mg    microgram  
ml    microlitre  
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  General Introduction 





1    General Introduction 
1.1 Mycobacteria and related species 
Mycobacterium tuberculosis, a causative agent of human tuberculosis (TB), remains one 
of the most successful bacterial pathogens. M. tuberculosis belongs to the genus 
Mycobacterium, the single genus within the family of Mycobacteriaceae, within the sub-
order of Corynebacterineae, and the order of Actinomycetales. The Actinomycetales 
contains a diverse range of bacterial genera including Corynebacterium, Norcardia, 
Rhodococcus and Streptomyces (Brennan and Nikaido, 1995). The generic name 
Mycobacterium was established in 1896 by Lehmann and Neumann (Lehmann and 
Neumann, 1896) that proposed the genus Mycobacterium to include pathogenic M. 
tuberculosis and Mycobacterium leprae and placed it in the current mycobacterial 
taxonomy.  
The genus Mycobacterium is a collection of non-motile, acid-fast, rod-shaped, Gram-
positive bacteria with high guanine and cytosine content (58-69%; Clark-Curtiss, 1990) 
in their DNA. Classification to Mycobacterium is highly associated with the complex cell 
envelope and its components, specifically, the presence of characteristic !-hydroxy-"-
alkyl branched long-chain fatty acids, termed mycolic acids. These acids contain 60-90 
carbons and are cleaved to C22 to C26 fatty acid methyl esters by pyrolysis (Levy-
Frebault and Portaels, 1992). This distinctive lipid-rich cell wall structure, thicker than in 
many other bacteria, acts as a permeability barrier and therefore contributes to the 






At present, over a 120 recognised species meet the criteria for inclusion into the genus 
Mycobacterium (Brown-Elliott et al., 2002). Species within this genus are traditionally 
divided into slow-growing and fast-growing mycobacteria (Figure 1). This is based on 
time for visible colonies to appear under optimal conditions of nutrients and temperature 
from diluted suspensions. The fast-growing species appear within seven days, while the 
slow-growing species require seven days or more to yield visible colonies under 
equivalent conditions. Characteristically, fast-growing species are mostly harmless 
saprophytes, whereas the slow-growing species include pathogens of both human and 
veterinary significance, such as M. tuberculosis, Mycobacterium leprae, the causative 


















The causative agents of mammalian TB are grouped into the Mycobacterium tuberculosis 
complex (MTBC) and include M. tuberculosis, M. bovis, Mycobacterium africanum, 
Mycobacterium canetti, Mycobacterium microti, Mycobacterium pinnipedii and 
Mycobacterium caprae.  These closely related Mycobacterium species share more than 
99.9 % genome sequence similarity (Brosch et al., 2002). A notable exception is M. 
canetti that possess a smooth colony morphology and contains recombinant segments of 
DNA in their chromosomes (van Soolingen et al., 1997). In addition, another complex 
termed the Mycobacterium avium complex (MAC) containing Mycobacterium kansasii, 
Mycobacterium fortuitum and Mycobacterium avium affect immunocompromised 
individuals, such as patients with human immunodeficiency virus (HIV) (Jarlier and 
Nikaido, 1994) 
1.2 History of tuberculosis 
TB is an ancient disease with a long and intricate history. It is believed that the genus 
Mycobacterium could have originated around 150 million years ago (Hayman, 1984, 
Daniel, 2006). Using extensive genetic analysis, Gutierrez et al. (2005) have 
demonstrated that human tubercle isolates from East Africa predate the modern MTBC 
members and, therefore, may correspond to progenitor species from which the MTBC 
strains have emerged. This ancestral species have been estimated to be nearly 3 million 
years old (Gutierrez et al., 2005). Although members of MTBC have a distinct host 
preference and different phenotypic characteristics, they show high genetic homogeneity 
at the nucleotide level, as well as a clonal population structure (Smith et al., 2009). Thus, 





35,000 years ago, resulting in a single common ancestor that later diversified into modern 
MTBC strains (Gutierrez et al., 2005, Smith et al., 2009). 
Archaeological evidence documents cases of TB in various civilisations across the world. 
TB was present in Eastern Mediterranean around 9,250-8,160 years ago as suggested by 
ancient DNA analysis and lipid profiles of skeletal remains (Hershkovitz et al., 2008). 
Genetic and molecular evidence of several ancient mummies confirms the presence and 
prevalence of TB in ancient Egypt around 5,000 years ago (Nerlich et al., 1997, Crubezy 
et al., 1998, Zink et al., 2003). In addition, skeletal abnormalities typical to TB were 
documented in written texts of ancient China dating back as far as 2,300 years ago 
(Daniel, 2006). Finally, genetic studies of mummified bodies from Central America 
revealed the presence of M. tuberculosis infections before European colonisation (Salo et 
al., 1994, Sotomayor et al., 2004).  
In 460 BC, ancient Greek physician Hippocrates described TB, known as Phthisis, as a 
wide spread disease accompanied by coughs, fever and consumption (Pease, 1940). 
Although the common believe was that TB was a hereditary disease, Aristotle (384-322 
BC) defined scrofula (swelling of the lymph nodes) as an indication for TB and claimed 
the disease to be infectious (Garisson, 1913). Thereafter, Claudius Galenus (131-201 
AD), a prominent physician in the Roman empire, described the classic symptoms of 
phthisis, including chronic coughs, blood-tinged sputum, fever, loss of appetite and 
weakness (Herzog, 1998). 
TB persisted thoughtout centuries until the early 17th century, when the TB epidemic 





termed as the Great White Plague to describe the enormity of challenges caused by TB. 
In 1679, Franciscus Sylvius de la Boe, a Dutch physician and scientist, published Opera 
Medica, where he first used the term “tubercle” to characterise nodules found in the lungs 
of patients with TB. He also indicated that “tubercles” could be observed in other organs 
that developed into cavities and ulcers (Keers, 1978). It was not until the 1720, when an 
English physician Benjamin Marten asserted TB to be highly contagious. In his 
manuscript he stated that consumption might be caused by miniature living creatures - 
“animalcules” - that lived in the lungs and caused lesions associated with TB (Doetsch, 
1978).  
In 1882, German bacteriologist Robert Koch gave a lecture entitled Die Aetiologie der 
Tuberculose, where he presented his discovery of M. tuberculosis bacilli as the 
etiological agent of TB (Koch, 1882). Koch demonstrated that bacilli extracted from the 
diseased animals or patients and subsequently injected into the guinea pigs resulted in the 
same disease. Employing his new staining technique, he showed that cultures from 
previously infected hosts and guinea pigs both contained mycobacteria. For his input into 
M. tuberculosis research, he was awarded a Nobel Prize. 
French bacteriologists, Albert Calmette and Camille Guerin started their work on TB 
vaccine development in the early 1910’s. Applying Edward Jenner’s discovery of 
smallpox vaccine as a paradigm, they attenuated a strain of M. bovis to a stage where the 
strain was incapable of causing TB in the animals (Calmette and Guerin, 1924, Calmette, 
1928). M. bovis BCG vaccine remains the only licensed vaccine against TB, regardless of 
its highly variable efficacy in many clinical trials (Doherty and Andersen, 2005). The 





of life-threatening diseases including TB. Further discovery of drugs against TB followed 
and included p-aminosalicyclic acid (PAS), isoniazid (INH), rifampicin (RIF), and 
ethambutol (EMB) (Zhang, 2005). Finally, Cole et al. (1998) deciphered a complete 
genome sequence of M. tuberculosis H37Rv in 1998 marking a significant milestone in 
combating TB.  
1.3 Global epidemiology of tuberculosis 
TB remains a major causes of mortality and morbidity from a single infectious organism. 
In 2012, an estimated 8.6 million people across the world developed TB and 1.3 million 
died from the disease (WHO, 2012). Globally, the highest numbers of TB cases are 
reported in low and middle income regions: South-East Asia (29 %), Africa (27 %) and 
Western Pacific (19 %) (Figure 2). Importantly, India and China alone account for 38 % 
of all new TB cases (WHO, 2012). Moreover, TB remains a global health problem with 
individuals living with HIV infection. It is estimated that at least 30 % of HIV patients 
worldwide have latent TB and, as a result, are 30 times more likely to develop active TB 
in their lifetime (WHO, 2012). In 2012, approximately 1.1 million people with HIV 
infection contracted TB and 0.3 million died from co-infection (WHO, 2012). The 75% 
of HIV/TB co-infection cases were registered in the regions of Africa (Figure 3). 
Although the rate of new TB cases is slowly declining, the number of TB associated 
deaths remains extremely high considering that TB is a treatable and preventable disease.  
A number of factors have contributed to the current TB incidence worldwide. The 
HIV/AIDS pandemic, high population density, the variable efficacy of the BCG vaccine, 





countries, which have led to the subsequent resurgence of the epidemic. These factors 
have also contributed to the emergence of drug resistant TB, which, according to World 










Figure 3 Estimated HIV prevalence in new TB cases worldwide in 2012 (WHO, 
2012). 
 
In 2012 alone, an estimated 450,000 cases of multi-drug resistant (MDR)-TB emerged 
worldwide and was documented in nearly all countries surveyed (WHO, 2012). Over half 
of these cases were registered in regions of Asia: China, India, and Russia. MDR-TB is 
defined as TB caused by M. tuberculosis strains that acquired resistance to at least INH 
and RIF, both of which are standard first-line drugs (Yew and Leung, 2006). Notably, 92 
countries to date have confirmed at least one case of extensively drug resistant (XDR)-TB 
(WHO, 2012). XDR-TB is a result of MDR-TB strains acquiring resistance to second-
line drugs, including amikacin (AMK), kanamycin (KAN), capreomycin (CAP), and 
fluoroquinolone (FQN) (WHO, 2012). Finally, a newly documented form of TB, totally 
drug resistant (TDR)-TB, has been recorded in Italy (Migliori et al., 2007), Iran (Velayati 
et al., 2009), India (Udwadia et al., 2012, Udwadia and Vendoti, 2013), and South Africa 





all available first- and second-line drugs. Emergence of these drug resistance clinical 
isolates has prompted the need for new drugs and new drug targets. 
1.4 Clinical manifestations  
M. tuberculosis infection most frequently affects the lungs and is termed pulmonary TB. 
The symptoms of pulmonary disease include fever, severe chronic cough, chest pain, 
night sweats, weight loss, and general weakness. However, infection may also develop in 
other parts of the body affecting bones, joints, lymph nodes, pleural cavity, nervous 
system, liver, or spleen causing extra-pulmonary TB (Sharma and Mohan, 2013). The 
diagnosis of this type of TB can be more difficult, since patients are lacking a severe 
cough that is so commonly associated with TB infections. Another type of TB, miliary-
TB, is spread throughout the body as a direct result of M. tuberculosis bacilli travelling 
from lungs and infecting multiple organs, such as the liver, kidneys or spleen (Sharma et 
al., 2005). The hallmark of miliary-TB is a unique pattern observed on radiographs of 
numerous tiny spots disseminated throughout organs. Approximately 20 % extra-
pulmonary TB cases are identified as miliary-TB (Ray et al., 2013). Patients that have 
this type of TB experience a diverse range of symptoms varying from fever and enlarged 
lymph nodes to multiple organ failure. Untreated miliary-TB proves almost always lethal 
to sufferers. 
1.5 Diagnosing tuberculosis 
Accurate and quick diagnosis is crucial in combating TB. Various methods have been 
developed to date and are employed in conjunction to detect TB (Pai, 2013). The 





A small dose of fluid termed tuberculin (purified protein derivative) is injected 
intradermally and read 48 to 72 hours later. An individual with previous TB exposure 
would develop an immune reaction to bacterial proteins and, as a result, form an 
induration. However, the skin test does not discriminate between active TB and latent TB 
infection. In addition, the skin test is broadly accepted to lack specificity, especially in 
individuals residing in areas of high TB prevalence or individuals that have received the 
BCG vaccine. Generally, a chest radiograph is also used in conjunction with the skin test 
to assess individuals with suspected active TB. A radiograph would detect any chest 
abnormalities, such as lesions, caused by TB. However, since it has relatively poor 
sensitivity, similar atypical features may originate from different diseases, and follow up 
tests are usually performed before the final diagnosis is confirmed. The WHO has 
strongly promoted the sputum smear test that utilises Ziehl-Neelsen staining technique as 
the preferred method for diagnosing M. tuberculosis infection in developing countries. 
Even though it is an easy, quick and cost-effective method to detect acid-fast bacilli, it 
does not necessarily confirm the diagnosis of TB. Therefore, cell culturing is performed 
subsequently to confirm the diagnosis. Over many years, M. tuberculosis culturing from 
primary samples has become the gold standard for confirmation of active TB. The 
limitation is, however, the long growth time of M. tuberculosis leading to a delayed 
diagnosis.  
Relatively recently developed methods, nucleic acid amplification test and blood assay, 
have also been employed in detecting active TB (Dorman, 2010). Nucleic acid 
amplification test, such as polymerase chain reaction, can amplify even the tiniest 





also capable in detecting most common drug resistant M. tuberculosis strains, including 
those resistant to RIF and INH. A high sensitivity interferon gamma release assay using a 
single blood specimen may contribute additional evidence to TB diagnosis. Although the 
test is estimated to be more accurate than the skin test in diagnosing active TB, it is also 
expensive and, thus, inaccessible to general public from low and middle income 
countries. 
1.6 Pathogenesis of tuberculosis 
M. tuberculosis is an airborne disease transmitted from an active TB sufferer through 
aerosol droplets generated by coughing and sneezing. Once bacilli are inhaled into the 
respiratory tract, the majority become trapped in the upper airways together with the 
larger particles. However, smaller droplets containing M. tuberculosis bacilli can reach 
the lung alveoli, where they are ingested by alveolar macrophages and dendritic cells 
(Russell, 2007). Three different outcomes have been identified at this stage of TB 
development: host immune system clears the infection; infection quickly progresses into 
an active TB (10 %); or infection is contained within the host with no symptoms present 
(90 %) (Kaufmann, 2001). Years of evolution allowed mycobacteria to acquire effective 
mechanisms that deceive initial host microbicidal defences, thus preventing the 
elimination of M. tuberculosis. The immune system unable to eliminate pathogenic bacilli 
protects the organism by isolating them. In case of containment, infected macrophages 
attract monocytes to the site of infection, where the lesion starts to develop (Russell, 
2007). Engulfed mycobacteria shed a variety of antigens, including lipids, glycolipids and 
lipoproteins that are packaged into vesicles and delivered to bystander cells. Dendritic 





the lipid antigens and present them to T-cells (Russell, 2001). At the lymph nodes, 
dendritic cells present these mycobacterial antigens to different types of T cells resulting 
in a release of inflammatory cytokines and development of additional lesions at the site of 
infection (Russell, 2001). This robust pro-inflammatory response leads to formation of 
the granuloma, an aggregation of infected macrophages surrounded by layers of 
lymphocytes and fibroblasts. Since access to oxygen and nutrients are limited inside the 
granuloma, the bacilli go into the state of dormancy (Russell, 2007). Such structures can 
persist for years in immunocompetent individuals, thus preventing the growth and 
dispersion of mycobacteria within the host. Rupture of the granuloma is frequently 
associated with the weakening of the immune system, notably HIV infection. M. 
tuberculosis and HIV co-infection hasten the progression of one another, accelerating the 
















Figure 4 Different outcomes of M. tuberculosis infection. There are three potential 
outcomes of M. tuberculosis infection in the human host. (i) Spontaneous healing, 
although it is estimated to be extremely rare. (ii) Disease progression to acute active TB, 
frequently observed in immunodeficient individuals. (iii) In majority of cases, 
containment of mycobacteria within the granuloma and, therefore, prevention of active 
TB. Briefly, M. tuberculosis bacilli are engulfed by alveolar macrophages and dendritic 
cells. The latter, present mycobacterial antigens to different T-cell populations including 
CD4+, CD8+, !", and CD1+. Subsequently, T-cells enhance the antibacterial activity of 
macrophages by releasing cytokines such as interferon-! that typically result in either 
arrest or clearance of the infection. In the case of containment, disease usually progresses 
later due to reactivation, when rupture of the granuloma leads to dissemination of M. 
tuberculosis bacilli throughout the host resulting in active TB. Reprinted by permission 






1.7 Tuberculosis drug treatments 
The present most effective TB drug regimen recommended by WHO is Directly 
Observed Treatment-Short Course (DOTS) introduced in 1991. This TB strategy, lasting 
at least six months, reaches approximately 95 % success rate and is divided into two 
phases: initial phase and continuation phase (WHO, 2012). Initial phase aims to kill 
actively growing and semi-dormant M. tuberculosis bacilli through administration of 
INH, RIF, pyrazinamide (PZA), and EMB for two months. Subsequent administration of 
INH and RIF for the following four months eliminates the remaining dormant bacilli in 
the continuation phase. If the isolate is resistant to one or more drugs, the treatment 
regimen is changed and extended. Emergence of MDR-TB prompted the need for a new 
drug strategy, specifically adjusted to treat drug resistant cases. Therefore, the DOTS-
Plus regimen was introduced by WHO and is currently adopted by many countries around 
the world as a national drug resistant TB control policy (WHO, 2004). This treatment 
strategy includes administration of second-line drugs that are generally more toxic and 
less effective than the first-line drugs. The treatment contains two or more antibiotics to 
which the M. tuberculosis strain is susceptible in addition to the primary drug given for at 
least six months. The duration of DOTS-Plus regimen is eighteen to twenty-four months. 
There is no regimen in place for XDR-TB cases, since different M. tuberculosis isolates 












1.8 Mycobacterial cell wall 
Despite belonging to the Gram-positive branch of classification, Mycobacterium species 
possess a cell envelope that distinguishes them from both Gram-positive and Gram-
negative organisms. Its cell wall has an unusually high content of lipids that act as a 
permeability barrier and hence contributes to resistance to common antibiotics and 
chemotherapeutic agents. The cell wall core of M. tuberculosis is composed of 
peptidoglycan (PG), covalently attached to arabinogalactan (AG), which is further 
esterified by mycolic acids – a model first proposed by Minnikin and later supported by 
McNeil and Brennan (Daffe et al., 1990, McNeil et al., 1990, McNeil et al., 1991, Besra 
et al., 1995, Dover et al., 2004, Kaur et al., 2009, Minnikin 1982, Minnikin et al., 2002). 
The outer membrane segment is comprised of solvent extractable lipids believed to either 
intercalate with the cell wall bound mycolates or form a more clearly defined interlayer 
(Liu et al., 1995, Hoffmann et al., 2008). Other important components of the 
mycobacterial cell wall include the phosphatidyl-myo-inositol mannosides (PIMs), and 
their more glycosylated products lipomannan (LM) and lipoarabinomannan (LAM) 
(Mishra et al., 2011a). These glycoconjugates display a broad range of 
immunomodulatory activities associated with TB pathogenesis (Mishra et al., 2011a). 
The cell wall structure is crucial for the growth, viability and virulence of M. tuberculosis 










Figure 5 Cell envelope of Mycobacterium tuberculosis. The cell wall core consists of 
peptidoglycan connected to arabinogalactan and covalently attached hydrophobic 
mycolic acids, which are intercalated with glycolipids and a diverse repertoire of complex 
lipids. Lipoarabinomannan is linked to the plasma membrane via the lipid portion of the 
phosphatidylinositol anchor and serves as a modulin with immunoregulatory effects 








PG is a complex macromolecular structure located directly above the plasma membrane 
and found in nearly all eubacteria (van Heijenoort, 2001a, van Heijenoort, 2001b, van 
Heijenoort, 2007). The mesh-like arrangement of PG provides strength to the bacterial 
cell wall, thus enabling it to counteract the osmotic pressure while retaining cell integrity 
and shape. Although mycobacterial PG has not been intensively studied, it is expected to 
be comparable to that of E. coli, as both of them fall into the A1! class of PG (Schleifer 
and Kandler, 1972). M. tuberculosis PG is comprised of glycan chains composed of 
alternating N-acetylglucosamine (GlcNAc) and N-glycolylmuramic acid (MurNGlyc) 
residues, linked together via a !-1,4 linkage. A side chain of L-alanine-D-glutamate-D-
isoglutaminsyl-meso-diaminopimelyl-D-alanine-D-alanine peptide substitutes the 
carboxylic acid group of each MurNGlyc residue (Petit et al., 1969). Notably, PG of E. 
coli contains N-acetylmuramic acid (MurNAc) residues rather than MurNGlyc, 
suggesting that the N-acetyl group has been oxidised to N-glycolyl to form MurNGly 
(Azuma et al., 1970). This distinguishing feature of M. tuberculosis PG may provide 
additional hydrogen bonding and, therefore, leading to a more robust mesh-like structure 
(Brennan and Nikaido, 1995). Moreover, the overall degree of cross-linking in 
mycobacteria is approximately 70-80 %, whereas in E. coli it is 30-50 % (Vollmer and 
Holtje, 2004). The majority of cross-links of the adjacent peptides are between the 
carboxyl group of a terminal D-alanine and the amino group of meso-diaminopimelic acid 
(DAP). The remaining cross-links are between the carboxyl group of one DAP unit and 
the amino group of another DAP. Finally, several MurNGly residues are used as an 





#-D-GlcNAc residue of the AG linker unit (Wietzerbin et al., 1974, Lederer et al., 1975, 
McNeil et al., 1990).  
PG biosynthesis begins with MurA (Rv1315) transferring an enoylpyruvate residue from 
phosphoenoylpyruvate to UDP-GlcNAc (Brown et al., 1995, Xu et al., 2014). 
Subsequently, MurB (Rv0482) reduces this enoylpyruvate moiety, yielding UDP-
MurNAc (Pucci et al., 1992, Kumar et al., 2011). The second monosaccharide donor, 
UDP-MurNGly, is generated utilising UDP-GlcNAc in a single reaction catalysed by 
NamH (Rv3818) (Raymond et al., 2005). The side chain peptide of MurNGlyc is 
synthesised by MurC (Rv2152c) (Liger et al., 1995, Mahapatra et al., 2000), MurD 
(Rv2155c) (Mengin-Lecreulx et al., 1989), MurE (Rv2158c) (Maruyama et al., 1988, 
Munshi et al., 2013), and MurF (Rv2157c) (Maruyama et al., 1988, Munshi et al., 2013) 
ligases adding L-alanine, D-glutamic acid, DAP, D-alanine, D-alanine, respectively. The 
translocase MurX (Rv2156c), previously designted MraY, then transfers the newly 
formed UDP-MurNAc with the side chain to undecaprenyl phosphate, yielding Lipid I 
(Bouhss et al., 1999, Bouhss et al., 2004). Subsequently, MurG transfers GlcNAc residue 
from UDP-GlcNAc to Lipid I, resulting in Lipid II (Ikeda et al., 1990). The yet unknown 






Figure 6 Biosynthesis of peptidoglycan in M. tuberculosis. The synthesis of UDP-
GlcNAc is initiated in the cytoplasm and mediated by MurA and MurB enzymes. MurC, 
MurD, MurE, and MurF catalyse further addition of L-alanine, D-glutamic acid, meso-
diaminopimelic acid, and D-alanine-D-alanine peptide to UDP-GlcNAc, respectively. 
This intermediate is transferred to undercaprenyl phosphate lipid carrier by MurX 
(previously designated as MraY) leading to formation of lipid I. Finally, MurG attaches 
the GlcNAc residue to generate lipid II and the entire molecule is translocated across the 
plasma membrane, where it is utilised in the biosynthesis of PG. Adapted by permission 
from Macmillan Publishers Ltd: Nature Reviews Microbiology, Pinho et al. (2013). 
 
1.8.2 Arabinogalactan 
1.8.2.1 Structural features of arabinogalactan 
AG is a key structural component of the mycolyl-arabinogalactan-peptidoglycan (mAGP) 
complex that constitutes approximately 35% of the mycobacterial cell wall mass. This 
heteropolysaccharide plays an important role in covalently anchoring the mycolic acid 
layer to the inner PG layer, and is unique in that all of its sugars are present in the 





polysaccharides, AG is comprised of several distinct structural motifs instead of repeating 
units (Daffe et al., 1990, McNeil et al., 1990, Besra et al., 1995). The whole mycolyl-AG 
structure is attached to PG via a specific linker unit and thus, it is believed to be the most 
vulnerable part of the complex. Characterisation of per-O-alkylated oligosaccharide 
alditols together with gas chromatography-mass spectrometry, fast atom bombardment-
mass spectrometry and nuclear magnetic resonance (NMR) analysis elucidated the 
structural details of AG. 
The galactan domain is composed of approximately 30 alternating !(1#5) and !(1#6) 
galactofuranosyl (Galf) residues connected in a linear fashion. At the reducing end of AG, 
the galactan chain is linked to the C-6 position of selected N-glycolylmuramic acid 
residues of PG via an "-L-Rhap-(1#3)-"-D-GlcNAc-1-phosphate linker unit (McNeil et 
al., 1990). Three similar D-arabinan chains comprising roughly 30 arabinofuranosyl 
(Araf) residues each are attached to the C-5 of specific !(1#6) linked-Galf residues 
(Besra et al., 1995). Since the AG structure is essential to M. tuberculosis, many gene 
deletion studies investigating AG have been performed in the Corynebacterium genus, 
where aspects of AG biosynthesis are non-essential. Knockout mutants in C. glutamicum 
together with mass spectrometry determined that the arabinan chains of AG are attached 
to the 8th, 10th, and 12th residue of the linear galactan chain (Alderwick et al., 2005) 
(Figure 7). Previous work demonstrated that the arabinan domain is present as a highly 
branched network synthesised on a backbone of "(1#5) linked sugars with branching 
introduced by the presence of 3,5-"-D-Araf residues (Daffe et al., 1990). The non-
reducing termini of arabinan structure consists of a distinct hexa-arabinofuranosyl motif 





Analysis of per-O-methylated mAGP and per-O-alkylated oligoglycosyl alditols 
determined that position 5 of both terminal !-D-Araf and the penultimate 2-"-D-Araf are 
the attachment sites for the mycolic acids (McNeil et al., 1991). Follow-up studies 
determined that mycolyl residues are located in clusters of four on the terminal hexa-
arabinofuranoside motifs, with only two-thirds of these being mycolated. 
 
Figure 7 The general structure of arabinogalactan present in M. tuberculosis. The 
galactan domain containing approximately 30 Galf residues is attached to the 
peptidoglycan layer via a linker unit. This linear galactan serves as a base for the three 
arabinan chains that are connected to the galactan at positions 8, 10 and 12. The branched 
arabinan domain is covalently attached to the mycolates through a unique 
hexaarabinofuranosyl motif. Succinyl or galactosamine residue is attached to the inner 
3,5-"-D-Araf residues, thus completing the structure of AG. Reprinted by permission 







An endogenous arabinase, which can cleave the arabinan, has been partially purified from 
M. smegmatis (Dong et al., 2006). The use of this enzyme together with matrix-assisted 
laser desorption/ionization-time of flight-mass spectrometry and NMR allowed the 
sequencing of very large fragments of arabinan chains released from the mycobacterial 
cell wall. Importantly, galactosamine (GalN) residues, previously detected as a minor 
covalently bound sugar residue of the cell envelope of slow growing mycobacteria, such 
as M. tuberculosis and M. avium (Draper et al., 1997), were shown to be located on the 
C-2 position of some of the internal 3,5-"-D branched Araf residues (Lee et al., 2006) and 
the stereochemistry of the GalN moiety was confirmed to be an "-anomer (Peng et al., 
2012) (Figure 7). In addition, succinyl groups were found located on the interior branched 
arabinosyl residues (Bhamidi et al., 2008). Approximately one of the three arabinan 
chains linked to the linear galactan contain a GalN group and one of three are 
succinylated (Bhamidi et al., 2008). In addition, succinyl residues were shown to be 
present only on the non-mycolated chains, thus suggesting a possible negative control 
mechanism for mycolylation. It is speculated that the GalN residue of AG may serve as a 
specific function during host infection (Bhamidi et al., 2008). 
 
1.8.2.2 Precursor formation 
The biosynthesis of the linkage unit employs two high-energy substrates, UDP-GlcNAc 
and dTDP-Rha (Figure 8). UDP-GlcNAc, a sugar donor for both the AG linker unit and 
the biosynthesis of PG, is formed via a four-step reaction. Three enzymes, glutamine 
fructose-6-phosphate transferase GlmS, phosphoglucosamine mutase GlmM and 





transferase GlmU catalyse the conversion of fructose-6-phosphate to UDP-GlcNAc in E. 
coli (Mengin-Lecreulx and van Heijenoort, 1993, Mengin-Lecreulx and van Heijenoort, 
1994, Mengin-Lecreulx and van Heijenoort, 1996, Klein and Ferre-D'Amare, 2006). 
Analysis of the genome sequence of M. tuberculosis determined that Rv3436c, Rv3441c 
and Rv1018c are homologous to the E. coli glmS, glmM, and glmU genes, respectively 
(Zhang et al., 2008). GlmS is responsible for the conversion of fructose-6-phosphate to 
glucosamine-6-phosphate, which is then converted to glucosamine-1-phosphate by 
GlmM. Recent gene deletion studies demonstrated that MSMEG_1556, a M. smegmatis 
gene encoding the homologue of glmM from E. coli, is essential for survival (Li et al., 
2012). Furthermore, it was shown that M. tuberculosis Rv3441c possesses 
phosphoglucosamine mutase activity and was able to compensate for the loss of 
MSMEG_1556 in the conditional mutant (Li et al., 2012), thus demonstrating that they 
share the same function. Mycobacterial GlmU is a bifunctional enzyme involved in the 
last two sequential steps of UDP-GlcNAc synthesis (Figure 8). Disruption of glmU in M. 
smegmatis resulted in gross morphological changes and loss of viability (Zhang et al., 
2008). Biochemical characterisation as well as the structure of M. tuberculosis GlmU has 
recently been established (Zhang et al., 2009, Zhou et al., 2011, Zhou et al., 2012). 
The second nucleotide donor utilised in the biosynthesis of the linkage unit is dTDP-Rha 
(Figure 8). Presence of L-rhamnose, a sugar absent in humans, makes the biosynthetic 
machinery of the mycobacterial linkage unit an attractive drug target. As a result, the 
rhamnosyl biosynthetic pathway has come under close investigation and a number of 
inhibitors targeting this pathway have been described (Ma et al., 2001, Babaoglu et al., 





reaction. Recognition of the genes involved in this pathway was revealed by comparison 
to known polysaccharide biosynthetic enzymes found in other bacteria, notably E. coli 
(Ma et al., 1997). RmlA (Rv0334) converts dTTP and "-D-glucose-1-P into dTDP-
glucose. A strain of E. coli lacking four rhamnose biosynthetic genes was complemented 
with rmlA from M. tuberculosis. The "-D-Glc-P thymidylyltransferase activity was 
observed in the cellular extract samples, therefore confirming its proposed function (Ma 
et al., 1997). The formed intermediate is utilised by dTDP-D-glucose-4,6-dehydratase 
RmlB (Rv3464), dTDP-4-oxo-6-deoxyglucose-3,5-epimerase RmlC (Rv3465), and 
dTDP-6-deoxy-L-lyxo-4-hexulose reductase RmlD (Rv3266) to finally form the 
nucleotide donor dTDP-Rha. Gene deletion studies in the presence of a rescue plasmid 
with a temperature sensitive origin of replication determined that all four rmlA (Qu et al., 
2007), rmlB (Li et al., 2006), rmlC (Li et al., 2006) and rmlD (Ma et al., 2002) genes 
were essential to M. smegmatis. Hence, dTDP-Rha is an essential sugar donor for 
mycobacterial growth and enzymes involved in its synthesis are potential 
chemotherapeutic targets. Finally, enzyme assays employing RmlA-D from M. 
tuberculosis to screen inhibitors for developing novel anti-TB therapeutics have been 
established (Ma et al., 2001, Sha et al., 2012). 
The high-energy nucleotide substrate UDP-Galf is formed via a three-step reaction 
(Figure 8). GalU (Rv0993) a glucose-1-phosphate uridylyltransferase catalyses the 
formation of UDP-Glcp from UTP and glucose-1-P (Lai et al., 2008). Recently, galU 
from M. tuberculosis was successfully expressed, purified and biochemically 
characterised (Lai et al., 2008). The second enzyme GalE is responsible for the 





Muller-Hill, 1986). Studies in M. smegmatis examined the reverse reaction using 
radiolabelled UDP-Galp and observed UDP-glucose-4-epimerase activity. Sequentially, 
the M. smegmatis protein was purified and its N-terminal sequence was shown to be 
similar to that of the M. tuberculosis product GalE1 (Rv3634c) (Weston et al., 1997). The 
transformation of UDP-Galp to the furanose form is catalysed by UDP-galactopyranose 
mutase Glf encoded by MSMEG_6404 from M. smegmatis and Rv3809c from M. 
tuberculosis (Nassau et al., 1996). Allelic exchange experiments of MSMEG_6404 
highlighted the essentiality of glf to mycobacteria (Pan et al., 2001). It has also been 
structurally characterised (Sanders et al., 2001, Beis et al., 2005). 
Arabinan biosynthesis utilises !-D-arabinofuranosyl-1-monophosphodecaprenol (DPA), 
the only known donor of Araf residues in mycobacteria and corynebacteria (Wolucka, 
2008). Recently, its membrane linked synthesis has been investigated in detail 
(Alderwick et al., 2005, Alderwick et al., 2011b) (Figure 8). The initial reaction involves 
activation of ribose-5-phosphate by a phosphoribosyl-1-pyrophosphate synthetase PrsA 
(Rv1017c) to yield 5-phosphoribosyl-1-pyrophosphate (pRpp) (Alderwick et al., 2011b). 
UbiA (Rv3806c) then transfers pRpp to a decaprenylmonophosphate producing 
decaprenylphosphoryl-5-phosphoribose (DPPR) (Alderwick et al., 2011b). Disruption of 
ubiA (NCgl2781) in C. glutamicum resulted in a complete loss of cell wall arabinan, 
demonstrating that DPA is the only Araf sugar donor used in AG biosynthesis (Alderwick 
et al., 2005). Remarkably, the mutant still generated a modified LAM version, which was 
arabinosylated even in the absence of DPA (Tatituri et al., 2007a). An alternative source 
and mechanism by which these Araf residues are added to this glycolipid is yet to be 





putative phospholipid phosphatase encoded by Rv3807c. Its homologue in M. smegmatis 
(MSMEG_6402) was shown to be a non-essential gene (Jiang et al., 2011). The DprE1 
(Rv3790) and DprE2 (Rv3791) heterodimer catalyses the epimerisation of DPR to DPA, 
which occurs via an oxidation-reduction mechanism. DPR is initially oxidised at the C2-
OH group to form the keto-sugar intermediate, decaprenol-1-monophosphoryl-2-keto-!-
erythro pentofuranose (DPX) that is subsequently reduced to DPA (Mikusova et al., 
2005). Deletion studies in C. glutamicum showed that dprE1 (NCgl0187) is essential to 
bacterial growth whereas dprE2 (NCgl0186) is not (Meniche et al., 2008). In the absence 
of dprE2, a different enzyme encoded by NCgl1429 was proposed to carry out the 
function of DprE2 since NCgl1429 showed a similar function in vivo and appeared to be 
essential in the NCgl0186-inactivated mutant (Meniche et al., 2008). Further 
investigation demonstrated that dprE1 (MSMEG_6382) is also an essential gene in M. 
smegmatis (Crellin et al., 2011). These results highlighted DprE1 as a novel drug target. 
Indeed, recent studies led to the discovery of two classes of potent compounds with 
specific activities against mycobacteria: dinitrobenzamide derivatives (DNB) and nitro-
compounds related to DNBs – nitro-benzothiazinones (BTZ), both of which were 
revealed to target the decaprenylphosphoryl-!-D-ribose 2$ epimerase encoded by dprE1 
(Christophe et al., 2009, Makarov et al., 2009). The structural complex of DrpE1-BTZ 
has been determined revealing the mode of inhibitor binding (Christophe et al., 2009, 
Batt et al., 2012). In addition, a BTZ mechanism of action was proposed in C. 
glutamicum. Grover et al. (2014) determined that in presence of the drug, bacteria 
accumulate the intermediate DPR and, therefore, fail to recycle decaprenyl phosphate. As 
a result, AG and LAM biosynthesis is inhibited ultimately leading to the cell death. 





the action of BTZ, demonstrating a new mechanism of drug resistance to the BTZ class 
of drugs (Grover et al., 2014). 
 
Figure 8 The biosynthesis of sugar donors required for mycobacterial 
arabinogalactan biosynthesis. Both UDP-GlcNAc and dTDP-Rha are utilised in the 
formation of the linker unit. UDP-Galf is the sugar donor of the galacfuranosyl residues 
used in the galactan chain formation. Decaprenylphosphoryl-D-arabinofuranose is the 
only known high energy nucleotide providing arabinofuranosyl residues to the arabinan 
domain of arabinogalactan. Reprinted by permission from ASM: Microbiology Spectrum, 







1.8.2.3 Biosynthesis of arabinogalactan 
The biosynthesis of AG begins with the formation of the linker unit synthesised on a 
decaprenyl phosphate lipid carrier. WecA (Rv1302) catalyses the first reaction by 
transferring GlcNAc-1-P from the sugar donor UDP-GlcNAc to the lipid carrier 
(Mikusova et al., 1996, Jin et al., 2010). Lipopolysaccharide analysis of a wecA-defective 
strain of E. coli complemented with either M. tuberculosis (Rv1302) or M. smegmatis 
(MSMEG_4947) homologue showed restoration of lipopolysaccharide biosynthesis, thus 
providing evidence it has the same function as the WecA protein from E. coli (Jin et al., 
2010). In addition, inactivation of wecA from M. smegmatis using a homologous 
recombination strategy resulted in drastic morphological changes and loss of viability (Jin 
et al., 2010). Rhamnosyltransferase WbbL (Rv3265c) is responsible for the transfer of the 
rhamnose residue from dTDP-Rha substrate to the 3-position of the GlcNAc of C50-P-P-
GlcNAc, thus yielding the full linkage unit C50-P-P-GlcNAc-Rha of AG. The key to the 
discovery of mycobacterial WbbL was the successful complementation of an E. coli 
mutant lacking WbbL activity with the Rv3265c gene from M. tuberculosis (Mills et al., 
2004). M. tuberculosis wbbL was expressed in E. coli and together with bioinformatics 
analysis used to establish its preliminary structure and characteristics (Wu et al., 2011). 
Moreover, it was demonstrated that wbbL (MSMEG_1826) is crucial to the growth and 
viability of M. smegmatis (Mills et al., 2004). 
The previously synthesised linker unit serves as an acceptor for the addition of Galf 
residues from the sugar donor UDP-Galf. Galactofuranosyltransferase (GalfT) GlfT1 
(Rv3782) recognises the linker unit and transfers the initial two Galf residues to C50-P-P-





et al., 2008, Belanova et al., 2008) (Figure 9). Further galactan polymerisation is carried 
out by the second transferase GlfT2 (Rv3808c), identified through the use of a 
neoglycolipid acceptor assay together with UDP-Galf and isolated E. coli membranes 
expressing glfT2. It was demonstrated that GlfT2 acts both as a UDP-Galf:$-D-(1%5) 
GalfT and a UDP-Galf:$-D-(1%6) GalfT, and is responsible for the majority of galactan 
biosynthesis by sequentially polymerising the galactan polysaccharide in alternating 
$(1%5) and $(1%6) linkages (Kremer et al., 2001, Rose et al., 2006, Wheatley et al., 
2012). In addition, structural data together with site-directed mutagenesis and kinetic 
studies provided evidence for a mechanism that explains the unique ability of GlfT2 to 
generate !(1#5) and !(1#6) linkages using a single active site (Wheatley et al., 2012). 
An arabinofuranosyltransferase (ArafT) from the emb locus, AftA (Rv3792), is 
responsible for addition of the first key Araf residue to the 8th, 10th and 12th Galf residues, 
thus “priming” the galactan chain for further attachment of "(1#5)-linked Araf units 
(Alderwick et al., 2005, Alderwick et al., 2006) (Figure 9). A homologue of aftA in M. 
smegmatis, MSMEG_6386, was shown to be essential for survival of mycobacteria. 
However, deletion of aftA in C. glutamicum resulted in a slow growing, but viable 
mutant. Cell wall analysis revealed the complete loss of arabinose leading to a truncated 
cell wall structure containing only a galactan chain (Alderwick et al., 2006). Further 
polymerisation of arabinan is predicted to be catalysed by EmbA (Rv3794) and EmbB 
(Rv3795) enzymes with #-1,5 transferase activity. Also, Emb proteins were demonstrated 
to play a key role in forming the terminal hexaarabinofuranosyl motif (Escuyer et al., 
2001). Although AG formation of mycobacteria is essential for its viability, the 





viable mutant with an impaired AG structure (Escuyer et al., 2001). Interestingly, in 
comparison with M. tuberculosis, C. glutamicum has been shown to have only one emb 
gene, which is not essential in this organism (Alderwick et al., 2005). Nevertheless, the 
deletion of this gene caused severe reduction of arabinose, resulting in a truncated AG 
structure with only terminal Araf residues (Alderwick et al., 2005). Recent deletion 
studies in M. smegmatis identified a branching enzyme AftC (MSMEG_2785, orthologue 
to Rv2673) that is responsible for the transfer of Araf residues from DPA to the arabinan 
domain to form "(1#3)-linked Araf residues of the internal arabinan domain at the non-
reducing end of AG and LAM (Birch et al., 2008, Birch et al., 2010). Yet another 
functional ArafT encoded by aftD (Rv0236c) has been shown to have "-1,3-branching 
activity on linear "-1,5-linked synthetic acceptors in vitro. Inactivation of aftD 
homologue in M. smegmatis, MSMEG_0359, was shown to be lethal to mycobacteria, 
while overexpression of aftD in M. smegmatis resulted in an overall increase of Araf 
residues (Skovierova et al., 2009). Finally, AftB (Rv3805c) catalyses the transfer of Araf 
residues to the arabinan domain to form the terminal !(1#2) linked Araf residues (Figure 
9). Disruption of aftB in C. glutamicum resulted in a viable mutant with complete absence 
of terminal !(1#2)-linked arabinofuranosyl residues and decreased abundance of cell 







Figure 9 Schematic representation of mycobacterial arabinogalactan biosynthesis. 
WecA catalyses the transfer of GlcNAc to decaprenyl phosphate, which is then used as an 
acceptor for addition of rhamnosyl residue by WbbL, therefore forming the full linker 
unit. The first two galactofuranosyl (Galf) residues are added to the linkage unit via 
GlfT1. The bifunctional GlfT2 adds the remaining Galf residues forming a linear galactan 
chain. Before the polymerisation with arabinofuranosyl (Araf) residues, the galactan 
domain is thought to be translocated across the plasma membrane by the unknown 
flippase. AftA initiates the transfer of Araf residues from the sugar donor 
decaprenylphosphoryl-D-arabinofuranose (DPA) to the 8th, 10th and 12th !(1#6)-linked 
Galf residues of the galactan chain. EmbA and EmbB proteins act as "-1,5- 
arabinosyltransferases utilising the same nucleotide donor DPA. The 3,5-linked Araf 
branching is introduced by AftC and AftD enzymes. Finally, the terminal Araf residues 
are added to the arabinan domain by the “capping” enzyme AftB. Reprinted by 
permission from ASM: Microbiology Spectrum, Jankute et al. (2013). 
 
1.8.2.4 Decoration of arabinogalactan and its attachment to peptidoglycan and 
mycolic acids 
Two decorating structures, succinyl and GalN residues, have been identified in the 
interior AG arabinan domain of M. tuberculosis, thus concluding a model of the complete 





chains towards the non-reducing end are yet to be determined (Bhamidi et al., 2008), 
however, the key components of the biosynthetic pathway of GalN have recently been 
elucidated (Skovierova et al., 2010). Glycosyltransferase PpgS (Rv3631) catalyses the 
transfer of GalNAc from UDP-GalNAc to polyprenyl-P yielding a sugar donor 
polyprenyl-P-GalNAc. This high-energy substrate is then presumably deacetylated by an 
as yet unknown deacetylase before or after being translocated to the extracellular space 
where the membrane associated enzyme Rv3779 transfers the GalNp (or GalNAc) 
residue to the C2 position of a portion of the internal 3,5-branched-D-Araf residues of 
AG. The synthesis of GalN was removed in both ppgS and Rv3779 deletion mutants in M. 
tuberculosis (Skovierova et al., 2010). It is worth noting that the GalN residue is only 
found in slow-growing mycobacteria. Hence expression of ppgS in the fast growing M. 
smegmatis species, otherwise devoid of the ppgS orthologue and any detectable 
polyprenyl-P-GalNAc synthase activity, allowed mycobacteria to synthesise polyprenyl-
P-GalNAc in vivo. The physiological role and pathogenesis of both succinyl and GalN 
residues as well as the biosynthetic origin of succinylation remains to be elucidated. 
Very little evidence has been obtained of how AG is ligated to PG to generate the 
complete cell wall core. In vitro assay in M. smegmatis utilizing cell-free extracts and 
radiolabelled substrates demonstrated the formation of simpler polyprenyl-P-P-GlcNAc-
Rha-(Galf)n intermediates followed by addition of AG and finally ligation to PG (Yagi et 
al., 2003). However, there are no reports on which enzymes are involved in the 
attachment of AG to PG. In addition, it is not fully understood when the AG structure is 
mycolylated, before or after, the attachement to PG. In vitro enzymatic assays have 





FbpC (Rv0129c), responsible for the transfer of mycolic acids onto trehalose leading to 
the formation of trehalose monomycolate (TMM) and trehalose dimycolate (TDM) 
(Belisle et al., 1997). Inactivation of fbpC (previously termed antigen 85C) by transposon 
mutagenesis resulted in a mutant with reduced capacity to transfer mycolic acids to the 
mycobacterial cell wall (Jackson et al., 1999). Similar mycolyltransferases from C. 
glutamicum, cmytA and cmytB, were deleted leading to a viable double mutant with 
significantly impaired ability to transfer corynomycolates to AG (Kacem et al., 2004). 
1.8.3 Lipoarabinomannan 
PIMs, LM and LAM are glycophospholipids built on a phosphatidyl-myo-inositol (PI) 
backbone by a series of modifications including glycosylation and acylation. It is still 
unclear whether these PI based glycophospholipids and lipoglycans are embedded in the 
plasma membrane or found in the outer membrane of mycobacteria. However, using 
surface labelling experiments it has recently been demonstrated that the lipoglycans are 
exposed at the surface of mycobacteria, located in the outer leaflet of the outer membrane 
(Pitarque et al., 2008). Such lipoglycans possess significant immunomodulatory effects in 
the host macrophages, including cytokine production, inhibition of phagosome 
maturation, and cross-protective immunity of mycobacteria (Mishra et al., 2011a). Recent 
biochemical and genetic studies have indicated that modifications of the PI anchor follow 
the order: PI # PIM # LM # LAM (Mishra et al., 2011a), where mannosylation of the 
PI anchor with four mannose residues produces PIM4, which is further modified with 





1.8.3.1 Structure of phosphatidyl-myo-inositol mannosides, lipomannan and 
lipoarabinomannan 
PIMs are glycolipids comprised of fatty acids attached to a glycerol unit linked to myo-
inositol via a phosphodiester moiety (Ballou et al., 1963). The precursor of these 
glycolipids is the PI unit, which is based on sn-glycero-3-phosphate-(1-D-myo-inositol). 
PI, when modified with mannose residues at positions O-2 and O-6, forms the mannosyl 
phosphate inositol anchor (MPI) (Chatterjee et al., 1992a, Severn et al., 1998), which 
may differ in number, position and nature of the fatty acids attached. PIM1 contains 
glycosylated PI with a #-D-mannopyranosyl (Manp) residue at position O-2, whereas 
PIM2 contains glycosylated PI with Manp at positions O-2 and O-6. In addition, FAB-MS 
and GC-MS analysis of the perdeuteroacetyl and permethyl derivatives of PIMs from M. 
tuberculosis and M. leprae, has shown that position C-6 of PIM2 mannose is esterified 
with a C16 fatty acyl substituent (Khoo et al., 1995b). There are four predicted sites of 
acylation in the MPI anchor: 1-OH and 2-OH of the glycerol unit, 3-OH of the inositol 
ring, and 6-OH of the Manp attached to position O-2 of the myo-inositol ring (Khoo et 
al., 1995b). Based on the acylation sites, two types of PIMs were described in 
mycobacteria. The first type is Ac1PIMY possessing an acyl group either at 3-OH of the 
inositol ring or at 6-OH of the Manp, whereas the second type is Ac2PIMY, which is 
acylated at both of these positions. The acylated form of Ac1PIM2 serves as a substrate 
for higher order PIMs, such as Ac1PIM6 and Ac2PIM6. A combination of NMR 
spectroscopy and mass spectrometry determined that PIM6 consists of Manp-"(1#2)-






LAM is the extended form of LM and is comprised of a MPI anchor, polysaccharide 
backbone and capping moieties (Figure 9). The polysaccharide chain, common to both 
LAM and LM, contains 21-34 Manp residues linked as a linear "(1#6) chain with 5-10 
units of single "(1#2) Manp side chains (Chatterjee et al., 1992a, Dinadayala et al., 
2006) (Figure 9). In LAM, this linear chain also possesses an arabinan domain containing 
approximately 55-70 Araf residues linked as a linear "(1#5) chain with "-1,3-branching 
(Dinadayala et al., 2006, Birch et al., 2010). Two types of branching patterns are 
observed in the arabinan domain of LAM. The first is a linear tetra-arabinoside 
comprising of !-D-Araf (1#2)-"-D-Araf (1#5)-"-D-Araf (1#5)-"-D-Araf, whilst the 
second is a hexa-arabinoside [!-D-Araf (1#2)-"-D-Araf ]2-3,5-"-D-Araf (1#5)-"-D-Araf 
(Chatterjee et al., 1991, Chatterjee et al., 1993). The disaccharide unit, Araf-!(1#2)-
Araf-"(1#.), is a common structural feature in both non-reducing ends of LAM arabinan. 
Finally, the capping moieties of arabinan contain manno-oligosaccharides (ManLAM) in 
slow growers, such as M. tuberculosis (Chatterjee et al., 1993), phosphoinositide units 
(PILAM) in fast growers, such as M. smegmatis (Khoo et al., 1995a), and uncapped 
LAM, known as AraLAM, in M. chelonae (Guerardel et al., 2002). In addition, the 
mannan cap of ManLAM in M. tuberculosis contains mono-, di- and tri-"(1#2)-D-Manp 






Figure 10 Structural features of acylated phosphosphatidyl-myo-inositol 
hexamannoside, lipomannan and lipoarabinomannan. Ac1PIM6/Ac2PIM6 are the end 
products of PIM biosynthesis generated by addition of four mannose residues to 
Ac1PIM2/Ac2PIM2 at position O-6 of inositol. The sugar backbone contains Manp-
"(1#2)-Manp-"(1#2)-Manp-"(1#6)-Manp-"(1#6)-Manp-"(1#.) unit  with acylation 
at either 3-OH of the inositol ring (R3) or 6-OH of the Manp attached to the O-2 position 
of the inositol ring (R4). In case of Ac2PIM6, both 3-OH and 6-OH are acylated. The 1-
OH and 2-OH of the glycerol unit in the MPI anchor represent the acylation sites R1 and 
R2, respectively. Lipomannan and lipoarabinomannan share the common MPI anchor, 
glycosylated at 2-OH and 6-OH of inositol. The common mannan core is composed of 
MPI anchor linked to 17-19 residues of Manp via "(1#6) linkage, branched frequently at 
position 2 with 5-10 single "-Manp units. The distinctive feature of the 
lipoarabinomannan is the arabinan domain, which contains approximately 55-70 residues 
and is linked to the mannan core. To date, the point of attachment of arabinan to the 
mannan remains unknown. Finally, the non-reducing termini of arabinan are capped with 
mannose residues, thus forming the mannose cap. The alphabets n, m, o and p depict 
different extent of species specific glycosylations in LAM. Reprinted by permission from 





1.8.3.2 Biosynthesis of phosphatidyl-myo-inositol mannosides, lipomannan and 
lipoarabinomannan 
PIMs are synthesised employing glycosyltransferases PimA, PimB', PimC and PimE that 
sequentially catalyse the glycosylation of PI in the following order: PI # PIM2 # PIM4 
# PIM6 (Besra and Brennan, 1997, Morita et al., 2006, Mishra et al., 2011a) (Figure 11). 
The biosynthesis is initiated by addition of a Manp residue to position O-2 of the inositol 
yielding PIM1, which is then mannosylated at position O-6 of inositol ring, and further 
acylated to form Ac1PIM2 (Kordulakova et al., 2002, Kordulakova et al., 2003). Four 
more mannose residues are added at position O-6 of inositol in Ac1PIM2, thus generating 
Ac1PIM6 (Mishra et al., 2011a). Ac1PIM2 acts as a scaffold in the PIM biosynthetic 
pathway on which other PIMs are assembled (Khoo et al., 1995b, Besra and Brennan, 
1997, Mishra et al., 2011a). 
PI synthesis begins with cyclisation of glucose-6-phosphate by inositol phosphate 
synthase (Ino1), encoded by Rv0046c, thus generating myo-inositol-1-phosphate. This 
intermediate is further dephosphorylated by inositol mono-phosphatase (IMP) yielding 
myo-inositol (Bachhawat and Mande, 1999, Movahedzadeh et al., 2004). In M. 
tuberculosis, putative ImpA (Rv1604), SuhB (Rv2701c), CysQ (Rv2131c) and ImpC 
(Rv3137) proteins contain the characteristic IMP domain, are homologues of IMP 
enzyme and, therefore, are suggested to contribute to the biosynthesis of inositol (Nigou 
and Besra, 2002, Brown et al., 2007, Movahedzadeh et al., 2010). Surprisingly, only 
impC has been shown to be essential to the growth and viability of mycobacteria 





catalyses esterification of the myo-inositol ring by transfering diacyl glycerol (DAG) 
from CDP-DAG (Jackson et al., 2000).  
PIM biosynthesis is initiated by PimA (Rv2610c), an "-mannopyranosyltransferase from 
GT-B superfamily (Guerin et al., 2007), that transfers the first Manp residue from UDP-
Manp to PI, thus generating PIM1. PIM1 can then be subsequently acylated by Rv2611, at 
the 6th position of the Manp residue to yield either Ac1PIM1 or Ac2PIM1 (Kordulakova et 
al., 2002, Kordulakova et al., 2003). PimB’ (Rv2188c), an "-D-mannose-"-(1#6) 
phosphatidyl-myo-inositol-mannopyranosyltransferase, is responsible for addition of 
Manp to the 6-OH position of inositol to yield either Ac1PIM2 or Ac2PIM2. Interestingly, 
acylation of PIM1 can precede the subsequent mannosylation step and is species 
dependent (Lea-Smith et al., 2008, Mishra et al., 2008b, Guerin et al., 2009). Deletion of 
pimB' in C. glutamicum resulted in accumulation of Ac1PIM1, implying that acylation of 
PIM1 occurred before the second mannosylation step (Kordulakova et al., 2003, Lea-
Smith et al., 2008, Mishra et al., 2008b). However, it was demonstrated that in M. 
smegmatis, Ac1PIM2 is generated after yielding PIM2 (Guerin et al., 2009). The Rv0557c 
was initially designated as PimB, an "-D-mannose-"-(1#6)-phosphatidyl-myo-inositol-
mannopyranosyltransferase, and was estimated to perform the same function as PimB' 
(Schaeffer et al., 1999). However, deletion of pimB in M. tuberculosis showed no effect 
on the biosynthesis of Ac1PIM2, indicating a case of redundancy or a different function 
(Torrelles et al., 2009). Interestingly, Rv0557c homologue in C. glutamicum was 
demonstrated to contribute to the synthesis of Cg-LM type-B (a LM variant) and 
ManGlcAGroAc2, a glucuronic acid diacyl-glycerol based glycolipid (Mishra et al., 





C. glutamicum !pimB'!mgtA double mutant were performed in order to elucidate the role 
of Rv0557. The mutant complemented with Rv2188c demonstrated restoration of "-D-
mannose-"-(1#6)-phosphatidyl-myo-inositol-mannopyranosyltransferase activity, which 
led to the synthesis of Ac1PIM2 and the corresponding lipoglycan. However, 
complementation of C. glutamicum !pimB'!mgt with Rv0557c resulted in the production 
of ManGlcAGroAc2 (Mishra et al., 2009).  As a result, C. glutamicum homologue of 
Rv0557c has been designated as MgtA with an "-mannosyl-glucopyranosylglucouronic 
acid transferase activity (Tatituri et al., 2007b). Recently, the crystal structure of PimB' 
co-crystallized with GDP and GDP-Man has been elucidated (Batt et al., 2010).  
RvD2-ORF1 from M. tuberculosis CDC1551, designated as PimC with Ac1PIM2:               
"-D-mannose-"-(1#6)-phosphatidyl-myo-inositol-mannopyranosyl transferase activity,  
catalyses the addition of a Manp residue to 6-OH of mannose at the non-reducing end of 
Ac1/Ac2PIM2 to generate Ac1/Ac2PIM3. Overexpression of PimC in a cell-free assay 
containing GDP-[14C]mannose, amphomycin (inhibitor of polyprenol phosphate-
requiring transferases) and membranes from M. smegmatis led to the synthesis of 
Ac1/Ac2PIM3. However, its inactivation in M. bovis BCG had no effect on PIM, LM and 
LAM biosynthesis, suggesting existence of redundant gene(s) or an alternative pathway 
that may compensate for PimC deficiency (Kremer et al., 2002). Polyprenylphosphate 
based mannose donors are employed for further elongation and branching of LM and 
LAM (Guerin et al., 2010). The "(1#6) mannosylation of Ac1/Ac2PIM3 to Ac1/Ac2PIM4 
is catalysed by either PimC or an unidentified mannopyranosyltransferase (Mishra et al., 
2011a). The pathway divides into two branches from Ac1/Ac2PIM4: one leads to the 





M. smegmatis, the LpqW channel regulates the amount of higher PIMs and lipoglycans 
formed, and directs Ac1/Ac2PIM4 towards LM synthesis (Kovacevic et al., 2006, Crellin 
et al., 2008). In the first branch, "(1#2) Manp is added to Ac1/Ac2PIM4 to form 
Ac1/Ac2PIM6 by two consecutive mannose additions catalysed by PimE (Rv1159), an 
"(1#2)-mannopyranosyl-transferase, and an additional uncharacterised putative 
glycosyltransferase speculated to be encoded by either Rv0051 or Rv0541 (Liu and 
Mushegian, 2003, Berg et al., 2007). In the second branch, Ac1/Ac2PIM4 is 
hypermannosylated by glycosyltransferases of the GT-C superfamily to generate LM and 
LAM. Recent studies have established the orthologs of MptB (Rv1459c) and MptA 
(Rv2174) in C. glutamicum to be involved in the synthesis of the mannan backbone, 
where MptB catalyses the synthesis of the proximal end through addition of 12-15 Manp 
residues to the backbone (Mishra et al., 2008a) and MptA that synthesises the distal end 
of the "(1#6) mannan core of LM (Kaur et al., 2007, Mishra et al., 2007). However, 
failure of MptB from M. tuberculosis to complement the C. glutamicum!mptB strain and 
its redundancy in M. smegmatis suggests that an uncharacterised orthologue substitutes 
for MptB, or MptA itself is involved in the extension of the proximal end (Mishra et al., 
2008a). The "(1#6)-mannan core synthesised by MptA and MptB is further branched by 
MptC (Rv2181) which adds "(1#2)-Manp residues to the side chain of LAM (Mishra et 
al., 2011b).   
The transition from LM to LAM is exclusively catalysed by EmbC (Rv3793) and 
involves the utilisation of LM primed with Araf units (Shi et al., 2006, Alderwick et al., 
2011a). An uncharacterised ArafT is suggested to perform the addition of first Araf 





al., 2006). EmbC is responsible for extension of the primed LM through addition of 12-
16 "(1#5)-Araf residues (Mishra, 2011). The addition of branch points is similar to AG, 
catalysed by AftC (Birch et al., 2008, Mishra, 2011). Skovierova et al. (2009) has 
identified a second branching enzyme termed AftD (Rv0236c) with an "(1#3)-ArafT 
activity (Skovierova et al., 2009). The arabinan domain is estimated to be terminated by 
AftB (Rv3805c) (Seidel et al., 2007). Although AftB primarily has !(1#2)-ArafT 
activity in AG biosynthesis, its probable role in LAM biosynthesis renders it bifunctional 
(Mishra et al., 2011a).  
Finally, the homologue of Rv1635c in M. tuberculosis CDC1551 was proposed to be 
involved in Man-LAM capping. Rv1635c mutants in M. bovis BCG and M. marinum are 
known to synthesise LAM lacking Man-caps (Appelmelk et al., 2008). This enzyme was 
later revealed to be an undecaprenyl phosphomannose-dependent "(1#5) 
mannosyltransferase, termed CapA. It recognises the fully synthesised arabinan domain 
and transfers the first Manp residue onto the non-reducing arabinan termini of LAM 
(Dinadayala et al., 2006, Appelmelk et al., 2008, Mishra et al., 2011a). ManLAM is 
completed by MptC (Rv2181) that elongates the cap with a second Manp residue (Mishra 






Figure 11 Biosynthesis of phosphatidyl-myo-inositol mannosides, lipomannan and 
lipoarabinomannan in M. tuberculosis. The first three mannosylation steps employ 
GDP-Man dependant PimA, PimB', PimC, and possibly PimC or an unidentified 
mannosyltransferase. Acylation of PIM1 is mediated by Rv2611c. AcPIM4 is flipped over 
to the periplasmic side by an unidentified flippase, where it is mannosylated by PimE to 
generate the metabolic end product - AcPIM6. AcPIM4 is sequentially extended by MptB, 
MptA, and MptC to yield LM. An unidentified arabinofuranosyltransferase primes LM 
with Araf residues. EmbC, AftC and AftD subsequently extend and branch arabinan 
domain, while AftB terminates the chain extension, thus completing LAM. LAM is 
further capped by CapA in conjunction with Rv2181 to generate ManLAM. Reprinted by 
permission from Future Medicine Ltd: Future Microbiology, Jankute et al. (2012). 
 
1.8.4 Ethambutol inhibits arabinogalactan and lipoarabinomannan biosynthesis 
Ethambutol [EMB; (S, S)-2, 2’-(ethylenediimino)di-1-butanol] is a bacteriostatic agent 





component of the multi-drug regimen used worldwide for TB therapy in combination 
with INH, PZA and RIF to prevent the emergence of drug-resistant TB strains. Although, 
this anti-mycobacterial agent has been administered for several decades, the mechanism 
of action and molecular genetic basis of resistance of this drug is yet to be fully 
understood. However, over the last forty years significant progress has been made in 
efforts to elucidate the intracellular mode of action of EMB. 
Earlier studies into the investigation of the intracellular target showed that treatment of 
M. smegmatis with EMB leads to rapid declumping of bacterial cells, indicating EMB 
involvement in alteration of the cell wall (Kilburn et al., 1977). The examination of the 
effects of EMB on mycobacteria has led to several hypotheses being proposed in relation 
to the mechanism of action over the years including inhibition of nucleic acid metabolism 
(Forbes et al., 1965), phospholipid metabolism (Kilburn et al., 1981), spermidine 
biosynthesis (Poso et al., 1983) and glucose metabolism (Silve et al., 1993). EMB was 
shown to act on the accumulation and secretion of trehalose mycolates and free mycolic 
acids in M. smegmatis leading to the rapid cessation of mycolic acid transfer to the cell 
wall (Kilburn and Takayama, 1981), establishing its effect on cell wall synthesis. 
However, the primary mode of action of EMB was proposed to specifically target the 
inhibition of AG biosynthesis (Takayama and Kilburn, 1989) and the synthesis of the 
arabinan core of LAM (Deng et al., 1995), which leads to the accumulation of DPA, a 
donor in the pathway of arabinan biosynthesis (Wolucka et al., 1994). 
The embAB gene cluster in Mycobacterium avium, was found to confer resistance to 
EMB when subcloned and overexpressed into M. smegmatis, and was first presented as 





ArafT involved in the polymerisation of arabinose into AG (Belanger et al., 1996). 
Subsequent studies identified a three gene operon, embCAB in M. tuberculosis and M. 
smegmatis as a putative target of EMB, which encode three ArafT enzymes that display 
approximately 65% similarity to each other (Telenti et al., 1997). The discovery of the 
emb gene cluster provided the opportunity to examine the molecular basis of resistance of 
mycobacteria. Telenti et al. (1997) demonstrated that high-level resistance to EMB might 
result from either overproduction of Emb protein(s) or a structural mutation in the EmbB 
protein. Further studies have shown genetic evidence for a key role of the EmbB protein 
in cell wall biosynthesis highlighting the fact it is the most EMB-sensitive protein in the 
gene cluster (Alcaide et al., 1997).  
Point mutations were identified in codons 289 and 292 of the embB gene of M. smegmatis 
that conferred resistance to EMB (Lety et al., 1997). As the embB region is highly 
conserved amongst M. tuberculosis, M. avium, M. leprae and M. smegmatis, similar 
mutations were found in codons 303 and 306 in the embB gene of EMB-resistant clinical 
isolates of M. tuberculosis (Lety et al., 1997, Telenti et al., 1997). The most frequently 
detected mutation occurred in codon embB306 resulting in a substitution of the wild-type 
methionine with isoleucine, leucine or valine, and was found in 50% of all EMB-resistant 
clinical isolates, which has been proposed to be positioned in a cytoplasmic loop that 
forms an EMB resistance-determining region (ERDR) (Telenti et al., 1997). This 
mutation was proposed as a key mechanism of resistance and a possible candidate marker 
for rapid detection of MDR-TB and XDR-TB strain (Starks et al., 2009). However, it is 
controversial as to whether it mediates EMB resistance due to the presence of this 





2005, Shen et al., 2007). Furthermore, it was shown that mutations in embB306 may 
predispose M. tuberculosis isolates to broad drug resistance rather than EMB resistance 
alone (Hazbon et al., 2005). Recent studies have reinforced the association of embB306 
mutations with EMB resistance (Starks et al., 2009) as shown by experimental evidence 
that the transfer of embB306 mutations to EMB susceptible M. tuberculosis strain 
increases the EMB minimum inhibitory concentration (MIC) in vitro (Safi et al., 2008). 
Although, the role of embB in relation to mediating resistance has been under much 
scrutiny, studies have indicated the existence of multiple molecular pathways to the EMB 
resistance phenotype (Ramaswamy et al., 2000). For example, there are a number of 
EMB resistant strains that do not possess ERDR mutations, thus other genes may be 
involved in EMB resistance.  
Inactivation of embA and embB in M. smegmatis resulted in a greater reduction of the 
arabinose content of arabinogalactan compared to levels observed in an embC deletion 
mutant (Escuyer et al., 2001). The hexaarabinofuranosyl motif was altered in both embA 
and embB deletion mutants in M. smegmatis when compared to the wild-type 
demonstrating both EmbA and EmbB proteins are involved in the formation of AG 
(Escuyer et al., 2001). Inactivation of embC in M. smegmatis resulted in no detectable 
LAM content demonstrating EmbC is required for synthesis of LAM (Zhang et al., 
2003).The deletion of Emb proteins and generation of viable mutants in M. smegmatis 
suggests that EMB targets two or more Emb proteins to cause growth inhibition. Since 
the embC deletion mutant could not be restored to its phenotype by complementation, it 
could not be confirmed that EmbC is critical for AG production in M. smegmatis 





essential in M. tuberculosis implying that EMB can target either of these proteins to arrest 
bacterial growth (Amin et al., 2008, Goude et al., 2008). Thus, the consequences of EMB 
action may differ between fast growing and slow growing mycobacteria. 
1.8.5 Mycolic acids 
Mycolic acids are vital components of the waxy cell wall of Corynebacterineae including 
M. tuberculosis, M. smegmatis, and C. glutamicum and are located either covalently 
attached to AG, or as free glycolipids: trehalose monomycolates (TMM), trehalose 
dimycolates (TDM), and glucose monomycolates (GMM) (Bhatt et al., 2007, de Souza et 
al., 2008, Luo et al., 2012, Verschoor et al., 2012). These #-branched, $-hydroxylated 
fatty acids account for reduced cell wall permeability and virulence in pathogenic 
mycobacteria (Asselineau and Lederer, 1950). Notably, the length of the fatty acids is 
species dependent. For instance, mycobacterial mycolic acids are 70-90 carbons in 
lengths (Goodfellow and Minnikin, 1977), whereas in corynebacteria they are 22-38 
carbons (Collins et al., 1982a, Collins et al., 1982b). In M. tuberculosis, mycolates are 
generally composed of C24-C26 saturated straight chain fatty acids to provide the "-alkyl 
branch and the meromycolate chain of up to 56 carbons in length. Three different distinct 
classes of M. tuberculosis mycolic acids have been identified: #-, methoxy-, and keto-. "-
Mycolates are the most abundant variety, which is non-oxygenated at both proximal and 
distal positions of the meromycolate chain and comprising of two cyclopropane rings in 
the cis configuration (Qureshi et al., 1978, Yuan et al., 1995, Minnikin et al., 2002). 
Methoxy- and keto-mycolates are both oxygenated lipid species containing one 
cyclopropane ring either in the cis and trans configuration, respectively (George et al., 





glycolipids. TMM contains a trehalose disaccharide esterified to one mycolic acid 
residue, whereas TDM is esterified to two mycolic acid residues. GMM is composed of a 
glucose unit and one mycolic acid residue. 
The biosynthesis of mycolic acids in mycobacteria is mediated through two fatty acid 
synthases: fatty acid synthase I (FAS-I) generates the C24-C26 saturated straight chain 
fatty acids, whereas fatty acid synthase II (FAS-II) provides the meromycolate backbone 
- C56 fatty acids (de Souza et al., 2008, Luo et al., 2012). FAS-I is a large eukaryote-like 
multifunctional enzyme encoded by a single fas (Rv2524c) gene. FAS-II further elongates 
the FAS-I end products, thus forming meromycolates (Bhatt et al., 2007). FAS-II multi-
enzyme synthase is comprised of a number of proteins including trans-2-enoyl-ACP 
reductase InhA (Rv1484), $-ketoacyl-ACP synthase composed of KasA (Rv2245) and 
KasB (Rv2246), $-ketoacyl-ACP reductase MabA (Rv1483), $-hydroxyacyl-ACP 
dehydratase comprised of HadA (Rv0635), HadB (Rv0636) and HadC (Rv0637). 
Subsequently, meromycolate chains are then modified introducing functional groups by 
various methyltransferases (Glickman et al., 2000, Glickman, 2003, Takayama et al., 
2005). The "-branch and the meromycolate backbone are then linked in a condensation 
reaction catalyzed by Pks13 (Rv3800c) (Portevin et al., 2004), and reduced by Rv2509 to 
finally form mature mycolic acids (Bhatt et al., 2008). Mycolyltransferases (the Antigen 
85 complex) catalyse the transfer of these newly synthesized mycolic acids to AG or 
other acceptors (Belisle et al., 1997, Jackson et al., 1999). A number of enzymes 
involved in mycolic acid biosynthesis have been identified, however further 
characterization of these key enzymes is needed to fully understand their roles in the 






Figure 12 Mycobacterium tuberculosis mycolic acid biosynthesis. FAS-I, and then 
FAS-II synthesise the long aliphatic acyl-chains that are further modified to produce the 
mature meromycolate chains of mycolic acids. Key steps in the biosynthesis of mycolic 
acids as well as the targets for the action of activated isoniazid (INH), ethionamide 
(ETH), triclosan (TRC), and thiolactomycin (TLM) are shown as indicated. TMM: 
trehalose monomycolate; TDM: trehalose dimycolate; mAGP: mycolyl-arabinogalactan-
peptidoglycan complex. Reprinted by permission from Future Medicine Ltd: Future 
Microbiology et al. (2012). 
 
1.9 Surrogate systems in M. tuberculosis research 
A distinctive quality of mycobacterial pathogens, such as M. tuberculosis and M. leprae, 
is their slow growth rate and fastidious culturing process. Therefore, various surrogate 
systems have been employed to facilitate M. tuberculosis research. A significant 
surrogate organism used in M. tuberculosis research is Mycobacterium smegmatis. In 





common in soil and aquatic environments (Lustgarten, 1884). Commercially, M. 
smegmatis is utilised for production of xylitol (dietary sweetener) and L-arabinose, 
whereas in scientific research it is most widely used in investigating mycobacterial 
pathogens. Classified as saprophytic species, M. smegmatis is one of the most rapid 
growing mycobacteria with a generation time of approximately 4 hours. Importantly, M. 
smegmatis shares a highly similar cell wall structure to other mycobacteria, including M. 
tuberculosis. Ease of genetic manipulation has allowed characterisation of a large number 
of M. smegmatis genes, some of which are homologues to M. tuberculosis (Bhatt and 
Jacobs, 2009, Rana et al., 2012, Varela et al., 2012). However, a limitation of using M. 
smegmatis as a model organism is the study of inhibitors of virulent M. tuberculosis. M. 
smegmatis is a non-pathogenic species lacking approximately 30 % of conserved 
homologues in M. tuberculosis (Altaf et al., 2010). Therefore, although M. smegmatis 
offers technical benefits, it is inappropriate to study pathogenesis and is less efficient 
when investigating potential drug targets. 
M. bovis, a member of MTBC, is the causative agent of bovine TB. It has been also found 
to cause disease in humans and other mammals that are not considered to be its primary 
host, therefore making M. bovis a zoonotic organism. M. bovis Bacillus Calmette Guerin 
(BCG) is a strain that was attenuated from M. bovis by serial passages in the laboratory 
and is the vaccine used for TB (King and Park, 1929, Kaplan, 1947). Although M. bovis 
BCG is a slow grower, it can be used under less stringent conditions. More importantly, 
M. bovis BCG shares approximately 99 % of conserved genes identical to M. tuberculosis 





using M. bovis BCG is that it lacks virulence factors that were lost in the process of 
attenuation. 
Another widely used model organism to study M. tuberculosis and other pathogenic 
mycobacteria is Mycobacterium marinum. It is an opportunistic human pathogen that 
causes TB like infections in fish and amphibians. M. marinum has a shorter generation 
time (8-12 hours) than compared to M. tuberculosis, responds to genetic manipulation 
and is a Category 2 organism. In addition, the genome comparisons of both M. marinum 
and M. tuberculosis demonstrate a close genetic relationship sharing over 3000 conserved 
orthologs (Stinear et al., 2008). Significantly, M. marinum has been demonstrated to enter 
and replicate within the macrophages in a similar manner to M. tuberculosis (Stamm and 
Brown, 2004). Therefore, M. marinum is widely used to study mechanisms of virulence 
as well as host-pathogen interactions utilising its primary host. In addition, fish infected 
with M. marinum develop granulomas, which is one of the main features of the host 
immune response to M. tuberculosis infection (Chan et al., 2002, Davis et al., 2002). 
Finally, infection studies are usually utilizing zebrafish those embryos are transparent, 
thus facilitating the observation process. 
Corynebacterium glutamicum has been isolated in the early 20th century in Japan where it 
was established in the industrial production of L-glutamate (Abe, 1967). C. glutamicum 
along with Corynebacterium diphtheriae, the causative agent of diphtheria, and 
Corynebacterium pseudotuberculosis, the causative agent of caseous lymphadenitis, 
belong to the same Corynebacterianeae family as M. tuberculosis and, thus, share a 
similar cell wall architecture. However, the cell envelope of C. glutamicum is less 





of homologues genes that are essential in, for example, M. tuberculosis (Alderwick et al., 
2006, Seidel et al., 2007, Birch et al., 2008). In addition, C. glutamicum is a non-
pathogenic bacterium with a generation time of 30 minutes and a number of genetic and 
molecular techniques that are available to manipulate it, thus making it an attractive 
model organism to study mycobacterial species. 
1.10 Project aims 
Over the past decade, researchers have been successful in identifying and characterising a 
number of enzymes involved in AG and LAM biosynthesis in C. glutamicum, M. 
smegmatis and M. tuberculosis. However, many components of these complex pathways, 
including multiprotein complex formation, still remain elusive. Furthermore, aspects of 
cell wall biosynthesis, such as regulation and turnover, remain poorly studied. 
The overall aim of this project was to gain an insight into the biosynthetic pathways 
leading to formation of AG and LAM with specific focus on characterisation of 
glycosyltransferases and their protein-protein interactions. The main project was split into 
three minor objectives: 
A. Construction and characterisation of knockout mutants of aftA, aftB and emb from 
Corynebacterineae 
This aim involved the construction of null mutants of either M. smegmatis mc2155 or C. 
glutamicum ATCC 13032 non-essential genes in order to determine their function in cell 
wall biosynthesis. In the case of genes being essential to M. smegmatis mc2155, 
conditional mutants were generated. Conditional expression-specialised transduction 





essentiality of individual genes in mycobacteria (Bhatt and Jacobs, 2009). Biochemical 
phenotypes and intermediates were analysed.  
B. Biochemical and structural characterisation of AftA, AftB and Emb from 
Corynebacterineae. 
Proteins encoded by candidate genes were overexpressed either in E. coli or C. 
glutamicum cells and purified for further analysis. In vitro activity assays using 
radioactive labelled substrates for individual glycosyltransferases were attempted. 
Furthermore, C-terminal hydrophilic domains of membrane proteins encoded by some of 
the candidate genes were overexpressed and purified for crystallisation studies. This 
approach was recently proved to be successful when investigating membrane 
glycosyltransferases with large characteristic hydrophilic loops (Alderwick et al., 2011a).  
C. Investigation of protein interaction network of AG biosynthetic enzymes. 
In order to assess protein-protein interactions of proteins encoded by candidate genes 
various methods were approached. The list of techniques included the in vivo bacterial 
two-hybrid system (BACTH), a novel lipodisq technology for membrane proteins, and 
pull-down assays. These methods provided an insight into physical interactions between 
proteins encoded by candidate genes and their interacting partners. 
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2   Elucidation of a protein-protein interaction network involved in Corynebacterium 
glutamicum cell wall biosynthesis as determined by bacterial two-hybrid analysis 
2.1 Introduction 
Over the past decade sophisticated genomic and molecular tools have advanced our 
understanding of biochemical and physiological processes of mycobacteria. The 
availability of the full genome sequences of various mycobacterial species, including M. 
tuberculosis (Cole et al., 1998), Mycobacterium marinum (Stinear et al., 2008), 
Mycobacterium leprae (Eiglmeier et al., 2001) and Mycobacterium BCG (Garnier et al., 
2003), have greatly facilitated the identification of large numbers of drug targets and 
antigens. Moreover, numerous genome sequences and rapidly evolving field of 
comparative genomics have allowed the research to focus on identifying and 
characterising gene products that play an important role in growth, viability, and 
virulence of M. tuberculosis. It has become increasingly obvious that networks of 
interacting proteins mediate pathways of these cellular processes. Therefore, methods to 
investigate protein-protein interactions have emerged as a valuable tool in the field of M. 
tuberculosis research. Currently, mycobacterial protein associations have been employed 
to study numerous cellular processes, such as signal transduction pathways (Lee et al., 
2012), inhibitors of mycobacterial interactions (Mai et al., 2011), formation of enzymatic 
complexes (Baulard et al., 2003, Veyron-Churlet et al., 2004, Veyron-Churlet et al., 
2005), and drug resistance pathways (Raman and Chandra, 2008, Cui et al., 2009, Wang 
et al., 2010).  
The essential mycobacterial cell wall structure –mAGP– represents a very attractive drug 
target. A key structural component of the mAGP complex is AG that plays an important 




research have obtained structural, physical and chemical evidence of this unique cell 
structure (General Introduction 1.8.2), there are still substantial gaps in our knowledge of 
AG biosynthesis. For instance, little is known about multi-protein complexes involved in 
AG assembly, perhaps due to a number of cell wall biosynthetic proteins being 
transmembrane or membrane bound. Recently, Zheng et al. (2011) shed light on potential 
protein-protein associations in membrane fractions of M. bovis BCG utilising blue native 
polyacrylamide gel electrophoresis (BN-PAGE) combined with liquid chromatography 
tandem mass spectrometry (LC-MS). Nine protein clusters have been identified 
representing multi-protein complexes. Notably, ArafTs encoded by emb genes embA, 
embB, and embC were identified in the study as a possible Emb protein complex (Zheng 
et al., 2011). EmbA and EmbB are responsible for elongation of the arabinan domain of 
AG (Escuyer et al., 2001, Alderwick et al., 2005), while EmbC is involved in the 
synthesis of LAM (Goude et al., 2008). Studies demonstrated that the EMB, a first line 
anti-TB drug, specifically inhibits AG biosynthesis with the precise molecular target 
being the embCAB locus in M. tuberculosis (Telenti et al., 1997). Disruption of these 
proteins leads to inhibition of mAGP synthesis and perhaps increased permeability of 
mycobacterial cell envelope (Telenti et al., 1997). Therefore, Emb proteins represent 
ideal targets for anti-TB drug development. Another recently published study has 
identified an in vivo interaction between GlfT1, responsible for initiating the 
polymerisation of the galactan domain of AG, and the small multi-drug resistance-like 
transporter Rv3789 (Larrouy-Maumus et al., 2012). It has been proposed that Rv3789 is 
involved in AG and LAM biosynthesis, where it translocates the DPA from the cytosol to 
the periplasmic space, enabling its utilisation by ArafTs, such as EmbA, EmbB and 




The closely related species M. smegmatis and C. glutamicum have proven useful as 
laboratory model organisms in the study of orthologues M. tuberculosis genes and 
proteins involved in mAGP synthesis (Alderwick et al., 2006, Seidel et al., 2007, Birch et 
al., 2008). Based on the use of pull-down assays and a bacterial two-hybrid system 
(BACTH) this study examines the construction of a protein-protein interaction network 
for the enzymes involved in the synthesis of AG, a major cell wall component in C. 
glutamicum. The pull-down binding assay is a relatively easy and straightforward 
technique to identify physical interactions between a tagged protein and its interacting 
partners in vitro. A tagged ‘bait’ protein is immobilised by the affinity of the ligand 
unique for the tag, followed by the incubation with the source of protein (e.g cell lysate or 
membrane preparation) that contains ‘prey’ proteins (Figure 1). Eluted protein complexes 
are then analysed by gel electrophoresis and mass spectrometry. BACTH, on the other 
hand, is based on the functional complementation between two fragments of the 
adenylate cyclase in vivo to restore cAMP signaling cascade in Escherichia coli  (Figure 
2) (Karimova et al., 1998). Importantly, BACTH is able to detect physical interactions 
between both cytoplasmic, as well as membrane proteins (Karimova et al., 2005, Maxson 
and Darwin, 2006, Hara et al., 2008, Karimova et al., 2009, Georgiadou et al., 2012). 
This is extremely useful, since many C. glutamicum cell wall glycosyltransferases are 
membrane proteins. 
In this study, we have identified twenty-four putative homotypic and heterotypic protein 
interactions in vivo. Our results demonstrate an association between glycosyltransferases, 
GlfT1 and AftB, and interaction between the sub-units of decaprenylphosphoribose 
epimerase, DprE1 and DprE2. These analyses have also show that AftB interacts with 




chain. Both AftA and AftB associate with other ArafTs, including Emb and AftC that 
elongate and branch the arabinan domain, respectively. Moreover, a number of proteins 
involved in AG biosynthesis were shown to form dimers or multimers. These findings 
provide a useful recourse for understanding the biosynthesis and function of the 





















Figure 1 Generalised scheme of a pull-down assay for detection of putative protein-
protein interactions. The purified ‘bait’ protein carrying a His6-tag is captured on 
agarose beads charged with Ni2+. The unbound protein is removed by a washing step and 
the lysate containing putative ‘prey’ proteins is incubated with immobilised ‘bait’. 
Several washing steps are performed to wash away the unbound or weakly bound 
proteins and possible protein-protein complexes are eluted with buffer containing 
increasing amounts of imidazole. Samples are analysed by 4-15 % SDS-PAGE and 






Figure 2 Organisation of Bordetella pertussis adenylate cyclase and principle of 
detecting protein-protein interactions using BACTH. The structure of adenylate 
cyclase domain is shown with T25 (1-224 residues) and T18 (225-399 residues) 
fragments colored in red and blue, respectively. A Expression of chimeric adenylate 
cyclase alone in E. coli cya- (BTH101) strain leads to residual cAMP synthesis. B 
Expression of individual T25 and T18 fragments results in lack of cAMP production. C If 
the hybrid proteins carrying T25 and T18 fragments interact, the adenylate cyclase 
domains are brought together and, thus, cAMP synthesis is restored. D BACTH method 
works for membrane or membrane associated proteins, providing that T25 and T18 
domains are facing the cytoplasm. The cAMP binds catabolite activator protein (CAP) 
and the complex regulates the expression of various genes, including lactose and maltose 
operons, which result in cya+ phenotype. Indicator plates (MacConkey/maltose, LB/X-
gal, and M63/maltose/X-gal) are used to identify positive interactions. Further, 
quantitative !-galactosidase assay is used to characterise the extent of protein-protein 





2.2 Materials and methods 
2.2.1 Construction of vectors overexpressing GlfT2 and AftA 
The pET28b-MSMEG_6403 expression vector was kindly donated by Dr. Talat Jabeen. 
Briefly, the coding region for GlfT2, annotated as MSMEG_6403, was amplified by PCR 
from M. smegmatis mc2155 genome using the primer pair: 5'-GA TCG ATC CATATG 
AGT GAC ATC CCT TCC GGC GCA CTC GAA-3' and 5'-GA TCG ATC CTCGAG 
TCA TCG TCC GAC TTT CTC CGG TGT CTC-3'. The PCR product was restricted 
with NdeI and XhoI enzymes and ligated into pET28b digested with identical enzymes, 
thus yielding pET28b-MSMEG_6403. The pET28b vector carries an N-terminal His6-tag 
sequence. The full length aftA (NCgl0185) was amplified from C. glutamicum ATCC 
13032 genomic DNA by PCR using forward 5'-CA TGC ATG CATATG ATG ATT 
AAC ACC TCT GAA G-3' and reverse 5'-CA TGC ATG GCGGCCGC CTC ATT GTG 
CGT TAC CAC CA-3' primers, where underlined nucleotides are NdeI and NotI 
restrictions sites, respectively. The purified DNA fragment was cloned into NdeI and 
NotI cutting sites of pMSX to express recombinant AftA tagged with His6 at its C-
terminus. DNA sequencing and construct verification was carried out at the Eurofins 
DNA Ltd. 
2.2.2 Pull-down detection of putative GlfT2 and AftA binding proteins 
In vitro binding assays were carried out by immobilising ‘bait’ proteins, pure His6-tagged 
GlfT2 or AftA, to Ni2+-NTA charged resin (Qiagen). The unbound protein was washed 
off with 20 ml purification buffer 50 mM KH2PO4 pH 7.9, 300 mM NaCl, 20 % glycerol 
and 50 mM KH2PO4 pH 7.9, 100 mM NaCl, 10% glycerol for GlfT2 and AftA, 




endogenous ‘prey’ proteins were incubated with immobilised GlfT2 and AftA proteins, 
respectively, and left to interact for 1 hour with gentle shaking at 4 °C. Two washing 
steps were performed with 20 ml purification buffer containing 50 mM imidazole to 
remove any unbound or weakly bound proteins. The possible protein complexes of GlfT2 
and AftA were eluted with 100-500 mM gradient of imidazole. Fractions were analysed 
by 4-15 % SDS-PAGE and Western blot using monoclonal anti-His6 antibody. 
2.2.3 Mass spectrometry and analysis of putative GlfT2 and AftA binding proteins 
Proteins were visualised on the SDS-PAGE gels by Coomassie blue staining as described 
in the General Materials and Methods 6.6.1. The intense bands or regions of interest were 
excised from the gels, reduced with 10 mM dithiothreitol (DTT), and subsequently 
alkylated with 75 mM iodoacetamide. Trypsin digestion of in-gel proteins was performed 
and extracted peptides were analysed by LC-MS/MS (Orbitrap Velos). MASCOT (Matric 
Science Ltd) protein search software together with NCBI database was employed to 
identify peptide sequences. 
2.2.4 Plasmid construction for BACTH analysis 
All recombinant DNA methods were performed using standard protocols. Briefly, the 
genes involved in C. glutamicum AG biosynthesis were amplified from genomic DNA of 
C. glutamicum ATCC 13032. The plasmids have been constructed by inserting gene 
sequences of interest in pKT25 (T25 fusion at N-terminus of the gene), pKNT25 (T25 
fusion at C-terminus of the gene), pUT18 (T18 fusion at C-terminus of the gene) and 
pUT18c (T18 fusion at N-terminus of the gene) (Karimova et al., 1998), using 
oligonucleotides provided in Table 1. Constructs were confirmed using DNA sequencing 




specific internal primers. The bacterial BACTH system kit was obtained from Euromedex 
and contained empty vectors together with positive control plasmids pKT25-zip and 
pUT18c-zip. Expressed T25-Zip and T18-Zip fusion proteins contain the leucine zipper 
region of yeast transcriptional activator GCN4. Dimerisation of leucine zipper motif 
results in reconstitution of adenylate cyclase domain and, sequentially, restoration of 
cAMP production.  
Table 1 Oligonucleotides used in this study. 







































































































aPlasmids contain the sequence generated by PCR amplification with the pair of primer on the right 
column 
bRestriction enzyme sites are underlined 
 
2.2.5 Bacterial two-hybrid system 
E. coli BTH101 cells were co-transformed with two plasmids (Table 2) expressing 
recombinant proteins bearing N- or C- terminal T25 and T18 fusions  as described in the 
General Materials and Methods 6.5.10. Cells were spread on LB plates containing 
streptomycin (100 µg/ml), ampicillin (100 µg/ml), kanamycin (50 µg/ml) and incubated 
at 30 °C for 48 hours. Several colonies were picked and used to inoculate 5 ml of LB 
supplemented with appropriate antibiotics and 0.5 mM IPTG to induce protein 
expression. Cultures were grown overnight at 30 °C with shaking. Samples were then 
washed three times in minimal M63 media and spotted (2 µl) onto LB, MacConkey or 






Table 2 Bacterial strains and plasmids used in this study. 
Plasmid or 
strain 
Description or genotype 





F-, cya-99, araD139, galE15, galK16, rpsL1 (Strr), hsdR2, mcrA1, 
mcrB1 strain 
pKT25 Cloning and expression vector, pSU40 derivative with T25 domain of 
CyaA, multiclonal sequence site (MCS) at the 3’ end of T25, Kanr 
pKNT25 Cloning and expression vector, pSU40 derivative with T25 domain of 
CyaA, MCS at the 3’ start of T25, Kanr 
pUT18 Cloning and expression vector, pUC19 derivative with T18 domain 
of CyaA, MCS at the 3’ start of T18, Ampr 
pUT18c Cloning and expression vector, pUC19 derivative with T18 domain 
of Cya, MCS at the 3’ end of T18, Ampr 
pKT25-zip Control plasmid, T25 domain of Cya fused in frame with leucine 
zipper of GCN4, Kanr 
pUT18c-zip Control plasmid, T18 domain of Cya fused in frame with leucine 
zipper of GCN4, Ampr 
pKT25-wecA pKT25 plasmid with cyaAT25-wecA fusion, Kanr 
pKNT25-wecA pKNT25 plasmid with wecA-cyaAT25 fusion, Kanr 
pUT18-wecA pUT18 plasmid with wecA-cyaAT18 fusion, Ampr 
pUT18c-wecA pUT18c plasmid with cyaAT18-wecA fusion, Ampr 
pKT25-wbbL pKT25 plasmid with cyaAT25-wbbL fusion, Kanr 
pKNT25-wbbL pKNT25 plasmid with wbbL-cyaAT25 fusion, Kanr 
pUT18-wbbL pUT18 plasmid with wbbL-cyaAT18 fusion, Ampr 
pUT18c-wbbL pUT18c plasmid with cyaAT18-wbbL fusion, Ampr 
pKT25-glfT1 pKT25 plasmid with cyaAT25-glfT1 fusion, Kanr 
pKNT25-glfT1 pKNT25 plasmid with glfT1-cyaAT25 fusion, Kanr 
pUT18-glfT1 pUT18 plasmid with glfT1-cyaAT18 fusion, Ampr 
pUT18c-glfT1 pUT18c plasmid with cyaAT18-glfT1 fusion, Ampr 
pKT25-glfT2 pKT25 plasmid with cyaAT25-glfT2 fusion, Kanr 
pKNT25-glfT2 pKNT25 plasmid with glfT2-cyaAT25 fusion, Kanr 
pUT18-glfT2 pUT18 plasmid with glfT2-cyaAT18 fusion, Ampr 
pUT18c-glfT2 pUT18c plasmid with cyaAT18-glfT2 fusion, Ampr 
pKT25-aftA pKT25 plasmid with cyaAT25-aftA fusion, Kanr 
pKNT25-aftA pKNT25 plasmid with aftA-cyaAT25 fusion, Kanr 
pUT18-aftA pUT18 plasmid with aftA-cyaAT18 fusion, Ampr 
pUT18c-aftA pUT18c plasmid with cyaAT18-aftA fusion, Ampr 
pKT25-aftB pKT25 plasmid with cyaAT25-aftB fusion, Kanr 
pKNT25-aftB pKNT25 plasmid with aftB-cyaAT25 fusion, Kanr 
pUT18-aftB pUT18 plasmid with aftB-cyaAT18 fusion, Ampr 
pUT18c-aftB pUT18c plasmid with cyaAT18-aftB fusion, Ampr 
pKT25-aftC pKT25 plasmid with cyaAT25-aftC fusion, Kanr 
pKNT25-aftC pKNT25 plasmid with aftC-cyaAT25 fusion, Kanr 
pUT18-aftC pUT18 plasmid with aftC-cyaAT18 fusion, Ampr 
pUT18c-aftC pUT18c plasmid with cyaAT18-aftC fusion, Ampr 




pKNT25-aftD pKNT25 plasmid with aftD-cyaAT25 fusion, Kanr 
pUT18-aftD pUT18 plasmid with aftD-cyaAT18 fusion, Ampr 
pUT18c-aftD pUT18c plasmid with cyaAT18-aftD fusion, Ampr 
pKT25-ubiA pKT25 plasmid with cyaAT25-ubiA fusion, Kanr 
pKNT25-ubiA pKNT25 plasmid with ubiA-cyaAT25 fusion, Kanr 
pUT18-ubiA pUT18 plasmid with ubiA-cyaAT18 fusion, Ampr 
pUT18c-ubiA pUT18c plasmid with cyaAT18-ubiA fusion, Ampr 
pKT25-dprE1 pKT25 plasmid with cyaAT25-dprE1 fusion, Kanr 
pKNT25-
dprE1 
pKNT25 plasmid with dprE1-cyaAT25 fusion, Kanr 
pUT18-dprE1 pUT18 plasmid with dprE1-cyaAT18 fusion, Ampr 
pUT18c-dprE1 pUT18c plasmid with cyaAT18-dprE1 fusion, Ampr 
pKT25-dprE2 pKT25 plasmid with cyaAT25-dprE2 fusion, Kanr 
pKNT25-
dprE2 
pKNT25 plasmid with dprE2-cyaAT25 fusion, Kanr 
pUT18-dprE2 pUT18 plasmid with dprE2-cyaAT18 fusion, Ampr 
pUT18c-dprE2 pUT18c plasmid with cyaAT18-dprE2 fusion, Ampr 
pKT25-emb pKT25 plasmid with cyaAT25-emb fusion, Kanr 
pKNT25-emb pKNT25 plasmid with emb-cyaAT25 fusion, Kanr 
pUT18-emb pUT18 plasmid with emb-cyaAT18 fusion, Ampr 
pUT18c-emb pUT18c plasmid with cyaAT18-emb fusion, Ampr 
 
2.2.6 !-Galactosidase assay 
Several colonies were picked from co-transformation plates and used to inoculate 5 ml 
LB supplemented with appropriate antibiotics and 0.5 mM IPTG to induce protein 
expression. Cultures were grown overnight at 30 °C with shaking. The liquid cultures 
were diluted 1:5 with M63 minimal media and the OD600 of each culture recorded. 
Bacterial cells were then permeabilised with 30 µl toluene and 30 µl 0.1 % SDS solution 
per 2.5 ml of diluted cell culture. The samples were vortexed for 30 seconds, lightly 
plugged with cotton wool and incubated at 37 °C with shaking for 45 minutes. 
Permeabilised cells (0.5 ml) were added to 0.5 ml of PM2 assay buffer (70 mM 
Na2HPO4"12H20, 30 mM NaH2PO4"H20, 1 mM MgSO4, 0.2 mM MnSO4 pH 7.0, 100 mM 
!-mercaptoethanol) and incubated at 28 °C for 5 minutes. A control tube containing 1 ml 




started with 0.25 ml 0.4 % o-nitrophenol-!-galactosidase (ONPG) and samples were 
incubated at 28 °C until the sufficient yellow color has developed. The reaction was 
stopped with 0.5 ml 1M Na2CO3. The OD420 and OD550 were then recorded for each 
sample. The !-galactosidase activity was calculated using the formula: 
! 
1 Miller unit =  1000 * (OD420 - (1.75 * OD550))
(t * v * OD600)
 
The values presented are the mean of 3 independent activity assays. 
2.2.7 Statistical analysis 
The results are expressed as the means ±S.D. and were analyzed using a Student’s t-test 
to determine significant differences (p<0.01) between samples. 
 
2.3 Results 
2.3.1 Network analysis of AG biosynthetic proteins 
We initially aimed to identify whether any of the proteins involved in AG biosynthesis 
have been predicted or demonstrated to interact as part of a multi-protein functional 
network. Focusing on the list of proteins associated with AG biosynthesis we used the 
STRING database of interactions (Szklarczyk et al., 2011) to reveal a putative protein 
association network with GlfT2 chosen as the network node (Figure 3). The interaction 
patterns of proteins had a high confidence score (>0.7) and served as a basis for selection 
of C. glutamicum proteins that were further analysed using either pull-down assays or 
BACTH. The generated network contained ABC family transporters (RfbD and RfbE), 




centered on GlfT2. Transmembrane ArafT Emb showed strong evidence for interaction 
with AftA and AftB, as well as the uncharacterised protein NCgl2596. The network also 
contained a putative phospholipid phosphatase NCgl2782 and proteins involved in DPA 
synthesis: DprE1, DprE2 and UbiA.  
 
Figure 3 Network of C. glutamicum proteins found to be important for cell wall 
assembly as determined by STRING 9.1 analysis. Lines connecting the nodes indicate 
various interaction data supporting the network, coloured by evidence type. Combining 
the probabilities from these different evidence channels, and then correcting for the 
probability of randomly observing an interaction STRING 9.1 database generates the 
confidence score. Gene number encoding respective proteins were used in the input and 
output, which were subsequently. Protein number encoding GlfT2 was used in the input 
resulting in the output data to contain the same nomenclature. For clarity, all protein 




2.3.2 Pull-down assay and detection of putative GlfT2 binding proteins from M. 
smegmatis 
A pull-down assay employing His6-tagged GlfT2 was performed in order to identify 
putative protein-protein interactions. Unfortunately, attempts to obtain highly purified C. 
glutamicum GlfT2 in soluble form were unsuccessful. Therefore, we employed standard 
pET expression system in E. coli BL21 (DE3) cells to over-express recombinant full-
length GlfT2 of M. smegmatis (Figure 4A). E. coli cells harbouring pET28b were grown 
to an early exponential phase and expression of MSMEG_6403 was induced with 1 mM 
IPTG at 16 °C. His6-tagged GlfT2 was purified by affinity chromatography and SDS-
PAGE analysis revealed an appreciable amount of protein at 200 mM, 300 mM, and 500 
mM imidazole fractions (Figure 4B). M. smegmatis GlfT2 migrated at the expected 
molecular weight – 72 kDa – and was estimated to be at least  >95% pure (Figure 4C).  
In the pull-down assay, purified GlfT2 was bound to the nickel affinity chromatography 
column followed by incubation with M. smegmatis clarified cell lysate. The column was 
subsequently washed with 50 mM imidazole to remove any non-bound or weakly bound 
components of the cell lysate. Proteins possibly interacting with GlfT2 were eluted along 
with GlfT2 using 250 mM imidazole and analysed by SDS-PAGE and Western blot 
(Figure 4D). To identify protein compositions in the SDS-PAGE gel, eight bands with 
high staining intensity were excised from the gel, digested with trypsin, and acquired 
tryptic peptides were analysed by LC-MS/MS. A parallel assay was performed lacking 
the GlfT2 protein and, hence, served as a negative control (Figure 4D). SDS-PAGE 
analysis demonstrated the absence of protein bands, thus reaffirming that eluted proteins 




In total, 33 distinct proteins were identified using Mascot algorithm against NCBI 
database (Table 3). Most of the detected proteins are involved in genetic information 
processing (27%). Additionally, six proteins are required for virulence, detoxification, 
and adaptation (18%), while the rest are involved in lipid metabolism (18%). Importantly, 
the essential GroEL2 molecular chaperone was identified in five out of nine analysed 
bands strongly suggesting an association with GlfT2. In mycobacteria, GroEL2 is 
proposed to provide a housekeeping chaperone function, where it promotes refolding and 
proper assembly of unfolded polypeptides and proteins (Stapleton et al., 2012). Thus, 
suggesting that over-expressed GlfT2 requires GroEL2 for appropriate folding. 
Moreover, Alderwick et al. (2008) have demonstrated that GlfT2 from M. tuberculosis 
requires chaperones for overexpression in E. coli. In addition, polyketide synthase Pks13 
and condensing enzyme KasA, both involved in mycolic acid biosynthesis, were also 
detected. Interactions between GlfT2 and enzymes involved in the assembly of mycolic 
acids are not surprising, since formation of large multi-protein complexes may enhance 
efficiency and fidelity of mAGP formation. Nevertheless, none of the identified proteins 





Figure 4 SDS-PAGE and Western blot analysis of M. smegmatis GlfT2 over-
expression, purification, and pull-down assay. A E. coli BL21 (DE3) cells were grown 
at 16 °C overnight and 1 mM IPTG was used to induce expression of MSMEG_6403. 
Lanes 2 and 3 correspond to crude and clarified cell lysates, respectively. B Recombinant 
GlfT2 with a polyhistidine tag was purified by nickel affinity chromatography column. 
Lanes 5, 6 and 7 correspond to elution fractions at 200 mM, 300 mM and 500 mM of 
imidazole, respectively. The arrows indicate the over-expressed GlfT2 protein. C Lanes 2 
(SDS-PAGE) and 3 (Western blot) correspond to purified GlfT2 fraction. D Pull-down 
assay where purified recombinant GlfT2 was used as a ‘bait’ and cell lysate of M. 
smegmatis served as a pool of ‘prey’ proteins. Lanes 5 (SDS-PAGE) and 7 (Western blot) 
represent the 250 mM imidazole elution fraction containing recombinant GlfT2 and co-
eluted proteins. Lanes 6 (SDS-PAGE) and 8 (Western blot) represent the 250 mM 
imidazole fraction, where GlfT2 protein was excluded from the affinity column and, 
therefore, served as a negative control. Samples were analysed by 4-15 % SDS-PAGE gel 
and stained with Coomassie Blue; the His-tagged GlfT2 was detected by Western blot 




Table 3 List of proteins that potentially form multi-protein complexes with GlfT2 from 
M. smegmatis identified in this study 
Banda Protein Description Scoreb Coveragec Peptidesd MW 
(kDa)e 
 GlfT2 galactofuranosyltransferase 252.31 61.92 46 71.53 
 Pks13 polyketide synthase 28.23 17.90 27 194.3 I 
 GroEL2 60kDa chaperonin 2 22.35 26.67 10 56.12 
 GlfT2 galactofuranosyltransferase 954.97 80.19 56 71.53 
 DnaK molecular chaperone protein 37.53 36.82 15 66.61 
 GroEL2 60kDa chaperonin 2 9.22 33.15 12 56.12 
II 
 MSMEG4474 acyl-CoA oxidase 6.60 8.28 5 70.45 
 GlfT2 galactofuranosyltransferase 221.14 65.94 43 71.53 
 GroEL2 60kDa chaperonin 2 108.28 51.85 28 56.12 
 RpsA 30S ribosomal protein S1 32.44 41.34 17 53.28 
 SppA signal peptide peptidase, 67K type 30.19 24.24 13 62.68 
 GroEL1 60kDa chaperonin 1 24.44 26.43 12 56.45 
 FadD15 AMP-binding enzyme 14.60 13.69 7 64.45 
 AccD4 propionyl-CoA carboxylase beta chain 10.64 14.12 5 56.13 
III 
 SdhA succinate dehydrogenase flavoprotein  6.06 8.73 5 64.35 
 GlfT2 galactofuranosyltransferase 203.09 61.76 39 71.53 
 FabG4 3-ketoacyl-(acyl-carrier-protein) reductase  101.31 65.78 24 46.47 
 FadA2 acetyl-CoA acetyltransferase 60.33 46.06 20 45.21 
 KasA 3-oxoacyl-(acyl carrier protein) synthase  48.24 48.56 13 43.76 
 RpoA DNA-directed RNA polymerase subunit  16.73 23.43 7 37.90 
 MSMEG4632 saccharopine dehydrogenase  12.09 33.41 10 43.61 
 Tuf translation elongation factor 11.76 24.75 8 43.71 
 DnaJ chaperone protein 10.69 23.36 5 40.31 
 AtpFH F0F1 ATP synthase subunit delta  8.98 22.02 8 47.42 
 ClpX ATP-dependent protease ATP-binding 
unit  8.98 26.06 
8 
46.65 
 CysS cysteinyl-tRNA synthetase  7.63 9.22 10 45.37 
 MSMEG2070 acyl-CoA dehydrogenase family protein  6.87 13.77 4 47.26 
 MSMEG6284 cyclopropane-fatty-acyl- synthase  6.53 22.65 5 48.61 
IV 
 GroEL2 60kDa chaperonin 2 6.10 21.85 7 56.12 
 GlfT2 galactofuranosyltransferase 82.97 50.46 30 71.53 
 MSMEG5117 proline dehydrogenase  14.11 31.23 9 35.40 
 GroEL2 60kDa chaperonin 2 8.32 7.41 4 56.12 
V 
 NudC NADH pyrophosphatase  7.55 16.40 5 34.12 
VI  GlfT2 galactofuranosyltransferase 31.88 40.87 21 71.53 
VII  GlfT2 galactofuranosyltransferase 26.03 40.87 20 71.53 
 GlfT2 galactofuranosyltransferase 53.91 34.21 24 71.53 
 RpsG 30S ribosomal protein S7  23.27 68.59 11 17.62 
 RplM 50S ribosomal protein L13  18.27 58.50 10 16.11 
 RplL 50S ribosomal protein L7/L12  17.52 46.92 6 13.45 
 RpsK 30S ribosomal protein S11  16.47 40.58 4 14.63 
 MSMEG4692 conserved hypothetical protein  10.58 57.96 5 15.89 
 HspX 14 kDa antigen 9.07 47.59 7 15.92 
 RplP 50S ribosomal protein L16 8.83 33.33 4 15.73 
 RplT 50S ribosomal protein L20  7.46 27.13 3 14.46 
VIII 
 MSMEG1077 conserved hypothetical protein 5.26 59.06 7 16.28 
IX  GlfT2 galactofuranosyltransferase 20.38 22.60 12 71.53 
a) number of excised SDS-PAGE gel band for protein identification; b) the Mascot score of protein 
identification; c) sequence coverage in % of the identified protein; d) number of identified unique peptides 
obtained for a particular protein; e) molecular weight in kDa of the respective protein. Yellow background 




2.3.3 Pull-down assay and detection of putative AftA binding proteins from C. 
glutamicum 
Recombinant full-length AftA from C. glutamicum was overexpressed in C. glutamicum 
ATCC13303. Cells previously transformed with pMSX-NCgl0185 were grown to an 
early exponential phase and expression of AftA with C-terminus His6 tag was induced 
using 1 mM IPTG at 16 °C. Notably, a high molecular weight (150 kDa and above) bands 
were observed in Westen blots of samples overexpressing C. glutamicum AftA, which 
may correspond to aggregated material (Figure 5A). However, it is tempting to speculate 
that this may be the evidence of multi-protein complex formation, where C. glutamicum 
AftA is forming a dimer or tetramer. AftA was purified by immobilised metal ion 
exchange chromatography and eluted fractions were analysed by SDS-PAGE. Protein 
bands of weak intensity were obtained at the expected size of 74.1 kDa at 100-200 mM 
imidazole fractions (Figure 5B). The purity of C. glutamicum AftA preparation was 
estimated to be greater than 95% (Figure 5C).  
A pull-down assay was performed employing purified AftA in order to identify its 
interacting partners. Immobilised AftA was incubated with C. glutamicum clarified 
lysate, washed with 50 mM imidazole, and ‘prey’ proteins bound to AftA were eluted 
with 500 mM imidazole (Figure 5D). Samples were subjected to SDS-PAGE analysis, 
major bands of possible protein complexes excised from the gel (I-VIII, Figure 5D), 
digested with trypsin, and analysed by LC-MS/MS. The negative pull-down control 
assay, excluding AftA as the ‘bait’, was performed analogously (Figure 5D). SDS-PAGE 
analysis demonstrated bands of weak intensity in the elution fraction, possibly 
represented by proteins that bound to the nickel affinity chromatography column either in 




nature of these bands when compared to the pull-down assay fraction, these were 
considered insignificant.  
Subsequent analysis using Mascot algorithm against NCBI database identified a list of 
proteins that potentially interact with AftA. The summary containing significant hits 
(score > 25, coverage > 20) and proteins associated with cell envelope biosynthesis is 
presented in Table 4. Proteins involved in the assembly of PG, notably MurA, MurC and 
MurG, were identified. Moreover, GalE epimerase and RfbE ABC transporter that play a 
role in UDP-Galf donor formation and transportation of cell wall lipopollysaccharides, 
respectively, were also observed. Importantly, five proteins involved in AG biogenesis 
were identified: GlfT2 GafT, AftD ArafT, DprE1 and DprE2, as well as decaprenyl-
phosphate phosphoribosyltransferase UbiA. These latter proteins were selected for further 






Figure 5 SDS-PAGE and Western blot analysis of C. glutamicum AftA over-
expression, purification, and a pull-down assay. A C. glutamicum cells were grown at 
16 °C overnight and 1 mM IPTG was used to induce expression of NCgl0185. Lanes 2 
(SDS-PAGE) and 4 (Western blot) represent the crude cell lysate of C. 
glutamicum::pMSX-NCgl0185, while lanes 3 (SDS-PAGE) and 5 (Western blot) 
correspond to clarified cell lysate. B Recombinant AftA with a His6-tag was purified by 
affinity chromatography. Lanes 7, 8 and 9 correspond to elution fractions at 100 mM, 150 
mM and 200 mM of imidazole, respectively. Note that due to the low amount of protein it 
is difficult to detect AftA in elution fractions. The arrows indicate the over-expressed 
AftA protein. C Pull-down assay employing recombinant AftA, where purified AftA was 
a ‘bait’ and membrane fraction preparation of C. glutamicum served as a pool of ‘prey’ 
proteins. Lanes 2 (SDS-PAGE) and 3 (Western blot) represent purified AftA fraction 
used in the assay. D Lanes 5 (SDS-PAGE) and 7 (Western blot) represent the 500 mM 
imidazole fraction containing recombinant AftA and co-eluted proteins. Lanes 6 (SDS-
PAGE) and 8 (Western blot) represent the 500 mM imidazole fraction, where AftA 
protein was excluded from the affinity column and, therefore, served as a negative 
control. Samples were analysed by 12 % SDS-PAGE gel and stained with Coomassie 





Table 4 List of proteins that potentially form multi-protein complexes with AftA from C. 
glutamicum identified in this study. 
Banda Protein Description Scoreb Coveragec Peptidesd MW 
(kDa)e 
GlgB glycogen branching enzyme 288.6 33.65 28 82.54 
NCgl0634  monomeric isocitrate dehydrogenase  104.1 41.73 30 80.03 
NCgl0104 acyl-CoA synthetase 94.75 37.57 26 75.41 
NCgl2859 cation transport ATPase 94.01 32.34 22 77.37 
DnaK molecular chaperone  91.37 54.05 36 66.25 
NCgl1471 methylmalonyl-CoA mutase 67.93 31.75 25 80.06 
NCgl2765 phosphoenolpyruvate carboxykinase 63.25 33.44 21 66.83 
NCgl1590 guanosine polyphosphate synthetase 56.48 38.16 38 84.39 
NCgl1053 membrane GTPase  55.74 33.44 26 68.66 
GlfT2 galactosyltransferase 52.03 38.57 26 72.93 
AftA arabinosyltransferase 36.86 19.52 11 72.52 
I 
Fas-IB fatty-acid synthase  30.55 12.39 38 314.9 
GorEL 60 kDa molecular chaperone 590.8 49.63 39 56.71 
ArgS arginyl-tRNA synthetase  125.8 52.36 24 59.69 
NCgl1165 F0F1 ATP synthase subunit beta  74.99 41.61 18 52.51 
NCgl2294 ABC-type transport systems  74.92 28 12 57.67 
AftA arabinosyltransferase 69.93 21.63 12 72.52 
AtpA F0F1 ATP synthase subunit alpha  69.01 45.16 27 58.71 
NCgl1233 hypothetical protein 67.22 29.59 23 67.15 
SerA phosphoglycerate dehydrogenase 63.81 50.38 21 55.27 
GlgB glycogen branching enzyme  56.81 28.59 18 82.54 
NCgl0578 inositol dehydrogenase  55.19 49.8 27 53.33 
PrpD propionate catabolism protein 54.66 32.74 19 55.36 
II 
GlfT2 galactosyltransferase 19.22 27.13 18 72.93 
GroEL 60 kDa molecular chaperone 267.8 48.7 33 56.71 
NCgl0461 putative regulatory protein 132.1 49.6 26 55.71 
AmyE ABC-type transporter 127.7 36.79 17 49.42 
ActA Acetyl-CoA hydrolase 99.85 33.53 20 55.91 
MgtE Mg/Co/Ni transporter 97.17 47.91 22 47.29 
NCgl0622 flotillin-like protein  84.30 56.74 33 49.72 
GlgB glycogen branching enzyme  65.64 29 20 82.54 
DprE1 decaprenylphosphoryl-beta-D-ribose 
2'-oxidase 
62.59 32.17 15 53.03 
AftA arabinosyltransferase 52.51 20.12 11 72.52 
MurC UDP-N-acetylmuramate-L-alanine 
ligase 
36.31 20.58 9 51.08 
III 
GlfT2 galactosyltransferase 14.89 29.73 20 72.93 
NCgl2383 hypothetical protein 233.0 54.06 20 42.33 
NCgl2377 ABC-type transporter 101.9 51.86 23 40.29 
GroEL 60 kDa molecular chaperone 92.49 39.96 22 56.71 
IspG 1-hydroxy-2-methyl-2-(E)-butenyl 4-
diphosphate synthase 
90.09 57.41 20 40.04 
NCgl1526 glyceraldehyde-3-phosphate 
dehydrogenase  
73.59 39.22 13 36.02 
PfkA phosphofructokinase  70.40 46.94 16 37.06 








GlgB glycogen branching enzyme  24.27 20.66 13 82.54 
LpqI beta-N-acetylglucosaminidase-like 
protein 
4.76 13.92 5 41.53 
 
AftD arabinosyltransferase 2.06 3.97 3 108.1 
PfkA 6-phosphofructokinase  195.8 63.85 27 37.06 
NCgl2383 hypothetical protein 103.1 55.33 19 42.33 
GroEL 60 kDa molecular chaperone 90.57 47.03 28 56.71 
RpsB 30S ribosomal protein S2 62.71 55.51 18 30.10 
AdhA alcohol dehydrogenase  62.50 27.83 10 36.79 
NCgl0347 glycosyltransferase  55.96 53.91 18 38.81 
GlgB glycogen branching enzyme  39.93 25.03 16 82.54 
GalE UDP-glucose 4-epimerase 36.45 29.48 9 35.24 
MurG UDP-N-acetylglucosamine:LPS N-
acetylglucosamine transferase  
29.62 34.68 15 38.44 
AftA arabinosyltransferase 12.13 9.23 5 72.52 
GlfT2 galactosyltransferase 2.31 17.23 12 72.93 
V 
RfbE ABC-type transporter 1.86 21.67 6 28.66 
PimT SAM-dependent methyltransferase 218.0 65.47 21 31.14 
GroEL 60 kDa molecular chaperone 109.0 45.35 28 56.71 
NCgl2487 
histone acetyltransferase HPA2-like 
protein 80.00 46.58 17 32.11 
NCgl2156 Zn-ribbon protein  62.37 50.21 16 26.12 
NCgl2383 hypothetical protein 53.34 43.91 13 42.33 
PfkA 6-phosphofructokinase  52.08 51.31 16 37.06 
DprE2 decaprenylphosphoryl-D-2-keto 
erythro pentose reductase 
41.83 45.06 12 26.71 
GluB glutamate ABC-type transporter 34.06 14.92 4 31.65 
NCgl1179 ABC-type transporter 32.39 37.2 10 32.31 
NCgl0353 glycosyltransferase  22.99 46.35 18 31.36 
AftA arabinosyltransferase 14.55 12.1 7 72.52 
GlfT2 galactosyltransferase 6.91 30.03 9 35.28 
DprE1 decaprenylphosphoryl-beta-D-ribose 
2'-oxidase 
6.37 11.48 4 53.03 
VI 
RfbE ABC-type transporter 2.31 22.05 7 28.66 
RplC 50S ribosomal protein L3  85.60 61.93 20 23.15 
NCgl1242 SAM-dependent methyltransferase  84.25 28.86 8 21.92 
GroEL 60 kDa molecular chaperone 83.15 45.35 26 56.71 
NCgl0811 inositol monophosphatase family 
protein  
81.90 43.65 11 27.26 
RplD 50S ribosomal protein L4  77.76 60.55 17 23.59 
RpsC 30S ribosomal protein S3 73.26 76.21 28 28.09 
NCgl2383 hypothetical protein  63.69 45.69 14 42.33 
NCgl1065 Rossmann fold nucleotide-binding 
protein  
56.46 49.22 18 28.67 
NCgl0286 cAMP-binding domain-containing 
protein  
54.14 62.56 17 24.97 
AmyE ABC-type transporter 37.30 21.9 10 49.42 
AftA arabinosyltransferase 32.98 17.85 10 72.52 
NCgl0319 glycosyltransferase  24.48 47.46 13 26.31 
RfbE ABC-type transporter 22.89 40.3 13 28.66 








 DprE1 decaprenylphosphoryl-beta-D-ribose 
2'-oxidase 
2.33 20.7 8 53.03 
NCgl2607 inorganic pyrophosphatase  92.53 60.13 14 17.89 
RplF 50S ribosomal protein L6  83.58 66.85 15 19.32 
GroEL 60 kDa molecular chaperone 82.80 45.91 28 56.71 
RpsG 30S ribosomal protein S7  76.86 85.16 17 17.47 
NCgl2383 hypothetical protein 73.63 49.24 15 42.33 
SmpB SsrA-binding protein  44.75 45.73 15 18.99 
AtpF F0F1 ATP synthase subunit B 44.59 40.43 13 21.08 
UreE urease accessory protein  43.02 49.04 9 17.63 
RplJ 50S ribosomal protein L10 42.99 61.4 15 17.95 
RplC 50S ribosomal protein L3  34.59 63.3 17 23.15 
RplB 50S ribosomal protein L2  33.35 58.93 16 31.11 
VIII 
AftA arabinosyltransferase 21.83 18 11 72.52 
a) number of excised SDS-PAGE gel band for protein identification; b) the Mascot score of protein 
identification; c) sequence coverage in % of the identified protein; d) number of identified unique peptides 
obtained for a particular protein; e) molecular weight in kDa of the respective protein. Yellow background 
indicates proteins that are involved in the biosynthesis of cell wall that were identified in the assay. 
 
 
2.3.4 Bacterial two-hybrid analysis of AG proteins  
To characterise the physical interactions between components of the C. glutamicum cell 
wall biosynthetic machinery, the following full-length proteins listed in Table 5, were 
tested systematically for pair-wise interactions using BACTH. Each protein was fused to 
the fragment of the catalytic domain of chimeric adenylate cyclase (T25 or T18) of 
Bordetella pertussis at either the C- or N-terminus. Interaction between two hybrid 
proteins leads to reconstitution of the fragments of adenylate cyclase resulting in 
restoration of cAMP production in a E. coli cya mutant (Figure 2) (Karimova et al., 
1998). The resulting cAMP forms a complex with the catabolite activator protein and 
binds to various promoters, thus regulating transcription of several genes, including the 
lactose and maltose operons. The activation of these operons can be detected on selective 
agar plates or using a !-galactosidase assay. Importantly, this bacterial two-hybrid system 




transmembrane or membrane associated proteins (Baulard et al., 2003, Clarke et al., 
2009).  




Despite several attempts, we did not succeed in generating pKT25 and pUT18 derivatives 
expressing UbiA and AftD proteins, respectively. This is probably due to the toxicity of 
hybrid proteins to bacterial cells when expressed at high levels, which is especially true 
of membrane proteins. Moreover, the UbiA-T18N and UbiA-T18C hybrid proteins, when 
co-expressed with several other hybrid proteins, reduced bacterial growth suggesting that 
UbiA production in large quantities is toxic to E. coli cells.  
To examine putative interactions between the hybrid proteins, E. coli BTH101 cells were 
co-transformed with pairs of recombinant plasmids Table 2. In total, 577 pairs were 
screened for protein-protein interactions in vivo. All co-transformants, together with the 
positive and negative controls, containing either pKT25-zip/pUT18c-zip or empty 
pKT25/pUT18, were then spotted onto selective agar plates and the colouration of the 
Protein Predicted topology Function 
WecA transmembrane UDP-GlcNAc-1-phosphatetransferase 
WbbL soluble #-3-L-rhamnosyltransferase 
GlfT1 soluble UDP-galactofuranosyltransferase 
GlfT2 soluble UDP-galactofuranosyltransferase 
AftA transmembrane arabinofuranosyltransferase 
AftB transmembrane arabinofuranosyltransferase 
AftC transmembrane arabinofuranosyltransferase 
AftD transmembrane arabinofuranosyltransferase 
Emb transmembrane arabinofuranosyltransferase 
DprE1 soluble decaprenylphosphoryl-#-D-ribose 2'-oxidase 
DprE2 soluble decaprenylphosphoryl-D-2-keto erythro  
pentose reductase 





colonies were observed after 48 hours of growth at 30 °C. In the absence of association 
between T25 and T18 fragments colonies appear white, whereas they are blue or red 
when functional complementation occurs. The results of this protein-protein interaction 
study are summarised in Table 6 whilst representative plates from the screening are 
shown in Appendix (Figure 1-13). The efficiency of functional complementation between 
T25 and T18 domains was quantified by measuring !-galactosidase activity of each 
resultant strain. Ultimately, 50 pairs of hybrid proteins resulted in a positive signal 
representing 24 putative homotypic and heterotypic protein-protein interactions.  
2.3.5 Self-association of C. glutamicum cell wall biosynthesis proteins 
Among all the tested proteins, dimerisation or multimerisation of WecA, GlfT1, GlfT2, 
AftA, AftB, AftC, DprE1, and DprE2 have been demonstrated employing BACTH. Co-
expression of transmembrane WecA-T25C and WecA-T18C hybrid proteins restored a 
cya+ phenotype and synthesis of cAMP in the E. coli cells, resulting in blue and red 
colonies on LB/M63-Xgal and MacConkey media, respectively (Appendix, Figure 1). 
The !-galactosidase assay revealed a significant increase in !-galactosidase activity (487 
± 47 Miller units) when compared to the negative control (86 ± 11 Miller units), 
containing empty pKT25, pKNT25, pUT18, and pUT18c plasmids (Appendix, Figure 1). 
Importantly, the transmembrane fusions have to be correctly inserted into the plasma 
membrane with the T18 and T25 domains facing the cytoplasm in order an interaction to 
be detected, therefore, suggesting that the C- terminus of GlcNAc-1-phosphate 
transferase WecA is cytoplasmic. This is in agreement with the predicted topology of 
WecA (Amer and Valvano, 2001). Physical self-dimerisation or multimerisation in vivo 
was also demonstrated for GlfT1 and GlfT2. Consistently, GlfT1-T25N and GlfT1-T18C, 




T18C, and GlfT2-T25C and GlfT2-T18N hybrids restored lac+ and mal+ phenotypes and 
resulted in significant !-galactosidase activity ranging from 266 ± 69 to 679 ± 118 Miller 
units (Appendix, Figure 1). Recently, the structure of the polymerising GlfT2 orthologue 
in M. tuberculosis has been solved revealing its assembly as a homotetramer (Wheatley et 
al., 2012), thus supporting the results obtained in this BACTH study.  
Transmembrane AftA, AftB and AftC, proteins also tested positive for self-association. 
Co-expression of AftA-T25N and AftA-T18N, AftB-T25N and AftB-T18N, AftC-T25C and 
AftC-T18C combinations yielded !-galactosidase activity of 714 ± 92, 1185 ± 265, and 
398 ± 23 Miller units, respectively (Appendix, Figure 2). The C-terminal region of AftA 
and AftB is predicted to face the periplasm (Alderwick et al., 2006, Seidel et al., 2007), 
therefore the lack of interaction between fusion pairs carrying C-terminal T25 or T18 
fragment was expected and supported by this study. In addition, BACTH experiments 
propose that the N- termini of AftA and AftB are cytoplasmic. In contrast to AftA and 
AftB, AftC is characterised by the absence of a periplasmic C- terminal extension (Birch 
et al., 2008). Hence it is unsurprising that multimerisation of AftC is observed with the 
fusion proteins tagged at the C- terminus. Interestingly, no evidence for 
homodimerisation could be obtained for Emb and AftD. Finally, DprE1 and DprE2, both 
involved in DPA synthesis, appeared positive for self-interaction. DprE1-T25N and 
DprE1-T18C, DprE1-T25C and DprE1-T18N fusions, as well as all four pairs of hybrid 
proteins co-expressing DprE2 led to a strong lacZ induction (ranged between 291 ± 33 





Table 6 Protein-protein interactions between C. glutamicum AG biosynthetic proteins 
determined by BACTH. 
 
2.3.6 In vivo interaction network among AG proteins 
Next, we examined the interactions between different proteins involved in AG 
biosynthesis. Our results indicate that in addition to homodimerisation, WecA is also able 
to interact with multiple partners of AG biosynthesis Table 6. WecA-T18C, when co-
expressed with AftB-T25N, AftC-T25C, Emb-T25N, and UbiA-T25C yielded significant !-
galactosidase activities 1082 ± 268, 1047 ± 186, 1346 ± 217, and 1018 ± 137 Miller units, 
respectively (Appendix, Figure 4-5). BACTH also revealed an interaction with the 
rhamnosyltransferase WbbL, when UbiA hybrids were used as the ‘bait’. Co-
transformation of either WbbL-T18C or WbbL-T18N together with UbiA-T25C led to a 
restoration of cAMP cascade with !-galactosidase activities of 1094 ± 93 and 1195 ± 78 
Miller units, respectively (Appendix, Figure 5). Our studies have demonstrated the 
physical interaction between GlfT1 and AftB (Appendix, Figure 6), as well as the DprE2 
involved in DPA formation (Appendix, Figure 7). Recent studies reported the physical 
interaction between GlfT1 and Rv3789, a small multidrug resistance-like transporter 
(Larrouy-Maumus et al., 2012). Rv3789 was proposed to target and stabilise membrane 




evidence for a physical interaction between UbiA and AftA-T25N (387 ± 22 Miller units) 
(Appendix, Figure 8), AftB-T25N (1015 ± 185 Miller units) (Appendix, Figure 10) and 
AftC- T25C (755 ± 118 Miller untis) (Appendix, Figure 12), responsible for the 
biosynthesis of the arabinan domain of AG. Most of these ArafTs could also establish 
multiple interactions with each other. AftA, which primes the galactan chain of AG, 
associated with Emb, AftC and AftB (Appendix, Figure 7-9). In addition, AftB also 
interacted with Emb and AftC hybrid proteins (Appendix, Figure 10-11). Finally, C. 
glutamicum DprE1 was also found to strongly interact with DprE2 as a heterodimer. 
DprE1-DprE2 association has been identified with seven different plasmid combinations 
resulting in a significant !-galactosidase activity ranging between 637 ± 52 and 1027 ± 
86 Miller units (Appendix, Figure 13). Previous studies reported that orthologues of 
DprE1 and DprE2 in M. tuberculosis were able to catalyse the epimerisation reaction in 
vitro, however, neither protein alone was sufficient to support this activity (Larrouy-
Maumus et al., 2012). Thus, strongly suggesting that DprE1 and DprE2 work in concert 
to catalyse the conversion of DPR to DPA. However, when the same M. tuberculosis 
orthologues were experimentally tested for interaction using BACTH, co-transformants 
yielded negative results (Larrouy-Maumus et al., 2012).  
2.3.7 Verification of recombinant protein expression  
Importantly, lack of lacZ induction might be a result of plasmid instability, insoluble or 
dissipating fusions, and not the lack of direct physical interaction. In order to determine 
whether the hybrid proteins are expressed appropriately for protein-protein interactions to 
be detected, Western blot analysis using antibodies against T25 and T18 fragments was 
performed. Single expression studies of hybrid proteins fused to T18 domain proved the 




GlfT1-T18N (53 kDa), GlfT1-T18C (53 kDa), GlfT2-T18N (92 kDa), GlfT2-T18C (92 
kDa), DprE1-T18N (71 kDa), DprE1-T18C (71 kDa), DprE2-T18N (45 kDa), DprE2-T18C 
(45 kDa), UbiA-T18N (54 kDa), WbbL-T18N (50 kDa), and WbbL-T18C (50 kDa) 
proteins (Figure 6). Emb-T18N (141 kDa), AftB-T18C (94 kDa), and WecA-T18C (58 
kDa) fusion proteins were all expressed and detected by a Western blot, however, their 
determined molecular weight was lower than expected, possibly due to degradation or the 
hydrophilic nature of these proteins. We have also observed lack of expression of AftA-
T18C, AftD-T18N, Emb-T18C, UbiA-T18C, AftC-T18C, AftC-T18N, and WecA-T18N.  
 
Figure 6 Single expression of hybrid proteins fused with T18 fragment as 
determined by Western blot analysis. A, B, and C Samples were analyzed by 12 % 
SDS-PAGE gel; fusions with T18 fragments were detected by Western blot analysis 
using monoclonal CyaA 3D1 antibody.  










































































































































Single expression studies of hybrid proteins fused to T25 fragment led to very low levels 
of protein expression that were undetectable on a Western blot (Figure 7A). This is 
perhaps a result of different replication origins, p15A of pKT25 and pKNT25 plasmids 
(low copy number), compared to ColE1 in pUT18 and pUT18c plasmids (high copy 
number), thus resulting in production of poor amounts of T25 tagged proteins. In 
addition, we have investigated the co-expression of GlfT2 recombinant proteins (Figure 
7B). Protein pairs (GlfT2-T25C and GlfT2-T18N; GlfT2-T25N and GlfT2-T18C), which 
were identified as interacting, showed expression and accumulation of both T25 and T18 
fused proteins. However, in the samples where negative interactions were observed, only 
T18 tagged protein production was detected (Figure 7B). This could be explained by the 
positive feedback loop triggered by cAMP/CAP complex (Figure 7C). Hybrid protein 
expression is induced using IPTG, however, cAMP/CAP complex facilitates lactose 
operon induction. Therefore, positive protein-protein interaction significantly increases 
cAMP levels, which results in a contribution to the promoter activation and sequentially 





Figure 7 Expression of GlfT2 fusions as determined by Western blot analysis. A 
Single-expression studies of GlfT2 hybrid proteins. B Co-expression studies of GlfT2 
hybrid proteins. C An interaction between proteins restores cAMP production, which 
results in a positive feedback loop – expression of lactose and maltose operons (Adapted 
from Battesti and Bouveret, 2012 with permission). Samples were analyzed by 12 % 
SDS-PAGE gel; the Glft2 hybrids fused with T25 and T18 fragments were detected by 
Western blot analysis using polyclonal CyaA b-300 and monoclonal CyaA 3D1 





The majority of bacterial polysaccharides important for maintaining cell structure and 
viability are built on a carrier lipid in the cytosolic side of the plasma membrane. 
Although it is not fully clear how and when these polymers are translocated to the 
periplasm, one could speculate that anchoring these macromolecules to the membrane, 
positions them closely to the transporters and glycosyltransferases, therefore promoting 
productive export across the plasma membrane. Formation of multi-protein complexes, 




is expected to be beneficial for the bacterial cell, since the tight arrangement of the 
biosynthetic reactions would retain productivity and accuracy of the polymerisation 
process.  
We have demonstrated that proteins responsible for the formation of the AG linker unit, 
WecA and WbbL, form a complex with decaprenylphosphoryl-5-phosphoribose synthase 
UbiA at the cytoplasmic membrane (Figure 8). WecA and UbiA directly employ 
decaprenyl-phosphate for the linker unit and DPPR formation, respectively (Mikusova et 
al., 1996, Mikusova et al., 2005, Huang et al., 2008). Proximal interactions between 
WecA, WbbL and UbiA could perhaps facilitate synchronised utilisation of decaprenyl-
phosphate for coordinated AG biosynthesis. In addition, UbiA show evidence for 
physical interaction between AftA, AftB and AftC proteins, which employ DPA as a 
substrate (Figure 8). It is possible that this multi-protein complex formation assists a 
mechanism similar to substrate channeling, where intermediary metabolic products of one 
enzyme are passed directly to another enzyme. Other DPA forming proteins, DprE1 and 
DprE2, showed evidence for a physical interaction. Interestingly, while both DprE1 and 
DprE2 are required for the epimerisation reaction, there is evidence that C. glutamicum 
NCgl1429 may play a similar function to DprE2 (Meniche et al., 2008). Investigation 
into potential DprE1-NCgl1429 complexes could provide insight into this gene 
redundancy. Notably, GT-A glycosyltransferases GlfT1 and GlfT2 showed evidence for 
homodimerisation using BACTH. GlfT1 transfers the first two Galf residues to the linker 
unit, whereas GlfT2 is responsible for addition of approximately 30 Galf residues in a 
linear chain (Kremer et al., 2001, Mikusova et al., 2006, Alderwick et al., 2008, 
Belanova et al., 2008). The recent crystal structure of M. tuberculosis GlfT2 and in 




Finally, AftA, AftB, AftC and Emb proteins involved in the assembly of arabinan domain 
in AG, indeed form a multi-protein complex at the cytoplasmic membrane (Figure 8). 
One could speculate that such a sophisticated complex would maintain the efficiency and 
fidelity of AG polymerisation.  
 
Figure 8 An interaction network of C. glutamicum proteins involved in AG 
biosynthesis. Graph was generated using yEd graph editor software. The circular arrows 
indicate self-association. 
BACTH is a powerful technique for the investigation of protein-protein associations, 
however, several important notes should be highlighted regarding the significance of the 
interaction data obtained from BACTH. Firstly, the lack of cAMP production might be a 
direct result of hybrid proteins being expressed inappropriately or not expressed at all. 
We could not analyse the co-expression of all the protein pairs, which were identified as 
non-interacting due to large quantity of samples. Therefore, the hybrid proteins that test 
negative for interactions may still interact in vivo. Moreover, since the output of the 
interaction – cAMP – requires to be generated in the cytoplasm, these negative results 
may also result from the incorrect topological orientation of functional T25 and T18 




overexpressed when compared to the expression levels of native cells. Under these 
conditions, BACTH could have revealed a number of weak interactions between AG 
biosynthetic proteins. Although such associations would not take place at low protein 
concentrations, they can still occur when AG is being synthesised, where the local 
concentrations of proteins should be significantly higher. Finally, it is possible that some 
of the identified interactions are a consequence of a non-specific interactions initiated by 
endogenous E. coli host proteins that act as a tethering agent. These indirect associations, 
caused by a third protein, cannot be simply rejected. 
In conclusion, our findings here suggest that enzymes involved in C. glutamicum cell 
wall assembly and precursor formation form complicated multi-protein complexes. We 
have identified 24 interactions in vivo between 12 proteins responsible for AG 
biosynthesis using BACTH. The challenge for the future will be to discover precisely 
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3 Molecular and biochemical characterisation of AftA and AftB 
arabinosyltransferases from Corynebacterineae 
3.1 Introduction 
The thick, carbohydrate and lipid rich cell wall with distinct lipoglycans enables M. 
tuberculosis to survive under hostile conditions, such as shortage of nutrients and 
antimicrobial exposure. The key features of this highly complex cell wall are the mAGP 
complex and phospatidyl-myo-inositol derived lipoglycans with potent 
immunomodulatory properties, notably LM and LAM. These structures are crucial for the 
growth, viability, and virulence of M. tuberculosis and therefore, are often the targets of 
effective chemotherapeutic agents against TB.  
Mycobacterial LAM is generated by elaborating LM with 55 to 70 Araf units forming an 
arabinan domain similar to that found in AG (Besra and Brennan, 1997). It is speculated 
that a yet uncharacterised ArafT primes LM for LAM synthesis. Further transition occurs 
by addition of 12 to 16 !(1"5)-Araf residues to the primed LM, a reaction exclusively 
catalysed by EmbC possessing !(1"5) activity (Shi et al., 2006, Goude et al., 2008, 
Alderwick et al., 2011). The linear arabinose polymer of LAM is branched similarly to 
AG by addition of !(1!3)Araf residues employing AftC, resulting in 3,5 Araf branch 
points (Birch et al., 2008, Birch et al., 2010). Recently, AftD was designated as a second 
enzyme with !(1!3) ArafT activity (Skovierova et al., 2009). In vitro assays using 
neoglycolipid acceptors and cell-free extracts from M. smegmatis showed that the 
enzyme was able to add !(1!3) Araf residues to the linear !-1,5-linked acceptor, 
resulting in branching of the linear arabinan. Therefore, its function is considered similar 
to that of AftC. The branched arabinose motif of LAM is further modified to either a 
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tetra-arabinoside or a hexa-arabinoside motif. The terminal #(1!2) Araf residues present 
in both tetra- and hexa-motifs are perhaps added by AftB (Rv3805c), which may have a 
dual functionality and play a role in both AG and LAM biosynthesis.  
A priming enzyme AftA has been identified in Corynebacterianeae as that attaches 
arabinose residues to the galactan chain of AG at 8th, 10th and 12th positions (Alderwick et 
al., 2006, Shi et al., 2008). The chromosomal region of aftA includes dprE1 (Rv3790) and 
dprE2 (Rv3791), which collectively encode a decaprenylphosphoryl-5-phosphoribose 
(DPPR) epimerase, and are responsible in generating the sugar donor DPA. Although, the 
function of AftA in AG biosynthesis has been defined in both M. smegmatis and C. 
glutamicum, its involvement in LAM biosynthesis remains unknown. The aftB locus of 
M. tuberculosis consists of UDP-Galp mutase Glf and the known GlfT1. Just upstream 
aftB is located ubiA, which encodes the decaprenylphosphoryl-5-phosphoribose (DPPR) 
synthase. The fbpA and fbpD genes are located downstream of aftB, and encode 
mycolyltransferases that decorate the terminal arabinan residues with mycolates (Belisle 
et al., 1997, Kremer et al., 2002). The essentiality of aftB is implied by its conservation 
within Corynebacterianeae, including all Mycobacterium and Corynebacterium species 
(Seidel et al., 2007a).  
In mycobacteria, biosynthesis of essential cell wall structures, including PG, AG, and 
LM/LAM, are mediated by different glycosyltransferases. These enzymes catalyse the 
transfer of a sugar residue to various targets forming glycosidic bonds. Three main 
glycosyltransferase superfamilies have been established based upon their protein fold; (i) 
a nucleoside-diphosphosugar transferase (GT-A) family that is characterised by a 
conserved DxD motif; (ii) GT-B family also known as GPGTF family, and (iii) a GT-C 
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family of integral membrane proteins with a modified DxD signature (Liu and 
Mushegian, 2003). Examples of GT-C family enzymes are found in all eukaryotes, but 
are missing from archaea, and are uncommon in prokaryotes with an exception of 
mycobacteria and related species of the order Actinomycetales. Whilst proteins belonging 
to both GT-A and GT-B are globular in nature, the GT-C family enzymes are large 
hydrophobic glycosyltransferases that are presented in the cell as transmembrane or 
membrane associated proteins with 8 to 13 predicted multiple transmembrane domains. 
The conserved element in this family is a modified DxD sequence (e.g., DxE, ExD, DDx, 
DEx, or EEx) typically located in the first or second extracytoplasmic loop and a long C-
terminal region directed toward the periplasm (Liu and Mushegian, 2003). The conserved 
modified DxD sequence is predicted to bind the lipid linked sugar donor substrate via a 
divalent cation most commonly Mn2+ or Mg2+ (Tarbouriech et al., 2001), however, the 
exact function of this motif has not been fully elucidated. Several studies employing site 
directed mutagenesis have demonstrated that substitution of specific conserved aspartic 
acid residues to alanine within the DxD sequence in PimE and EmbC of M. smegmatis, 
have led to a loss of enzymatic activity (Berg et al., 2005, Morita et al., 2006). Similarly, 
topology and mutational analysis of the single Emb from C. glutamicum highlighted the 
importance of the conserved aspartic residues within the modified DXD motif to the 
function of Emb (Seidel et al., 2007b). In addition, 20-40 amino acids downstream of the 
DxD motif, conserved proline residue(s) and a partially conserved acidic amino acid have 
been identified and, in conjunction to DxD sequence, is referred to as the GT-C motif 
(Berg et al., 2007).  Finally, the study by Zhang et al. (2003) suggested that Emb proteins 
utilise their N-terminal region to recognise the acceptor, while the long periplasmic C-
terminal region is responsible for arabinan formation. Recently, Alderwick et al. (2011) 
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unravelled the structure of the hydrophilic C-terminal domain of EmbC (EmbCCT) GT-C 
family glycosyltransferase, which is essential to M. tuberculosis growth and viability. 
EmbC is responsible for the elongation of the arabinan domain of LAM and is inhibited 
by the front-line anti-TB drug EMB (Goude et al., 2008, Goude et al., 2009). The 
structure of EmbCCT contains two sub-domains both associated with two separate 
carbohydrate binding sites (Alderwick et al., 2011). The sub-domain I showed weak 
structural similarity with the C-terminal domain of oligosaccharyltransferase STT3 from 
Pyrococcus furiosus, whereas sub-domain II demonstrated distinct similarity to lectin-
like carbohydrate-binding modules (Alderwick et al., 2011). Site-directed mutagenesis of 
the conserved tryptophan residues located in sub-domain I and II led to the disruption of 
EmbC enzymatic activity, thus confirming EmbCCT function as a carbohydrate binding 
module (Zhang et al., 2003, Alderwick et al., 2011). Mycobacterial glycosyltransferases, 
such as ArafTs, represent ideal targets for drug development and are targeted by several 
anti-TB drugs, however their structure and mode of action remain poorly understood.  
Structural and functional analysis of membrane proteins lags behind that of soluble 
proteins. This stems from the inherent challenge of extracting pure membrane proteins 
from their native membrane in an active state, a process that is not required when 
purifying soluble proteins. The low success rate of conventional detergent or surfactant 
based solubilisation, which greatly limits the number and type of membrane proteins 
available for study, has been attributed to many factors, the most significant being the 
inability of detergents to recreate the complex architecture of native membranes within 
which proteins normally reside. In recent years new approaches have addressed this 
limitation (Ritchie et al., 2009, Popot, 2010, Jamshad et al., 2011). The most prominent 
being the use of membrane associated peptides to produce nano-dimensional, disc-shaped 
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segments of membrane bilayers into which membrane proteins can be inserted (Ritchie et 
al., 2009, Velez-Ruiz and Sunahara, 2011). However, this method does not allow 
membrane proteins to be solubilised directly from a source membrane. Instead, the 
protein must first be extracted with detergent and then inserted into a membrane disc. The 
inexpensive and biocompatible poly(styrene-co-maleic acid) polymer, which added to a 
liposome result in instantaneous formation of 11 nm diameter bilayer discs, encapsulate 
active bacterial membrane proteins without the use of detergent (Figure 1) (Knowles et 
al., 2009, Jamshad et al., 2011). This polymer can be used to extract a range of 
membrane proteins from different host membranes, and the resultant ‘poly(Styrene-co-
Maleic Acid)–Lipid Particles’ (SMALPs) can be subjected to purification and subsequent 
study. 
 
Figure 1 Transmembrane protein encapsulated in SMALP disc. SMALPs preserve 
the functional and structural integrity of !-helical and "-barrel transmembrane proteins. 
They form approximately 11 nm particles that are monodispersed, biocompatible, 
thermostable and water-soluble allowing diverse membrane proteins to be simply and 
rapidly prepared for an in vitro analysis. Adapted by permission from Macmillan 
Publishers Ltd: Nature Protocols, Shi et al. (2013).  
 
Chapter 3  
 
98 
This study focuses on defining the involvement of AftA and AftB in LM/LAM 
biosynthesis through the use of a novel conditional expression-specialised transduction 
essentiality test (CESTET), and subsequent analysis of the cellular composition of 
mutants. In addition, we employ a number of biochemical techniques in order to 
characterise full-length AftA and AftB membrane proteins as well as their C-termini.  
 
3.2 Materials and methods 
3.2.1 Construction of merodiploid strains  
The 1875 bp and 1938 bp coding regions for aftA (MSMEG_6386) and aftB 
(MSMEG_6400), respectively, were amplified by PCR from M. smegmatis mc2155 
genomic DNA using the primer pairs (restriction sites underlined): 5’-GAT CGA TCG 
GAT CCG TGG CGG CCA GGG TTC TCG-3’ (aftA forward), GAT CGA TCA TCG 
ATT CAG TGG CCA TCG GTC TCC-3’ (aftA reverse), 5’-GAT GAT CGG ATC CGT 
GCG CAT CAG CCT GTG GC-3’ (aftB forward) and 5’-GAT CGA TCA TCG ATC 
TAC GGT CCC GTT GCC GGC-3’ (aftB reverse). The single copy integrating 
constructs pMV306-aftA and pMV306-aftB were generated by ligating a 2.6 kb XbaI-
BamHI inducible acetamide promoter and either aftA or aftB digested with BamHI-ClaI 
into XbaI-ClaI digested pMV306 yielding pMV306 constructs containing the aftA or aftB 
gene cloned downstream of the acetamide promoter. The merodiploid strains were 
generated by electroporating wild type M. smegmatis mc2155 with pMV306-aftA and 
pMV306-aftB and selecting for kanamycin resistant colonies. 
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3.2.2 Construction of aftA and aftB deletion mutants in M. smegmatis 
Approximately 1 kb of upstream and downstream flanking sequences of MSMEG6386 
(aftA) and MSMEG6400 (aftB) were PCR amplified from M. smegmatis mc2155 genomic 
DNA using the primer pairs: MS6386LL (5’-TTT TTT TTC CAT AAA TTG GGG CTT 
GGA GCT GCA GTA G-3’) and MS6386LR (5’-TTT TTT TTC CAT TTC TTG GAG 
CGC ACC CAG GCG CGC C-3’), and MS6386RL (5’-TTT TTT TTC CAT AGA TTG 
GGC CGC ACT CGA CGA GCT G-3’) and MS6386RR (5’-TTT TTT TTC CAT CTT 
TTG GGT CGG CGC AGT CCA GCA C-3’) for aftA from M. smegmatis; MS6400LL 
(5’-TTT TTT TTC CAT AAA TTG GGA GTT ACA CCA GCA GCT ACC-3’) and 
MS6400LR (5’-TTT TTT TTC CAT TTC TTG GAC CAG CAC ACC ATC ATC C-3’), 
and MS6400RL (5’-TTT TTT TTC CAT AGA TTG GAT GGG CAT GCT GGG CAT 
GAA CG-3’) and MSMEG6400RR (5’-TTT TTT TTC CAT CTT TTG GCA CCG AGA 
TGC CCG AGT TGT AG-3’) for aftB from M. smegmatis. Following restriction 
digestion of the primer incorporated Van91I sites, the PCR fragments were cloned into 
Van91I-digested p0004S to yield the knockout plasmids p$MSMEG6386 and 
p$MSMEG6400. The obtained vectors are sequenced and subsequently linearised by 
PacI and cloned into the PacI-digested phAE159 phasmid. The ph$MSMEG6386 and 
ph$MSMEG6400 phasmids were then packaged into the temperature-sensitive 
mycobacteriophage particles as described previously (Bardarov et al., 2002). Generation 
of high titre phage particles and specialised transduction were performed as described 
earlier (Bardarov et al., 2002). Deletion of the gene of interest was confirmed using 
Southern blot analysis. DNA sequencing and construct verification were carried out at 
Eurofins DNA Ltd. 
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3.2.3 Plasmid construction for overexpression of full-length AftA and AftB from 
M. tuberculosis and C. glutamicum 
The coding regions for Rv3792, Rv3805c, NCgl0185 and NCgl2780 were amplified by 
PCR from M. tuberculosis H37Rv and C. glutamicum ATCC 13032 genomic DNA, 
respectively, using the primer pairs provided in the Table 1. The DNA fragments were 
restricted with the appropriate enzymes and ligated into pMSX or pEKEx5 digested with 
identical enzymes, thus yielding pMSX-Rv3792, pMSX-NCgl0185, pEKEx5-Rv3792, 
pEKEx5-NCgl0185, pMSX-Rv3805c, pMSX-NCgl2780, pEKEx5-Rv3805c and pEKEx5-
NCgl2780. Both pMSX and pEKEx5 vectors carry a C-terminal and an N-terminal His6-
tag sequence, respectively. DNA sequencing and construct verification were carried out 
at Eurofins DNA Ltd. 
Table 1 Primers used in this study. 
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3.2.4 Plasmid construction for overexpression of C-terminal domain of AftA and 
AftB from M. tuberculosis 
The pET16b-aftACT, pET16b-aftBCT constructs were kindly provided by Dr. L. 
Alderwick, University of Birmingham. Specifically, the C-terminus region of aftA 
(Rv3792), and aftB (Rv3805c) were amplified from M. tuberculosis H37Rv genomic 
DNA using oligonucleotides pairs (restriction sites underlined): 5’-GAT CGA TCC ATA 
TGC CCG ACG TGT TGC GGC CGG-3’ (aftACT forward), 5’-GAT CGA TCG GAT 
CCT CAC GCG CTC TCC TGC GGC-3’ (aftACT reverse), 5’-GAT CGA TCC ATA 
TGA ACT CGC CGG GCA TGG GTG-3’ (aftBCT forward), 5’-GAT CGA TC G GAT 
CCT CAC TCC CGC GGT GGC GGG-3’ (aftBCT reverse). Purified DNA fragments 
were cloned into appropriate cutting sites of pET16b vectors to express recombinant 
proteins tagged with His6 at the N-terminus.  DNA sequencing and construct verification 
was carried out at Eurofins DNA Ltd.  
3.2.5 Genomic DNA extraction from M. smegmatis 
M. smegmatis cells were resuspended in 450 µl of lysis buffer (25 mM Tris-HCl pH 8.0, 
10 mM EDTA, 50 mM glucose, 1 mg/ml lysozyme) and the cell slurry incubated at 37 °C 
for 12 hours. A further 500 µl of 10 % SDS (Sigma Aldrich) and 250 µl of Protease K (10 
mg/ml, Sigma Aldrich) were added and samples incubated at 55 °C for 4 hours. Ionic 
bonds between genomic DNA and proteins were disrupted by addition of 1 ml of 5 M 
NaCl at 65 °C and proteins were removed using chloroform: isoamyl alcohol (24:1, 
Sigma Aldrich) extraction. The DNA was precipitated using 2.8 ml of isopropanol, and 
the DNA pellet washed twice using 70 % ethanol and air-dried at room temperature. The 
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genomic DNA pellets were dissolved in Tris-EDTA buffer (10 mM Tris-HCl, 1 mM 
EDTA) and stored at -20 °C until further use.  
3.2.6 Southern blot analysis 
Genomic DNA extracted from wild type M. smegmatis, merodiploid strains 
(mc2155::pMV306-aftA and mc2155::pMV306-aftB) and deletion mutants 
(mc2155#aftA::pMV306-aftA and mc2155#aftB::pMV306-aftB) were digested with either 
EcoRI (for aftA) or SacI (for aftB). Digested samples were subjected to gel 
electrophoresis followed by gel depurination in 0.25 M HCl for 10 minutes. The agarose 
gel was then denaturated in 1.5 M NaCl, 0.5 M NaOH for 15 minutes and subsequently 
neutralised for 30 minutes in 0.5 M Tris-HCl pH 7.2, 1 M NaCl. The separated digested 
genomic DNA samples were transferred from the agarose gel onto a nylon membrane 
(Roche) by capillary transfer using 3 M NaCl, 0.3 M sodium citrate pH 7.0. DNA was 
then fixed to the nylon membrane by UV cross-linking. The membrane was further used 
for hybridisation, labelling and detection as described in DIG High Primer DNA 
Labelling and Detection Starter Kit (Roche).  
3.2.7 Conditional depletion of AftA and AftB 
M. smegmatis strains were grown in either TSB or minimal medium (Chang et al., 2009) 
supplemented with 0.05 % Tween-80 (TBST) and 0.2 % acetamide to an OD600 of 0.5. 
Cells were washed twice with media to remove traces of acetamide and resuspended in 
the original volume of appropriate media. Culture was used as a 20 % inoculum in either 
TBST or minimal media and grown for 12 hours to deplete intracellular AftA or AftB. 
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The depleted sub-culture served as inoculum (5 %) for cultures with or without 0.2 % 
acetamide.  
3.2.8 Protein production  
DNA constructs were appropriately electroporated into C. glutamicum ATCC 13032 cells 
or transformed into E. coli BL21 (DE3), C43 (DE3), Tuner (DE3), and Rosetta (DE3) 
pLysS cells, and selected for resistance to appropriate antibiotics on BHI or LB agar 
plates, respectively. Recombinant cells harbouring constructs of interest were used to 
inoculate a pre-culture of 5 ml media supplemented with appropriate antibiotic. This pre-
culture was then used to inoculate 1 l media containing appropriate antibiotic and 
incubated at 30 ºC or 37 ºC with shaking until an OD600 of 0.5-0.8. IPTG was then used at 
a final concentration of 0.1 mM or 1 mM to induce protein expression and cells were 
further cultivated for additional 4 hours at 30 ºC/37 ºC or 12 hours at 16 ºC. Cells were 
harvested, washed with phosphate buffered saline and pellets frozen at -20 ºC until 
further use.  
3.2.9 Purification of M. tuberculosis AftACT  
For protein purification, pellet was thawed and resuspended in 50 mM KH2PO4 pH 7.9, 
300 mM NaCl and 20 mM imidazole, containing one complete protease inhibitor coctail 
tablet (Roche). The cell suspension was disrupted by sonication (MSE Soniprep 150, 12 
micron amplitude, 30 seconds ON, 90 seconds OFF for a total of 10 cycles) and the cell 
slurry centrifuged for 30 minutes, 27,000 g at 4 ºC. Supernatant was collected and passed 
over a 1 ml HiTrap Ni2+-NTA agarose column (GE Healthcare), which was previously 
equilibrated with 50 mM KH2PO4 pH 7.9, 300 mM NaCl and 20 mM imidazole. Elution 
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occurred via a stepwise gradient of 50-500 mM imidazole in 50 mM KH2PO4 pH 7.9, 300 
mM NaCl and 10 ml fractions collected. Pure protein fractions were determined by 12% 
SDS-PAGE analysis. AftACT was dialysed against either 4 L of 50 mM Tris-HCl pH 7.5, 
300 mM NaCl or 100 mM sodium acetate pH 4.2, 200 mM NaCl or 20 mM NaAc pH 
6.0, 200 mM NaCl. 
3.2.10 Differential scanning fluorimetry with AftACT 
Protein unfolding was observed using the SYPRO Orange fluorescence dye (Invitrogen), 
which binds non-specifically to hydrophobic surfaces of unfolded proteins. Differential 
scanning fluorimetry (DSF) was set up in 96-well plates using a reaction volume of 40 µl. 
Firstly, the following buffers: sodium citrate pH 4.0, sodium acetate pH 4.2, sodium 
acetate pH 4.8, sodium citrate pH 5.0, sodium acetate pH 5.4, MES pH 5.7, sodium 
citrate pH 6.0, Bis-Tris pH 6.0, MES pH 6.1, imidazole pH 6.4, MES pH 6.5, Bis-Tris pH 
6.5, Bis-Tris pH 7.0, HEPES pH 7.0, imidazole pH 7.1, Tris pH 7.2, HEPES pH7.5, 
imidazole pH 7.6, HEPES pH 8.0, Tris pH 8.0, Tris pH 8.6, CHES pH 8.6, CHES pH 9.1, 
and CHES pH 9.6 containing either 190 mM or 340 mM NaCl were aliquoted to the 96-
well plate. The final concentration of all buffers was 100 mM. Secondly, since SYPRO 
Orange dye is supplied in 100 % (v/v) DMSO and high concentrations of solvent have a 
tendency to damage proteins, the dye was diluted (1:1,000) into the buffers prior to 
addition of the protein. Finally, the AftACT protein dialysed in 100 mM sodium acetate 
pH 4.2 containing 200 mM NaCl was aliquoted into the 96-well plate to a final 
concentration of 100 ng/ml. Fluorescence measurements were collected employing real-
time PCR machine (Agilent MX3005P with MxPro QPCR Software) using a temperature 
scan from 25 °C to 80 °C at 1 °C/min. Data was analysed using GraphPad Prism 
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software. Fluorescence intensities were plotted as a function of temperature. The effects 
of increasing temperature were expressed as #Tm.  
3.2.11 AftACT crystallisation trials 
Purified AftACT was concentrated to either 15 mg/ml or 30 mg/ml. The Molecular 
Dimensions optimised sparse matrix screens Structure screen I & IITM, Pact premierTM, 
JCSG-plusTM, MorpheusTM, MIDASTM as well as Hampton Research Crystal screen I & 
IITM were used to identify conditions that were most suitable for crystal growth. The 
sitting drop vapour diffusion format was used in a 96-well plate. The Mosquito nano-drop 
crystallisation robot was employed to aliquot the concentrated pure protein and different 
buffers. 
3.2.12 Styrene maleic acid solubilisation 
Membranes were prepared from C. glutamicum::pMSX-aftA as described in General 
Materials and Methods 6.5.13, re-suspended to a final concentration of 60 mg/ml (wet 
membrane weight) and homogenised in 50 mM Tris-HCl pH 8.0 supplemented with 500 
mM NaCl and 5 mM imidazole. An equal volume of 5 % (w/v) styrene maleic acid 
resuspended in the same buffer was added to the membrane sample to yield a final 
concentration of 2.5 %. The sample was then incubated for 12 hours at 30 °C with gentle 
agitation. Removal of insoluble material was performed by centrifugation at 100,000 g 
for 1 hour at 4 °C. Once formed, SMALP encapsulated proteins were found to be stable 
and could be purified using a Ni2+ affinity purification method. 
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3.2.13 Purification of C. glutamicum AftA within SMALP 
SMALP encapsulated C. glutamicum membranes containing recombinant AftA were 
incubated with 2 ml of Ni2+-NTA linked agarose (Qiagen) resin for 12 hours at 4 °C with 
gentle agitation. The sample was then transferred to 10 ml of disposable gravity flow 
column (Thermo Fisher), which was previously equilibrated with 5 column volumes of 
50 mM Tris-HCl pH 8.0, 500 mM NaCl and 5 mM imidazole.  Elution of C. glutamicum 
AftA was achieved using a step-wise imidazole gradient of 50-500 mM imidazole in 50 
mM Tris-HCl pH 8.0, 500 mM NaCl and 1 ml fractions were collected and analysed 
using standard 12 % SDS-PAGE and Western blot analysis. Immunological detection of 
immobilised proteins was performed using a primary anti-hexa-His monoclonal antibody 
(Takara) and an anti-mouse IgG HRP-conjugated secondary antibody (Sigma Aldrich) 
according to manufacturer’s instructions. Fractions containing C. glutamicum AftA were 
pooled, dialysed in 50 mM Tris-HCl pH 8.0 and concentrated. The protein concentration 
was determined using the bicinchoninic acid procedure (Pierce) and bovine serum 
albumin used as a standard. 
3.2.14 Circular dichroism spectroscopy 
Circular dichroism experiments were recorded at 20 °C using a Jasco J-810 
spectropolarimeter fitted with a Peltier heating block using a path length of 0.01 mm. 
SMALP encapsulated C. glutamicum AftA protein was diluted to a final concentration of 
0.25 mg/ml of Tris-HCl pH 8.0. Spectra were recorded at a scan speed of 100 nm/min 
with band width of 1 nm and wavelength range of 190 nm and 260 nm. Spectra were 
normalised by subtracting the spectrum of buffer alone. Data were processed using the 
program Spectra Manager I (JASCO).  
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3.2.15 Thermostability analysis of C. glutamicum AftA within SMALP 
SMALP encapsulated C. glutamicum AftA was diluted to a concentration of 0.5 mg/ml in 
10 mM Tris-HCl pH 8.0. Denaturation of AftA was measured by monitoring the 
temperature dependent changes of ellipticity at 222 nm in a 0.2 mm path length Quartz 
cuvette with a temperature gradient of 1 °C/min. 
3.2.16 Tryptophan fluorescence binding assay 
Intrinsic tryptophan fluorescence spectroscopy experiments were performed using a PTI 
QuantaMaster 40 spectrofluorimeter and recorded using the FeliX32 software package. 
The excitation wavelength was set to 283 nm and the fluorescence emission (Femmision) 
was recorded between 300-380 nm for each ligand aliquot added to a total of 300 µl 
solution containing 2 µM of SMALP encapsulated C. glutamicum AftA in 50 mM Tris-
HCl pH 8.0. The change in fluorescence emission (!Femmision) intensity was plotted 
against ligand concentration [L] (3 independent experiments) and fitted to the saturation 
binding equation using GraphPad Prism Software. 
 
3.2.17 Analytical ultracentrifugation 
SMALP encapsulated C. glutamicum AftA was diluted to a concentration of 0.5 mg/ml in 
10 mM Tris-HCl pH 8.0 and analysed by sedimentation velocity analytical centrifugation. 
The sample was centrifuged at 129,000 g at 4 °C using Beckman XL-1 analytical 
ultracentrifuge. The protein motion was monitored at absorbance of 280 nm with 1780 
datasets. Data was analysed using SEDFIT and SENDTERP software. 




3.3.1 Molecular and biochemical characterisation of AftA 
3.3.1.1 Evidence suggesting that AftA from M. smegmatis is an essential gene 
In order to delete aftA from M. smegmatis and study possible consequences in LAM, we 
generated a conditional M. smegmatis!aftA::pMV306-aftA mutant using CESTET. 
Deletion of chromosomal aftA was achieved only in the presence of a rescue plasmid 
carrying a second copy of aftA, strongly suggesting that aftA is essential to viability of M. 
smegmatis. The replacement of the native chromosomal copy of aftA by a hygromycin 
resistance cassette in the transductants was confirmed by a Southern blot (Figure 2). 
These results are comparable to those by Shi et al. (2008), where aftA disruption in M. 
smegmatis was only possible with a rescue plasmid present.  
Previous studies demonstrated that conditional depletion of essential enzymes in 
CESTET-derived conditional M. smegmatis mutants resulted in cell lysis (Bhatt et al., 
2005, Brown et al., 2007, Rana et al., 2012). The growth of M. 
smegmatis!aftA::pMV306-aftA in liquid medium with and without acetamide was 
monitored over 24 hours. While the strain grew normally in the medium containing 
acetamide, the culture lacking acetamide showed a decrease in OD600 with time, resulting 
in a clearly lysed culture after 24 hours of incubation (Figure 3A). However, the presence 
of M. smegmatis cells that persisted throughout depletion of AftA has also been noticed 
(Figure 3A). Therefore, M. smegmatis!aftA::pMV306-aftA cells were grown for 24 hours 
with and without acetamide and subsequently plated onto appropriate agar plates (Figure 
3B). Although a significant decrease in cell numbers was observed in the media lacking 
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acetamide, colonies formed by persisters were still visible (Figure 3B). Often conditional 
mutant strains acquire mutations in the acetamide promoter region resulting in continues 
production of the protein of interest, thus rescuing the cell.  
 
 




Figure 2 Generation of conditional M. smegmatis!aftA::pMV306-aftA mutant. A The 
map of the aftA (MSMEG_6386) region in the parental M. smegmatis strain and its 
corresponding region in the M. smegmatis"aftA::pMV306-aftA mutant; hyg – 
hygromycin resistance gene from Streptomyces hygroscopicus, sacB – sucrose counter 
selectable gene from Bacillus subtilis. EcoRI-digested bands expected in a Southern blot 
are depicted as I, II and III. B Southern blot analysis of EcoRI-digested genomic DNA 
from the wild type M. smegmatis, merodiploid and conditional mutant strains with 
expected bands I, II and III. The asterisk indicates a band appearing as a result of a 

























































Figure 3 Growth of M. smegmatis!aftA pMV306-aftA with and without acetamide. A 
M. smegmatis strains to be tested were grown in minimal media  supplemented with 0.05 
% Tween-80 and 0.2 % acetamide to an OD600 of 0.5. Cells were washed twice to remove 
traces of acetamide and resuspended in the original volume of media supplemented with 
0.05 % Tween-80. This cell culture was used as a 20 % inoculum in minimal media and 
grown for 12 hours to deplete intracellular AftA. The depleted sub-culture served as 
inoculum (5 %) for cultures grown with or without 0.2 % acetamide for at least 24 hours. 
B Cultures grown with and without acetamide and 10 µl of 10-fold serial dilutions of 
cultures were spotted onto ±acetamide plates and incubated at 37 °C for 3 days. 
 
3.3.1.2 Overexpression and purification of recombinant AftACT 
The hydrophilic C-terminal domain encoded by aftACT of M. tuberculosis was cloned into 
pET expression vectors and transformed into E. coli BL21 (DE3), C43 (DE3), Tuner 
(DE3), and Rosetta (DE3) competent cells. SDS-PAGE and Western blot analyses of 
bacterial cultures were used to assess expression and solubility of recombinant proteins 
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lines, but the best expression of soluble protein was observed using E. coli BL21 (DE3) 
cells at either 16 °C or 37 °C using 1mM IPTG or E. coli C43 (DE3) at 16 °C using 1 
mM IPTG (Figure 4). Notably, production of AftACT was detected in the culture samples 
without the addition of the inducer IPTG. This is probably due to incomplete repression 
of the promoter, commonly seen with lac promoters that leads to low levels of expression 
without induction. Since expression of AftACT at 16 °C using 1 mM IPTG yielded plenty 
of soluble recombinant protein, these conditions were chosen for large scale protein 
expression. 
Since expression in BL21 (DE3) cells resulted in a higher amount of protein, this 
condition was replicated for large protein expression. AftACT was purified employing 
HiTrap Ni2+-NTA agarose column and during purification eluted at 50 mM - 1 M 
imidazole fractions (Figure 6). The purity of the AftACT was determined by a large single 
band running at ~22 kDa on the SDS-PAGE gel. The 250 mM - 1M imidazole fractions 
containing pure AftACT were pooled together and dialysed against Tris buffer (50 mM 
Tris pH 7.5, 300 mM NaCl). A considerable amount of AftACT was lost due to 
precipitation throughout dialysis and only a low concentration of 4 mg/ml was obtained. 
Thus, different buffers were explored to dialyse purified AftACT including Tris, HEPES 
(50 mM HEPES pH 7.5, 300 mM NaCl), and MES (50 mM MES pH 6.5, 300 mM NaCl), 
however, a high degree of precipitation of the recombinant protein was still observed. As 
a result, higher volumes of bacterial culture have been used to obtain protein 
concentrations suitable for protein crystallisation. 
 




Figure 4 SDS-PAGE (A and C) and Western blot (B and D) analysis of AftA C-
terminus from M. tuberculosis overexpressed in E. coli BL21 (DE3) and C43 (DE3) 
cells. E. coli cells harbouring pET16b-aftACT plasmid were grown at 37°C for 1 h. 
Expression of AftA C-terminus was induced with 1 mM IPTG and cells were further 
cultivated at either 37 ºC for 4 hours or at 16 ºC overnight. Subsequently, cells were 
harvested, lysed and separated into two fractions: crude cell lysate (IN) and clarified cell 
lysate (SOL). Samples were analysed by 4-15 % SDS-PAGE gel and stained with 
Coomassie Blue; the His-tagged AftACT was detected by a Western blot using a 
monoclonal anti-His6 tag antibody. The arrows indicate the overexpressed AftACT (22 
kDa). 
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Figure 5 SDS-PAGE (A and C) and Western blot (B and D) analysis of AftA C-
terminus from M. tuberculosis overexpressed in E. coli Rosetta (DE3) pLysS and 
Tuner (DE3) cells. E. coli cells harbouring pET16b-aftACT plasmid were grown at 37°C 
for 1 h. Expression of AftA C-terminus was induced with 1 mM IPTG and cells were 
further cultivated at either 37 ºC for 4 hours or at 16 ºC overnight. Subsequently, cells were 
harvested, lysed and separated into two fractions: crude cell lysate (IN) and clarified cell 
lysate (SOL). Samples were analysed by 4-15 % SDS-PAGE gel and stained with 
Coomassie Blue; the His-tagged AftACT was detected by a Western blot using a 
monoclonal anti-His6 tag antibody. The arrows indicate the overexpressed AftACT (22 
kDa). 
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Figure 6 SDS-PAGE analysis of M. tuberculosis AftACT purification. E. coli BL21 
(DE3) cells harbouring pET16b-aftACT were grown at 37 °C until an OD600 0.5, 1 mM 
IPTG was used to induce protein expression, and cells were further cultivated for 12 
hours at 16 °C. The C-terminus of AftA (22 kDa) was purified using HiTrap Ni2+-NTA 
agarose column via a stepwise gradient of 50–1000 mM imidazole. Fractions were 
analysed by 12% SDS-PAGE and visualised by Coomassie Blue staining. 
 
3.3.1.3 Differential scanning fluorimetry profile of AftACT 
Since AftACT demonstrated a tendency to precipitate in a number of buffers it was 
dialysed against, a high throughput thermostability screen employing differential 
scanning fluorimetry (DSF) was performed. Thermostability assessment identifies 
solution conditions that facilitate protein conformational integrity and resistance to 
temperature stress (Niesen et al., 2007). Numerous studies have demonstrated that buffer 
conditions or ligands that stabilise proteins, reduce their tendency to unfold and 
aggregate, and improve protein purification and subsequent crystallisation (Murphy, 
2001, Elleby et al., 2004, Vedadi et al., 2006, Niesen et al., 2007). DSF measures the 
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sensitive to hydrophobic areas of the protein. Fluorescence is negligible in solution 
lacking the probe, however, it increases significantly in the presence of unfolded protein 
as exposure of protein’s inner hydrophobic regions allows the dye to bind. A total of 48 
different buffer conditions covering a pH range from 4 to 9 and two different salt 
concentrations (190 mM and 340 mM NaCl) were screened employing DSF. The typical 
DSF profile of AftACT is shown in Figure 7. Effects of pH and buffer composition on the 
thermostability of AftACT are also presented as differences in melting temperature (#Tm), 
where Tm obtained in the original buffer (20 mM sodium acetate pH 4.2, 200 mM NaCl) 
was subtracted from Tm with different buffer content (Figure 8). In more than 70 % of 
the cases, a condition was identified that stabilised AftACT compared to the original 
buffer. Moreover, in the majority of cases higher concentration of salt resulted in an 
increased stabilisation of AftACT, however buffers containing sodium acetate, sodium 
citrate and MES ranging from pH 4 to 6 demonstrated a higher stabilisation effect on 
AftACT with lower salt concentration. In several instances, the destabilising effect was 
more pronounced in conditions containing HEPES and Tris buffers (HEPES pH 7.0, 
HEPES pH 7.5 and Tris pH 8.6), thus resulting in negative #Tm values. Overall, the most 
significant thermal stabilisation was observed in buffers containing sodium acetate, which 
was independent of both pH and salt concentration. Therefore, 20 mM sodium acetate pH 
6.0, 200 mM NaCl buffer was chosen as a stabilising solution for the purification, 
concentration and crystallisation of AftACT.  





Figure 7 Fluorescence of SYPRO Orange acquired by differential scanning 
fluorimetry (DSF) in the presence of AftACT domain as a function of temperature. 
SYPRO Orange fluorescent dye was diluted into twenty-four buffers differing in their salt 
concentration and pH to a final dilution of 1:1000. The final concentration of all buffers 
was 100 mM, while the AftACT concentration was 100 ng/ml. The detailed DSF 
procedure is described in Materials and Methods 3.2.10. The SYPRO Orange is depicted 
here as a three-ring aromatic molecule, whereas AftACT is represented by a purple sphere. 
A basic fluorescence intensity is excited  by light of 492 nm and is depicted as green 
strokes. During protein unfolding, hydrophobic areas of the protein are exposed, thus 
allowing fluorescent dye to bind. As a result, a strong fluorescent light of 610 nm is 
emitted (orange strokes). Finally, increasing temperature leads to gradual precipitation 
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Figure 8 The effects of different buffers and pH expressed as #Tm for AftACT 
domain. Differential scanning fluorimetry was employed as described in Materials and 
Methods 3.2.10 with AftACT concentration of 100 ng/ml. Formulations included twenty-
four conditions as indicated in the figure labels. The #Tm values were obtained by 
subtracting Tm value obtained in the reference blank (AftACT of 100 ng/ml in 100 mM 
sodium acetate pH 4.2, 200 mM NaCl) from those with different contents. The results are 
expressed as means ±S.D. of two independent experiments. 
 
3.3.1.4 Crystallisation trials of M. tuberculosis AftACT 
Purified AftACT was dialysed against Tris buffer (50 mM Tris-HCl pH 7.5, 300 mM 
NaCl) or sodium acetate buffer (20 mM sodium acetate pH 6.0, 200 mM NaCl) and 
concentrated to 15 mg/ml and 30 mg/ml. The Molecular Dimensions optimised sparse 
matrix screens Structure screen I & IITM, Pact premierTM, JCSG-plusTM, MorpheusTM, 
MIDASTM as well as Hampton Research Crystal screen I & IITM were used to identify 

































































































































































































































190 mM NaCl 
340 mM NaCl 
Chapter 3  
 
119 
format was used in a 96-well plate. Unfortunately, none of the screens that were set up 
generated crystals. 
3.3.1.5 Overexpression studies of recombinant AftA from M. tuberculosis and C. 
glutamicum 
Full-length AftA from M. tuberculosis and C. glutamicum encoded by Rv3792 and 
NCgl0185, respectively, were cloned into both pMSX and pEKEx5 expression vectors 
and transformed into C. glutamicum ATCC 13032. SDS-PAGE and Western blot 
analyses of bacterial cultures were used to assess expression and solubility of 
recombinant proteins employing four different conditions: 16 °C for 12 hours using 0.1 
mM IPTG, 16 °C for 12 hours using 1 mM IPTG, 30 °C for 4 hours using 0.1 mM IPTG 
and 30 °C for 4 hours using 1 mM IPTG. Appreciable amounts of AftA in soluble form 
were generated at 16 °C for 12 hours using 1 mM IPTG, 30 °C for 4 hours using 0.1 mM 
IPTG and 30 °C for 4 hours using 1 mM IPTG (Figure 9). Since a greater quantity of 
protein seemed to be expressed at 16 °C using 0.1 mM IPTG, this condition was used for 
further experiments. Notably, a ladder effect was observed in the samples overexpressing 
C. glutamicum AftA at approximately 150 kDa and above. It is tempting to speculate that 
this may be the evidence of a multi-protein complex formation, where C. glutamicum 
AftA is forming a dimer or tetramer.  




Figure 9 SDS-PAGE (A) and Western blot (B) analysis of full-length AftA from C. 
glutamicum overexpressed in C. glutamicum ATCC 13032 cells. C. glutamicum cells 
harbouring pMSX-aftA plasmid were grown at 30 °C for until an early growth phase. 
Expression of AftA was induced using either 0.1 mM or 1 mM IPTG and cells were 
further cultivated at either 30 ºC for 4 hours or at 16 ºC overnight. Subsequently, cells 
were harvested, lysed and separated into two fractions: crude cell lysate (IN) and clarified 
cell lysate (SOL). Samples were analysed by 12 % SDS-PAGE gel and stained with 
Coomassie Blue; the His-tagged AftA was detected by a Western blot using a 
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3.3.1.6 Complementation of C. glutamicum"aftA mutant with C. glutamicum AftA 
to verify its intact enzyme function 
Since the expression vector in use – pMSX – carries a C-terminal His6 tag sequence and 
the C-terminal region of AftA may play a crucial role in enzyme function, we 
complemented C. glutamicum strain lacking chromosomal aftA with recombinant AftA-
His6. The pMSX-aftA construct was electroporated into C. glutamicum$aftA and 
overexpressed at 16 °C for 12 hours using either 0.1 mM IPTG or 1 mM IPTG. SDS-
PAGE and Western blot analysis confirmed that C. glutamicum AftA was successfully 
expressed under both chosen conditions in the C. glutamicum$aftA mutant (Figure 10). 
Importantly, empty pMSX plasmid was electroporated into C. glutamicum$aftA and 
served as a negative control (Figure 10). To reaffirm that recombinant C. glutamicum 
AftA is fully functioning, cell walls from wild type C. glutamicum, C. glutamicum!aftA, 
and C. glutamicum!aftA::pMSX-aftA were analysed using glycosyl compositional 
analysis. As expected, the presence of rhamnose, arabinose and galactose was observed in 
alditol acetates from C. glutamicum mAGP (Figure 11). In contrast, alditol acetates 
prepared from C. glutamicum#aftA lacked arabinose and only contained rhamnose and 
galactose residues as reported previously (Alderwick et al., 2006). Complementation of 
the C. glutamicum#aftA mutant with plasmid encoded aftA from C. glutamicum restored 
the glycosyl composition to that of wild type C. glutamicum (Figure 11), thus, 
demonstrating that recombinant C. glutamicum AftA is fully active and the His6 tag does 
not interfere with its enzymatic function. 
 




Figure 10 SDS-PAGE (A) and Western blot (B) analysis of C. glutamicum#aftA 
complemented with either pMSX-aftA (I) or empty pMSX plasmid (II). C. 
glutamicum cells harbouring appropriate plasmid were grown at 30 °C for until an early 
growth phase. Expression of AftA was induced with either 0.1 mM or 1 mM IPTG and 
cells were further cultivated at either 16 ºC for 12 hours. Subsequently, cells were 
harvested, lysed and separated into two fractions: crude cell lysate (IN) and clarified cell 
lysate (SOL). Samples were analysed by 12 % SDS-PAGE gel and stained with 
Coomassie Blue; the His-tagged AftA was detected by a Western blot using a 


















































































































































Figure 11 Glycosyl compositional analysis of cell walls of C. glutamicum, C. 
glutamicum!aftA, and C. glutamicum!aftA::pMSX-aftA. Samples of purified mAGP 
were hydrolysed with 2 M trifluoroacetic acid, reduced, per-O-acetylated, and subjected 
to GC analysis. 
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3.3.1.7 Purification of SMALP encapsulated AftA from C. glutamicum 
Since AftA expression at 16 °C for 12 hours using pMSX-aftA at 0.1 mM IPTG resulted 
in the highest amount of recombinant protein, this condition was replicated for large 
protein expression. Cultures were used to prepare membrane fractions that were 
subsequently mixed with styrene maleic acid polymer and incubated at 30 °C for 12 
hours to allow encapsulation of transmembrane proteins. Insoluble material was removed 
by centrifugation and the supernatant was subjected to HiTrap Ni2+-NTA agarose gravity 
column in order to purify SMALP encapsulated His6 tagged AftA. Recombinant protein 
eluted at 50-200 mM imidazole fractions that were pooled, dialysed against 50 mM Tris-
HCl pH 8.0 and concentrated to 2 mg/ml yielding for the first time a preparation of high 
purity full-length C. glutamicum AftA. 
 
Figure 12 SDS-PAGE (A) and Western blot (B) analysis of SMALP encapsulated 
AftA purification. A C. glutamicum cells harbouring pMSX-aftA were grown at 30 °C 
until an OD600 of 0.5, protein expression was induced using 0.1 mM IPTG and cells were 
further cultivated for 12 hours at 16 °C. Harvested C. glutamicum::pMSX-aftA cultures 
were used to prepare membrane fractions as described in General Materials and Methods 
6.5.13. Membranes were homogenised to a final concentration of 60 mg/ml in 50 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 5 mM imidazole and 2.5 % (w/v) styrene maleic acid. 
Mixture was incubated at 30 °C for 12 hours with gentle agitation. Once formed, SMALP 
encapsulated AftA was purified using Ni2+–NTA linked agarose via a stepwise gradient 
of 50-200 mM imidazole. Fractions were analysed by 12% SDS-PAGE and visualised by 
Coomassie Blue staining. B The polyhistidine tagged AftA was detected by Western 
blotting using a monoclonal anti-His tag antibody.  
B A 
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3.3.1.8 Biophysical characterisation of SMALP encapsulated AftA from C. 
glutamicum 
Further, we wanted to characterise the biophysical properties of AftA encapsulated within 
SMALPs. Firstly, we analysed sample homogeneity by analytical centrifugation, which 
revealed a single major peak, thus indicating stable, monodispersed species (Figure 13A). 
A circular dichroism (CD) spectrum was obtained for C. glutamicum AftA within the 
SMALP to estimate the structural state of the transmembrane protein in the intact native 
membrane environment (Figure 13B). Since no protein is required to form the 
nanoparticles they have negligible CD absorbance, as previously demonstrated by 
Knowles et al. (2009). The AftA structure was maintained within SMALPs: far-UV CD 
spectra show shoulders at 222 nm and 208 nm, indicating the expected !-helical 
structures that are characteristic of the folded state of the protein (Figure 13B). Finally, 
we hypothesised that the lipid environment surrounding transmembrane AftA protein 
would retain and possibly increase protein stability when compared to protein purification 
without SMALPs. Thus, we examined the thermostability of SMALP encapsulated AftA, 
where the folded state was monitored over time with increasing temperature (Figure 
13C). Excellent stability of AftA was observed with unfolding temperature of 
approximately 65 °C. 
 




Figure 13 Biophysical characterisation of SMALP encapsulated AftA from C. 
glutamicum. A Analytical ultracentrifugation analysis of AftA within SMALPs. B Far-
UV circular dichroism analysis of AftA within SMALPs. C Circular dichroism thermal 
denaturation studies of AftA within SMALPs. 
 
3.3.1.9 Ligand binding assays of AftA from C. glutamicum 
The binding properties of SMALP encapsulated AftA from C. glutamicum were 
examined with three synthetic substrates #-D-Galf(1"5)-#-D-Galf-O-(CH2)7CH3 (G5G), 
#-D-Galf(1"6)-#-D-Galf-O-(CH2)7CH3 (G6G) and (#-D-Galf(1"6)-#-D-Galf(1"5))6-#-
D-Galf(1"4)-!-L-Rhap-GlcNAc-O-(CH2)7CH3 (Acc13). Nonlinear regression analysis of 
#Femission against G5G showed a typical saturation ligand-binding curve with a 
calculated Kd of 1.372 mM (Figure 14A). The same analysis was performed where G6G 
acceptor was used as a substrate for AftA and demonstrated a higher specificity with Kd 
A B 
C 
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of 0.9959 mM than compared to G5G (Figure 14B). This is unsurprising, since it was 
previously shown that AftA can transfer an arabinose residue to the C-5 position of the 
internal 6-linked galactose and, therefore, would bind the G6G neoglycolipid acceptor 
more strongly. Finally, a much longer Acc13 acceptor was used as a substrate for C. 
glutamicum AftA enzyme and resulted in a saturation ligand-binding curve with Kd of 
7.314 µM (Figure 14C). The data show that AftA ArafT binds Acc13 with higher affinity 
than compared to both G5G and G6G.   
 
Figure 14 Binding kinetics of SMALP encapsulated AftA from C. glutamicum to 
different substrates. Ligand binding was analysed by intrinsic tryptophan fluorescence 
spectroscopy employing three substrates: A "-D-Galf-(1$5)-"-D-Galf-(CH2)7CH3; B "-
D-Galf-(1$6)-"-D-Galf-(CH2)7CH3; C ("-D-Galf-(1$6)-"-D-Galf-(1$5))6-"-D-Galf-
(1$4)-!-L-Rhap-GlcNAc-O-(CH2)7CH3. The excitation wavelength was set to 283 nm 
and the fluorescence emission was recorded between 300-380 nm for each ligand aliquot 
added to a total of 300 µl solution containing 2 µM SMALP encapsulated C. glutamicum 
AftA in 50 mM Tris-HCl pH 8.0. The change in fluorescence emission intensity was 
plotted against ligand concentration (3 independent experiments) and fitted to the 
saturation binding equation using GraphPad Prism Software. 
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3.3.2 Molecular and biochemical characterisation of AftB 
3.3.2.1 Evidence suggesting that AftB from M. smegmatis is an essential gene 
We constructed a knockout phage phMSMEG6400 designed to replace the chromosomal 
aftB in M. smegmatis with a hygromycin resistance cassette. Several attempts to obtain an 
aftB null mutant in M. smegmatis were unsuccessful suggesting that aftB, unlike its 
homologue in C. glutamicum, is an essential gene (Seidel et al., 2007a). We then 
employed CESTET to generate an aftB conditional deletion mutant by transducing a 
meridiploid strain containing a second, inducible copy of aftB (Bhatt and Jacobs, 2009). 
The correct replacement of the native chromosomal copy of aftB with a hygromycin 
cassette in the transductants was confirmed by Southern blot analysis (Figure 15).  
In order to confirm aftB essentiality and study the fate of mycobacterial cells depleted of 
AftB we monitored the growth of M. smegmatis!aftB::pMV306-aftB in liquid medium 
with and without acetamide (second copy of aftB is on and off, respectively) over 28 
hours (Figure 16). While the mutant strain grew normally in the presence of acetamide, 
the culture without the inducer showed a decrease in OD600 with time, resulting in a 
clearly lysed culture after 28 hours of incubation (Figure 16). Since growth of the 
conditional aftB mutant is dependent on the acetamide inducible expression of the second 
recombinant copy of aftB, cell lysis in the culture lacking acetamide demonstrated the 
essentiality of aftB gene to M. smegmatis viability. 




Figure 15 Generation of conditional M. smegmatis!aftB::pMV306-aftB mutant. A 
The map of the aftB locus (MSMEG6400) region in the parental M. smegmatis strain and 
its corresponding region in the M. smegmatis"aftB::pMV306-aftB mutant; hyg – 
hygromycin resistance gene from Streptomyces hygroscopicus, sacB – sucrose counter 
selectable gene from Bacillus subtilis. SacI-digested bands expected in a Southern blot 
are indicated as I, II and III. B The Southern blot of SacI-digested genomic DNA from 
from the wild type M. smegmatis, meridiploid and conditional mutant strains with 
expected bands I, II and III. The asterisk indicates a band appearing as a result of a 
































































Figure 16 Growth of M. smegmatis!aftB::pMV306-aftB in liquid minimal medium 
with and without acetamide (Ac). M. smegmatis strains to be tested were grown in 
minimal media  supplemented with 0.05 % Tween-80 and 0.2 % acetamide to an OD600 
of 0.5. Cells were washed twice to remove traces of acetamide and resuspended in the 
original volume of media supplemented with 0.05 % Tween-80. This cell culture was 
used as a 20 % inoculum in minimal media and grown for 12 hours to deplete 
intracellular AftB. The depleted sub-culture served as inoculum (5 %) for cultures grown 
with or without 0.2 % acetamide for at least 24 hours. 
 
3.3.2.2 Lipid characterisation of the M. smegmatis#aftB::pMV306-aftB conditional 
mutant 
To study the function of mycobacterial aftB deletion, its cellular composition was 
analysed. Firstly, the wild type M. smegmatis, merodiploid strain and M. 
smegmatis#aftB::pMV306-aftB grown with and without acetamide and analysed for AG 
esterified mycolic acids and cell wall associated lipids, from an equivalent starting 
amount of biomass for each strain due to differences in growth rate. As expected, wild 
type M. smegmatis, M. smegmatis::pMV306-aftB and the conditional mutant grown with 
acetamide exhibited a typical profile of cell wall bound !-, !’- and epoxy-mycolic acid 
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methyl esters (MAMES) (Figure 17B). In contrast, M. smegmatis#aftB::pMV306-aftB 
cells cultivated lacking acetamide demonstrated drastically reduced amounts of all three 
types of mycobacterial MAMES (Figure 17B). Analysis of the cell wall associated lipids 
highlighted an apparent increase in TMMs and TDMs in the mutant strain depleted of 
AftB (Figure 17A). M. smegmatis strains producing AftB exhibited the known free lipid 
profile containing TDMs (on average approximately 685 CNT/mm2) and TMMs (337 
CNT/mm2). In contrast, M. smegmatis#aftB::pMV306-aftB grown without acetamide 
included a significant 1.5 fold increase in TMMs (563 CNT/mm2) and a smaller 1.3 fold 
increase in TDMs (935 CNT/mm2). These lipid profiles compared well with the data 
observed in the C. glutamicum#aftB mutant and suggest that AftB is involved in key 
aspects of arabinan biosynthesis in AG. 
 





Figure 17 Analysis of cell wall lipids from M. smegmatis, merodiploid and M. 
smegmatis!aftB::pMV306-aftB strains grown with and without acetamide. A. 
Analysis of cell wall associated [14C]-lipids from M. smegmatis, merodiploid and M. 
smegmatis!aftB::pMV306-aftB strains grown with and without acetamide. Lipids were 
extracted from cells by a series of organic washes as described in General Materials and 
Methods 6.5.14. Equivalent aliquots (25,000 cpm) from each strain were subjected to 
TLC using silica gel plates (5725 silica gel 60F254, Merck) developed in 
chloroform/methanol/water (60:16:2, v/v/v) and visualised by autoradiography using 
Kodak BioMax MR films. B. Analysis of cell wall bound [14C]-lipids from M. smegmatis, 
merodiploid and M. smegmatis!aftB::pMV306-aftB strains grown with and without 
acetamide. An equivalent amount of cells (100 mg) were delipitated using three 
extractions of chloroform/methanol/water (10:10:3, v/v/v) at 50 °C for 4 hours, and 
bound mycolic acids were released by addition of tetra-butyl ammonium hydroxide at 
100 °C for 12 hours and subsequently methylated. An equal amount of sample from each 
strain was subjected to TLC using silica gel plates  (5725 silica gel 60F254, Merck) and 
developed thrice in petroleum ether/acetone (95:5, v/v). MAMES were visualised by 
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3.3.2.3 Lipoglycan analysis of M. smegmatis#aftB::pMV306-aftB conditional 
mutant 
Three mycobacterial ArafTs have been identified so far to play a role in LAM 
biosynthesis: an !(1$5) ArafT EmbC and !(1$3) branching ArafTs AftC and AftD 
(Goude et al., 2008, Skovierova et al., 2009, Birch et al., 2010, Mishra et al., 2012). 
Since AftB attaches terminal #(1!2) Araf residues to AG, we hypothesised that AftB 
plays a dual role and adds the terminal Araf residues to the tetra-arabinoside and hexa-
arabinoside motifs of LAM. Therefore, cultures of wild type M. smegmatis, M. 
smegmatis::pMV306-aftB and M. smegmatis!aftB::pMV306-aftB (grown with and 
without acetamide) were labelled with [14C]-glucose, radioactive lipoglycans extracted 
and equal amount of radioactive samples analysed employing 15 % SDS-PAGE. Extracts 
from all strains showed presence of [14C]-LAM, -LM and –PIMs (Figure 18A). Although 
densitometry analysis revealed a degree of variation in terms of [14C]-LAM amounts 
extracted from wild type, merodiploid and the conditional mutant cultivated with and 
without acetamide strains (963 CNT/mm2, 1201 CNT/mm2, 1255 CNT/mm2 and 875 
CNT/mm2, respectively), no significant difference between lipoglycan samples was 
observed. To further assess the effects of AftB depletion on incorporation of arabinose 
into the LAM, radioactive lipoglycan extracts were analysed for their sugar content 
(Figure 18B). The [14C]-arabinose content remained similar in M. 
smegmatis!aftB::pMV306-aftB mutants with and without depletion of AftB (Figure 
18B). It is worth noticing that a considerable amount of other sugar residues were present 
in the samples, most likely due to contamination with !-glucan or intermediate molecules 
of mAGP. 




Figure 18 SDS-PAGE analysis of lipoglycans extracted from M. smegmatis, 
merodiploid and M. smegmatis!aftB::pMV306-aftB strains grown with and without 
acetamide. A Bacterial cells were refluxed with 50 % ethanol to extract crude 
lipoglycans. Samples were then subjected to hot phenol treatment and dialysed against 
water to yield a pure lipoglycan fraction. Equivalent aliquots (20,000 cpm) from each 
strain were analysed by SDS-PAGE and visualised by autoradiography employing Kodak 
BioMax MR film. B Lipoglycans were hydrolysed and samples of equivalent aliquots 
(20,000 cpm) loaded onto HPTLC-Cellulose TLC (Merck) and developed thrice in 
formic acid/water/tert-butanol/methyl ethyl ketone (3:3:8:6, v/v/v/v). The 14C-containing 
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3.3.2.4 Role of AftB in the synthesis of hexa-arabinan motif of LAM 
Extracted lipoglycans from wild type M. smegmatis, M. smegmatis::pMV306-aftB and M. 
smegmatis!aftB::pMV306-aftB cells grown with and without acetamide were further 
analysed by immunoblot employing a monoclonal antibody F30-5, which specifically 
recognises the hexa-arabinan motif of AraLAM (Kolk et al., 1984, Appelmelk et al., 
2008). All strains reacted with the antibody F30-5, with an exception of M. 
smegmatis!aftB::pMV306-aftB strain depleted of AftB (Figure 19). This data suggest 
that loss of AftB enzymatic activity in the conditional mutant results in a variant of LAM, 
that lacks terminal #(1!2) Araf residues in the classic hexa-arabinan motif and, thus is 
no longer recognised by F30-5 monoclonal antibody.  
 
Figure 19 SDS-PAGE immunoblot of mycobacteria probed with anti-arabinan 
monoclonal antibody F30-5. Bacterial cells were refluxed with 50 % ethanol to extract 
crude lipoglycans. Samples were then subjected to hot phenol treatment and dialysed 
against water to yield pure lipoglycan fraction. Equivalent aliquots (50,000 cpm) from 
each strain were subjected to SDS-PAGE and subsequently immunoblot employing 
monoclonal antibody F30-5, which recognises the hexa-arabinan motif of LAM as 
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3.3.2.5 Overexpression studies of recombinant AftB from M. tuberculosis and C. 
glutamicum 
In a similar fashion to AftA expression studies, the hydrophilic C-terminal domain 
encoded by aftBCT of M. tuberculosis was cloned into pET16b and transformed into E. 
coli BL21 (DE3), C43 (DE3), Tuner (DE3), and Rosetta (DE3) competent cells. SDS-
PAGE and Western blot analyses of bacterial cultures demonstrated moderate amounts of 
AftBCT expressed under various conditions, however none was produced in the soluble 
form (Figure 20-21). In addition, full-length AftB from M. tuberculosis and C. 
glutamicum encoded by Rv3805c and NCgl2780, repectively, were cloned into both 
pMSX and pEKEx5, and electroporated into C. glutamicum to assess expression and 
solubility of recombinant AftB. Unfortunately, a lack of expression in soluble or 
insoluble form was observed under all four different conditions: 16 °C for 12 hours using 
0.1 mM IPTG, 16 °C for 12 hours using 1 mM IPTG, 30 °C for 4 hours using 0.1 mM 
IPTG and 30 °C for 4 hours using 1 mM IPTG. Therefore, production of recombinant 
AftB was not pursued further. 
 
 




Figure 20 SDS-PAGE (A and C) and Western blot (B and D) analysis of AftB C-
terminus from M. tuberculosis overexpressed in E. coli BL21 (DE3) and C43 (DE3) 
cells. E. coli cells harbouring pET16b-aftBCT plasmid were grown at 37°C for 1 hour. 
Expression of AftB C-terminus was induced with 1 mM IPTG and cells were further 
cultivated at either 37 ºC for 4 hours or at 16 ºC overnight. Subsequently, cells were 
harvested, lysed and separated into two fractions: crude cell lysate (IN) and clarified cell 
lysate (SOL). Samples were analysed by 12 % SDS-PAGE gel and stained with 
Coomassie Blue; the His-tagged AftBCT was detected by a Western blot using a 
monoclonal anti-His6 tag antibody. The arrows indicate the overexpressed AftBCT (28 
kDa). 
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Figure 21 SDS-PAGE (A and C) and Western blot (B and D) analysis of AftB C-
terminus from M. tuberculosis overexpressed in E. coli Rosetta (DE3) pLysS and 
Tuner (DE3) cells. E. coli cells harbouring pET16b-aftBCT plasmid were grown at 37°C 
for 1 hour. Expression of AftB C-terminus was induced with 1 mM IPTG and cells were 
further cultivated at either 37 ºC for 4 hours or at 16 ºC overnight. Subsequently, cells 
were harvested, lysed and separated into two fractions: crude cell lysate (IN) and clarified 
cell lysate (SOL). Samples were analysed by 12 % SDS-PAGE gel and stained with 
Coomassie Blue; the His-tagged AftBCT was detected by a Western blot using a 
monoclonal anti-His6 tag antibody. The arrows indicate the overexpressed AftBCT (28 
kDa). 
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Both LM and LAM display immunoregulatory and anti-inflammatory properties that 
affect the host immune response (Mishra, 2011, Jankute et al., 2012). Species specific 
capping moieties of the arabinan domain in LAM including manno-oligosaccharides 
(ManLAM) in slow growers, such as M. tuberculosis (Chatterjee et al., 1993), 
phosphoinositide units (PILAM) in fast growers, such as M. smegmatis (Khoo et al., 
1995), and uncapped LAM known as AraLAM in M. chelonae (Guerardel et al., 2002) 
have been demonstrated to play a role in modulating host response during infection 
(Khoo et al., 1995, Gilleron et al., 1997, Nigou et al., 1997, Nigou et al., 1999, Khoo et 
al., 2001). Although structures of the arabinan domain and its capping motifs in LAM are 
well defined, the biosynthesis of both remains somewhat incomplete. Nevertheless, 
mycobacterial ArafTs with dual functionalities that are involved in LAM biosynthesis in 
addition to AG have been successfully identified, for example, AftC and AftD that both 
act as !(1$3) ArafTs in the assembly of AG and LAM (Skovierova et al., 2009, Birch et 
al., 2010). We have investigated the potential role of known ArafTs AftA and AftB from 
M. smegmatis in the biosynthesis of LAM.  
Previous study by Shi et al. (2008) reported that aftA (MSMEG_6386) from M. smegmatis 
is essential gene for AG biosynthesis and survival of mycobacteria. In order to analyse 
the effects of aftA deletion on LAM biosynthesis, we constructed a knockout phage 
designed to replace MSMEG_6386 in M. smegmatis with a hygromycin cassette. We 
were unsuccessful in obtaining any null mutant transductants and therefore employed 
CESTET to construct aftA deletion in the presence of a second copy of inducible aftA. 
Conditional depletion of AftA in derived M. smegmatis!aftA::pMV306-aftA mutants 
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resulted in cell lysis. However, depletion of AftA protein in the mutant strain also yielded 
persisters, mycobacterial cells that acquired mutations in the acetamide promoter region 
resulting in continues production of AftA. Thus, a careful selection from generated 
transductants has to be performed in order to segregate true aftA conditional mutants in 
M. smegmatis. Further in vitro cell free assays and chemical characterisation of 
lipoglycans extracted from aftA conditional mutant would provide evidence of AftA role 
or the lack of it in the biosynthesis of LM/LAM. 
The biosynthesis of mycobacterial AG and LAM requires a panel of glycosyltransferases 
including transmembrane ArafTs members whose structures are largely unknown 
(General Introduction 1.8.2). Due to inherent hydrophobicity of integral membrane 
proteins their expression and purification can be extremely difficult. Here we employed a 
strategy to express and purify the hydrophilic C-terminal domain of AftA from M. 
tuberculosis. Overexpression of glycosyltransferase AftACT from M. tuberculosis was 
investigated in standard microbial expression systems. Soluble pure recombinant AftACT 
was obtained in suitable amounts for crystallisation trials. However, a significant degree 
of precipitation was observed during protein purification. High throughput 
thermostability screening employing DSF was completed for AftACT in order to identify 
buffer conditions that reduce the protein’s tendency to unfold and precipitate. Several 
solution compositions containing sodium acetate, varying in pH and salt concentration 
were determined as stabilising and, thus, were included in AftACT purification and 
crystallisation processes. However, none of the 96-well plate screens generated protein 
crystals. 
The hydrophilic C-terminal domain of AftA glycosyltransferase can be further 
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characterised using a diverse range of methods. Binding assays employing purified 
AftACT as well as synthetic acceptor analogous would provide information on ligand 
preferences and extent of their interactions. Recombinant AftACT carrying single residue 
substitutions of conserved residues used in ligand-binding assays would identify amino 
acid residues critical for the specific ligand-binding interaction. Moreover, several other 
solution conditions identified by DSF could be tested for improved stability of AftACT, 
and result in higher protein yield and possibly facilitate further crystallisation efficacy. 
Finally, NMR spectroscopy could be applied in determining the structure of AftACT. 
Although sensitivity and resolution of NMR spectroscopy is inferior compared to that of 
X-ray crystallography, a number of successfully solved protein structures utilising NMR 
have been reported (Stehle et al., 2012, Priya et al., 2013, Kim et al., 2014). 
Recent studies have demonstrated that SMALPs offer a universal method for extracting, 
purifying and studying membrane proteins in their native lipid environment (Jamshad et 
al., 2011, Orwick-Rydmark et al., 2012, Gulati et al., 2014, Paulin et al., 2014). Here, we 
employed the SMALP method and purified AftA membrane protein directly from C. 
glutamicum membranes without the need of detergent. The non-peptide nature of the 
styrene maleic acid reagent ensured that spectroscopic studies of AftA structure and 
function remained unaffected allowing biochemical characterisation of the protein. In 
addition, ligand binding studies utilising neoglycolipid acceptors and recombinant AftA 
within SMALP demonstrated a markedly stronger affinity for the longer Acc13 (#-D-
Galf(1"6)-#-D-Galf(1"5))6-#-D-Galf(1"4)-!-L-Rhap-GlcNAc-O-(CH2)7CH3) acceptor 
compared to G5G (#-D-Galf(1"5)-#-D-Galf-O-(CH2)7CH3) and G6G (#-D-Galf(1"6)-#-
D-Galf-O-(CH2)7CH3). It is tempting to speculate that by having a higher affinity to 
longer linear Galf acceptor, AftA may more conveniently locate the acceptor for further 
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addition of first three Araf residues to the galactan chain. Overall, we have shown that 
detergent-free SMALP solubilisation and extraction of membrane proteins does work for 
membrane proteins from Corynebacterineae. This advance may remove a major 
bottleneck in the study of mycobacterial membrane proteins and opens new opportunities 
for structural and functional studies on some of the least studied molecules in 
mycobacterial research. 
Similarly to AftA, we have demonstrated that the homologue of Rv3805c in M. 
smegmatis (MSMEG_6400) is an essential gene. The failure to obtain aftB null mutant in 
the absence of second inducible copy of aftB, coupled with inability of M. smegmatis to 
grow in the media without acetamide, an inducer that activates aftB expression, showed 
that AftB enzymatic function is crucial for the viability of M. smegmatis. Although aftB 
homologue in C. glutamicum has been reported to be non-essential (Seidel et al., 2007a), 
high density mutagenesis studies by Sassetti et al. (2003) suggest that Rv3805c in M. 
tuberculosis is an essential gene. AftB has been reported to act as #(1$2) ArafTs, which 
attaches Araf residues to the nonreducing end of the arabinan domain of AG in C. 
glutamicum (Seidel et al., 2007a). SDS-PAGE and sugar analyses of lipoglycans 
extracted from both parental and conditional mutant strains did not exhibit significant 
difference between each other, however monoclonal antibody F30-5 generated against 
hexa-arabinan motif of LAM no longer recognised LAM extracted from the aftB mutant, 
thus suggesting a loss of terminal #(1!2) Araf residues. Further chemical 
characterisation of the LAM from aftB conditional mutant by glycosyl linkage analysis or 
NMR is necessary to confirm our predictions. 
Expression of the full length AftB and its hydrophilic C-terminal domain from M. 
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tuberculosis and C. glutamicum was also examined. Production of full length AftB was 
not observed under any conditions, whereas AftBCT was produced exclusively as 
insoluble inclusion bodies in all E. coli cell lines tested. The overexpression of 
recombinant proteins in E. coli host is commonly utilised to generate proteins in large 
amounts. However, approximately 70 % of recombinant proteins expressed in E. coli 
either degrade or form insoluble inclusion bodies (Yang et al., 2011). A number of 
methods have been developed to obtain soluble protein from inclusion bodies, but a 
general strategy involves solubilising aggregated protein in denaturant, followed by 
subsequent refolding resulting in soluble and biologically active protein (Cabrita and 
Bottomley, 2004, Singh and Panda, 2005, Burgess, 2009). This strategy could be 
employed with recombinant AftBCT that has generated in large amounts, but formed 
insoluble inclusion bodies. Moreover, reducing the rate of protein synthesis in E. coli host 
by lowering inducer concentration or using a lower copy number plasmid could 
potentially improve protein solubility. Finally, alterations of the host strain, changes of 
the construct encoding AftBCT or co-expression of proteins with molecular chaperones 
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4 Molecular and biochemical characterisation of Emb arabinosyltransferase from 
Corynebacterium glutamicum  
4.1 Introduction 
AG is a key structural component of the mAGP complex that plays an important role in 
covalently anchoring the mycolic acid layer to the inner PG, and is unique in that all of its 
sugars are present in the furanose ring form (McNeil et al., 1987). Moreover, unlike most 
bacterial polysaccharides, AG lacks repeating units and is instead composed of a few 
distinct structural motifs (Daffe et al., 1990). Previous research has demonstrated that the 
whole mAGP complex is covalently attached to PG via a specific linker unit, which 
connects the linear galactan chain to selected MurNGly residues of PG (McNeil et al., 
1990). These cell wall components are crucial for the growth, viability and virulence of 
M. tuberculosis and, therefore, are often the targets of effective chemotherapeutic agents, 
such as EMB. 
The galactan component of AG is present in the form of approximately 30 alternating 
!(1"5) and !(1"6) Galf residues combined in a linear fashion. Three arabinan chains, 
each containing approximately 30 Araf residues, are linked to this linear galactan at C-5 
of some of !(1"6) Galf residues (Daffe et al., 1990, Bhamidi et al., 2008). The arabinan 
domain, in contrast to the linear galactan, is highly branched. Since the AG component is 
essential to mycobacteria, its structure was also investigated in the related 
Corynebacterium genus, in which AG is non-essential. Deletion studies in C. glutamicum 
coupled with mass spectrometry analysis determined that the three arabinan chains are 




majority of Araf residues form a backbone containing #-5-linked #-D-Araf residues with 
branching introduced at the C-3 hydroxyl forming 3,5-Araf linked residues (Daffe et al., 
1990). At the non-reducing end of AG, the highly branched arabinan domain is 
covalently attached to the mycolic acids of the outer membrane, thus completing the 
whole mAGP complex (Kaur et al., 2009). Previous research has shown that the non-
reducing termini of the arabinan structure consists of a distinct Ara6 motif [!-D-Araf-
(1"2)-#-D-Araf]2-3,5-#-D-Araf-(1"5)-#-D-Araf], with the mycolic acids attached to 
position 5 of both the terminal !-D-Araf units and the penultimate 2-#-D-Araf units 
(McNeil et al., 1991).  
Earlier studies demonstrated that EMB, a front-line anti-TB drug, specifically inhibits AG 
biosynthesis with the precise molecular target being the embCAB locus in M. tuberculosis 
(Telenti et al., 1997) and embRAB locus in M. avium (Belanger et al., 1996). Individual 
disruption of embA, embB or embC in M. smegmatis resulted in three slow growing 
viable mutants. In comparison to wild type M. smegmatis, the Ara6 motif of AG was 
altered in both embA and embB mutants, whereas the embC deletion resulted in 
diminished LAM synthesis (Escuyer et al., 2001, Goude et al., 2008). These studies 
suggest that both EmbA and EmbB are involved in the formation of AG, specifically 
Ara6, while EmbC is involved in the biosynthesis of LAM. Interestingly, in comparison 
with M. tuberculosis, C. glutamicum has been shown to have only one emb gene, which is 
not essential to this organism (Alderwick et al., 2005). Nevertheless, the deletion of this 
gene caused severe reduction of arabinose in the cell wall, resulting in a truncated AG 
structure with terminal Araf residues on the galactan chain (Alderwick et al., 2005). It is 




tuberculosis, the LAM structure is significantly different in terms of arabinosylation. 
Specifically, LAM from C. glutamicum lacks high-branching arabinose domain and 
contains single Araf residues attached to the mannan core by AftE (NCgl2096). 
Another ArafT from the emb locus, AftA (Rv3792), has been demonstrated to catalyse the 
addition of the very first Araf residue from the DPA onto the galactan chain at positions 
8, 10 and 12, thus priming the galactan for further extension by unknown #(1"5) 
ArafT(s) (Alderwick et al., 2006). Recent knockout studies in M. smegmatis 
demonstrated aftA to be essential for viability, however an aftA deletion in C. glutamicum 
resulted in a slow growing mutant with a cell wall lacking arabinose, as well as cell wall 
bound mycolates (Alderwick et al., 2006). Knockout studies in M. smegmatis identified 
AftC (MSMEG_2785, orthologue of Rv2673), which is responsible for the #-1,3-
branching of the internal arabinan domain at the non-reducing end of AG and LAM 
(Birch et al., 2008, Birch et al., 2010). A functional ArafT encoded by aftD (Rv0236c) in 
M. tuberculosis was assigned as possessing #-1,3-branching activity (Skovierova et al., 
2009). Due to its size, AftD has been suggested to have other additional functions in AG 
and LAM biosynthesis. For example, it may act as a scaffold for the multi-enzyme 
machinery involved in arabinan synthesis (Skovierova et al., 2009). The terminal !(1"2) 
Araf residues are transferred onto the arabinan domain by AftB (Rv3805c), thus marking 
the end-point of AG biosynthesis before decoration with mycolic acids (Belisle et al., 
1997, Seidel et al., 2007).  
In this study we examined effects of an aftA and emb double deletion mutant on AG 
biosynthesis in C. glutamicum. Analysis of its cell wall revealed a complete absence of 




the loss of cell wall bound mycolates. In addition, by employing an in vitro cell free assay 
using various C. glutamicum mutants (C. glutamicum!aftA, C. glutamicum!emb, C. 
glutamicum!aftB!aftD, C. glutamicum!aftA!emb) and use of synthetic oligosaccharide 
acceptors, !-D-Galf-(1"5)-!-D-Galf-(1"6)[#-D-Araf-(1"5)]-!-D-Galf and !-D-Galf-
(1"6)-[#-D-Araf-(1"5)]-!-D-Galf-(1"5)-!-D-Galf, we demonstrated that the transfer 
of Araf residue from DPA to the primed galactan in C. glutamicum is catalysed by Emb 
ArafT with #(1"5) activity.  
4.2 Materials and Methods  
4.2.1 Construction of plasmids and strains 
C. glutamicum!aftB!aftD and C. glutamicum!aftA!emb strains were kindly provided by 
Dr Lothar Eggeling, Jülich Research Centre, Germany. Briefly, to construct the deletion 
vector pK19mobsacB!aftD (NCgl2757) PCR was applied with primer pairs AB (A, 5’-
CGC TTC TAG ACC ACG TCA TGG CAT ACG AAA CTG-3’; B, 5’-CCC ATC CAC 
TAA ACT TAA ACA CAC CAC AAA ACC CAG CAC-3’) and CD (C, 5’-TGT TTA 
AGT TTA GTG GAT GGG GCT GCG CTA TTT GCT GG-3’; D, 5’-GCG GGA ATT 
CGC ATG GCA AGC CGG TAA G-3’) and genomic DNA of the wild type of C. 
glutamicum ATCC 13032 used as template. Both amplified products were used in a 
second PCR with primer pairs AD to generate a 620 bp fragment consisting of sequences 
adjacent to C. glutamicum aftD, which was ligated with XbaI-EcoRI-cleaved 
pK19mobsacB. 
All plasmid inserts were confirmed by sequencing. The chromosomal deletion of C. 




selection (Schafer et al., 1994), and its successful deletion was verified by use of two 
different primer pairs hybridising in the genome. In order to construct the aftB/aftD 
double mutant C. glutamicum!aftB!aftD, the deletion vector pK19mobsacB!aftD was 
also used and introduced into the previously reported strain C. glutamicum!aftB (Figure 
1) (Seidel et al., 2007). Similarly, the deletion vector pK19mobsacB!aftA constructed 
previously (Alderwick et al., 2006) was employed and introduced into previously 
reported strain C. glutamicum!emb (Alderwick et al., 2005), thus generating C. 
glutamicum!afta!emb (Figure 1).  
 
Figure 1 Construction strategy of C. glutamicum!aftB!aftD (A) and C. 




























4.2.2 Extraction and purification of arabinogalactan from C. glutamicum 
The mAGP samples of wild-type C. glutamicum and C. glutamicum!aftA!emb were 
prepared as described in General Materials and Methods 6.5.16. Mycolic acids were 
removed from the mAGP by saponification: using 2 % potassium hydroxide in methanol-
toluene (1:1) for 48 hours. The insoluble residue was recovered by centrifugation at 
27,000 g. The sample was washed 3-5 times with methanol and the resulting AGP 
complex freeze-dried. The AGP (2 g) preparation was treated with 75 ml of 2 M sodium 
hydroxide for 16 hours at 80 °C. The supernatant, which contains solubilised AG, was 
recovered by centrifugation at 27,000 g for 30 minutes. The crude AG preparation was 
neutralised with acetic acid, re-centrifuged and dialysed to remove residual salts (MWCO 
3,500). A precipitate that was formed during dialysis was removed by centrifugation. The 
supernatant was diluted in cold ethanol (80 %, v/v) and left at -20 °C overnight to 
precipitate the base-solubilised AG, which was recovered by centrifugation, lyophilised 
and stored at 4 °C. 
4.2.3 NMR spectroscopic analysis of AG from C. glutamicum and C. 
glutamicum!aftA!emb  
NMR spectra of AG from wild-type C. glutamicum and C. glutamicum!aftA!emb 
samples were recorded using Bruker DMX-500. Samples were repeatedly exchanged in 
deuterium oxide (99.9 atom % D, Sigma Aldrich) with intermediate lyophilisation, and 
finally dissolved in 0.5 ml deuterium oxide and analysed at 313 K. The 1H and 13C NMR 




respectively. Data was collected and analysed using Bruker XWIN-NMR software. 
Details concerning NMR sequences used and experimental procedures were described 
previously (Daffe et al., 1990). 
4.2.4 Extraction and purification of lipoglycans from C. glutamicum and C. 
glutamicum!aftA!emb 
Wild-type C. glutamicum and C. glutamicum!aftA!emb cells (10 ml) were grown to an 
early exponential growth phase (OD600 of 0.6), labelled with [14C]-glucose 1 µCi/ml and 
incubated for a further 12 hours at 30 °C with shaking. The labelled cells were harvested 
and washed twice in phosphate buffered saline. The pellet was resuspended in 4 ml of 50 
% ethanol in water (v/v) and the mixture refluxed at 85 °C for 6 hours. The supernatant 
was recovered by centrifugation and transferred to a fresh tube. The extraction process 
was repeated five times and the supernatant fractions pooled and dried. The crude 
lipoglycans were subjected to a 90 % phenol treatment at 65 °C for 1 hour. After cooling, 
the sample was centrifuged and the upper aqueous layer recovered and dialysed against 
water (MWCO 3500 kDa). An equal amount of radioactivity was subjected to 15 % SDS-
PAGE and [14C]-labelled purified lipoglycans were visualised by autoradiography 
employing Kodak BioMax MR films.  
4.2.5 Preparation of C. glutamicum membranes 
After cultivation, C. glutamicum cells (wet weight 10 g) were resuspended in 50 mM 
MOPS pH 7.9, 5 mM !-mercaptoethanol and 10 mM MgCl2. Cell slurry was sonicated 
(MSE Soniprep 150, 12 micron amplitude, 60 seconds ON, 90 seconds OFF for 10 




centrifuged again at 100,000 g for 90 minutes at 4 °C and isolated cell membranes were 
collected and concentrated to 15-20 mg/ml in 50 mM MOPS pH 7.9, 10 mM MgSO4, 5 
mM !-mercaptoethanol. 
4.2.6 Preparation of C. glutamicum P60 cell wall material 
C. glutamicum cells (wet weight 10 g) were resuspended in 50 mM MOPS pH 7.9, 5 mM 
!-mercaptoethanol and 10 mM MgCl2. The cell slurry was sonicated (MSE Soniprep 150, 
12 micron amplitude, 60 seconds ON, 90 seconds OFF for 10 cycles) and centrifuged at 
27,000 g for 20 minutes at 4 °C. Resultant pellet was resuspended in buffer containing 50 
mM MOPS pH 7.9, 10 mM MgSO4, 5 mM !-mercaptoethanol (24 ml) and Percoll (32 
ml) (Sigma Aldrich), mixed thoroughly and centrifuged at 27,000 g for 60 minutes at 4 
°C. The upper band, corresponding to C. glutamicum cell wall ‘P60’ material was 
carefully removed, washed using 50 mM MOPS pH 7.9, 10 mM MgSO4, 5 mM !-
mercaptoethanol to remove Percoll and the final cell wall fraction resuspended in 50 mM 
MOPS pH 7.9, 10 mM MgSO4, 5 mM !-mercaptoethanol to a final protein concentration 
of 10 mg/ml.  
4.2.7 [14C]-pRpp synthesis 
Radiolabelled [14C]-glucose (200 µCi) was dried and resuspended in 500 µl of ice-cold 
50 mM KH2PO4, 5 mM MgCl2. Both ATP and NADP were added to the reaction mixture 
to a final concentration of 1 mM and 4 mM, respectively. Hexokinase/ glucose-6-
phosphate dehydrogenase mixture (5 units, Roche) was added to the reaction, gently 
mixed and incubated at 37 °C for 15 minutes. Subsequently, 6-phosphogluconic 




incubated at 37 °C for 15 minutes followed by addition of phosphoriboseisomerase (5 
units, Sigma Aldrich) and incubation at 30 °C for 15 minutes. Purified phosphoribosyl 
pyrophosphate synthetase PrsA from M. tuberculosis prepared as described in Alderwick 
et al. (2011) was added to the reaction and incubated at 37 °C for 30 minutes. The 
reaction mixture was passed through a protein concentrator to remove enzymes used in 
the assay and the [14C]-pRpp was purified employing ion exchange LC-SAX column. All 
unbound material was removed using water (2 ml) and [14C]-pRpp eluted via a gradient 
of sodium acetate (100 mM-2M). Fractions containing pure [14C]-pRpp were collected 
and stored at -20 °C for further use. 
4.2.8 Arabinofuranosyltransferase activity using membrane preparations of C. 
glutamicum, C. glutamicum!aftA, C. glutamicum!emb, C. 
glutamicum!aftA!emb and C. glutamicum!aftB!aftD 
Membrane and P60 fractions were prepared as described earlier (Materials and Methods 
4.2.5 and 4.2.6, respectively). Neoglycolipid acceptors MJ-13-77 and MJ-14-01 (2 µl of 
20 mM, stored in ethanol) and decaprenyl phosphate (1 µl of mg/ml, stored in ethanol) 
were aliquoted into 1.5 ml Eppendorf tubes and dried. IgePalTM (Sigma-Aldrich) was 
added (0.1%, v/v) with the appropriate amount of buffer (50 mM MOPS pH 7.9, 10 mM 
MgSO4, 5 mM !-mercaptoethanol) to a final volume of 80 µl. Samples were sonicated for 
15 minutes to resuspend lipid linked substrates and then mixed with the remaining assay 
components: membrane protein and ‘P60’ fraction (1 mg each) from either C. 
glutamicum, C. glutamicum!aftA, C.glutamicum!emb, C. glutamicum!aftA!emb, C. 
glutamicum!aftB!aftD, 1 mM ATP, 1 mM NADP, p[14C]Rpp (25,000 cpm) and in some 




by the addition of 533 µl of chloroform/methanol (1:1, v/v) and mixed for 30 minutes. 
Supernatant was recovered following centrifugation at 27,000 g for 30 minutes and dried 
under nitrogen. The residue was resuspended in of 750 µl ethanol/water (1:1, v/v) and 
loaded onto 1 ml SepPak ion exchange columns, pre-equilibrated with ethanol/water (1:1, 
v/v). The column was washed twice with 2 ml of ethanol (100 %) and the eluate collected 
and dried. Sample was resuspended in a mixture of water-saturated n-butanol (3 ml) and 
water (3 ml), mixed and the organic phase recovered following centrifugation. The 
aqueous phase was extracted once again with n-butanol (3 ml) and the organic phases 
pooled. The extracts were further washed using n-butanol-saturated water (3 ml). Finally, 
the n-butanol fraction was dried and resuspended in 200 µl of n-butanol. The 
incorporation of [14C]Araf was determined by subjecting samples to TLC using silica gel 
plates (5735 silica gel 60F254, Merck) developed in isopropanol:acetic acid:water (8:1:1, 
v/v/v) and visualised by autoradiography employing Kodak BioMax MR films. 
4.2.9 Analysis of arabinofuranosytransferase reaction products prepared from C. 
glutamicum and C. glutamicum!aftA!emb membranes 
Large-scale reactions were performed containing cold pRpp (25 mM, Sigma Aldrich). 
Membranes and ‘P60’ fraction were prepared as described in Materials and Methods 
4.2.5 and 4.2.6, respectively. Neoglycolipid acceptors MJ-13-77 and MJ-14-01 (8 µl of 
20 mM, stored in ethanol) and decaprenyl phosphate (4 µl of mg/ml, stored in ethanol) 
were aliquoted into glass tubes and dried. IgePalTM (Sigma-Aldrich) was added (0.1%, 
v/v) with the appropriate amount of buffer (50 mM MOPS pH 7.9, 10 mM MgSO4, 5 mM 
!-mercaptoethanol) to a final volume of 320 µl. Samples were sonicated for 15 minutes to 




membrane proteins and ‘P60’ fraction (1 mg each) from either C. glutamicum and C. 
glutamicum!aftA!emb, 1 mM ATP, 1 mM NADP, cold pRpp (25 mM, Sigma Aldrich) 
and in some cases EMB (1 mg/ml). The reaction mixture was incubated at 37 °C for 1 
hour. The assays were replenished with fresh membranes and ‘P60’ and re-incubated at 
37 °C for 1hour with the entire process repeated thrice. Reaction products were extracted 
with n-butanol/water phase separation as described earlier (4.2.8). Products together with 
a radiolabelled reference product were subjected to preparative TLC plates, developed in 
isopropanol:acetic acid:water (8:1:1, v/v/v) and the reference sample visualised by 
autoradiography employing Kodak BioMax MR films. The cold products were recovered 
from the TLC plate by n-butanol extraction. The butanol phases were washed with water 
saturated with n-butanol and dried. Samples were analysed by MALDI-MS and MS/MS 
as previously described (Lee et al., 2006, Shi et al., 2008). 
4.3 Results  
4.3.1 Lipid characterisation of C. glutamicum!afta!emb mutant 
To compare the double-deletion C. glutamicum!afta!emb mutant to previously reported 
phenotypes of C. glutamicum!aftA (Alderwick et al., 2006) and C. glutamicum!emb 
(Alderwick et al., 2005) its cellular composition was studied. Firstly, wild type C. 
glutamicum and C. glutamicum!afta!emb strains were analysed for AG esterified 
corynomycolic acids and cell wall associated lipids, both from an equivalent starting 
amount of biomass for each strain due to differences in growth rate. As expected, cell 
wall bound corynomycolic acid methyl esters (CMAMES) were abolished in the C. 




to the wall of C. glutamicum (Figure 2B). Analysis of the cell wall associated lipids in the 
mutant highlighted an apparent increase in trehalose dicorynomycolates (TDCM) and 
trehalose monocorynomycolates (TMCM), the equivalent of mycobacterial TDMs and 
TMMs, respectively (Figure 2A). This was verified quantitatively by labelling cultures 
with [14C]-acetate and loading equal amounts of radioactive extractable free lipids from 
C. glutamicum and C. glutamicum!afta!emb. As expected, wild type C. glutamicum 
exhibited the known free lipid profile containing non-polar lipids (130 CNT/mm2), 
TDCMs (134 CNT/mm2), TMCMs (97 CNT/mm2), and phospholipids (356 CNT/mm2). 
In contrast, densitometry based analysis of the C. glutamicum!aftA!emb mutant 
demonstrated a significant 3.5 fold increase in TDCMs (503 CNT/mm2) and a 2.5 fold 
increase in TMCMs (234 CNT/mm2). These results are consistent with previous studies 
and inficate that AftA and Emb from C. glutamicum are involved in key steps of arabinan 














Figure 2 Analysis of cell wall lipids from C. glutamicum and C. 
glutamicum!aftA!emb. A. Analysis of cell wall associated [14C]-lipids from C. 
glutamicum and C. glutamicum!aftA!emb. Lipids were extracted from cells by a series 
of organic washes as described in General Materials and Methods 6.5.14. Equivalent 
aliquots (25,000 cpm) from each strain were subjected to TLC using silica gel plates 
(5725 silica gel 60F254, Merck) developed in chloroform/methanol/water (60:16:2, 
v/v/v) and visualised by autoradiography using Kodak BioMax MR films. B. Analysis of 
cell-wall bound lipids from C. glutamicum and C. glutamicum!aftA!emb cells. An 
equivalent amount of cells (100 mg) were delipitated using three extractions of 
chloroform/methanol/water (10:10:3, v/v/v) at 50 °C for 4 hours, and bound mycolic 
acids were released by addition of tetra-butyl ammonium hydroxide at 100 °C for 12 
hours and subsequently methylated. An equal amount of sample from each strain was 
subjected to TLC using silica gel plates  (5725 silica gel 60F254, Merck) and developed 
in petroleum ether/acetone (95:5, v/v). CMAMES were visualised using 







































4.3.2 Structural characterisation of C. glutamicum!aftA!emb 
GC analysis of alditol acetates prepared from C. glutamicum mAGP demonstrates 
presence of rhamnose, arabinose and galactose sugar residues as reported previously 
(Alderwick et al., 2005, Alderwick et al., 2006, Seidel et al., 2007). However, analysis of 
alditol acetates derived from C. glutamicum!aftA!emb mAGP revealed a total loss of 
arabinose. Previous independent deletion studies of either emb (Alderwick et al., 2005) or 
aftA (Alderwick et al., 2006) in C. glutamicum resulted in a drastically truncated structure 
of AG possessing only t-Araf residues and a total loss of remaining Araf residues, 
respectively. Consequently, the loss of cell wall arabinose was expected in the C. 
glutamicum!aftA!emb mutant.  
Further analysis of base solubilised AG from C. glutamicum and C. 
glutamicum!aftA!emb were performed using NMR spectroscopy. The 1H-NMR 
spectrum of wild type C. glutamicum-AG (Figure 4A) was highly complex when 
compared to the anomeric region of C. glutamicum!aftA!emb-‘AG’ (Figure 4B). Indeed, 
the cell wall ‘AG’ of the double mutant 1D 1H spectrum exhibited two major well-
defined resonances characterised by several overlapping resonances arising from two 
different classes of glycosidic residues: 5-!-Galf (d110.6, d5.18 ppm) and 6-!-Galf 
(d111.4, d4.98). Based on our data for wild type C. glutamicum-AG and previously 
published work by Daffe et al. (1990), the 13C resonance at d104.2 ppm correlates to an 
anomeric proton at d5.1 ppm, and was assigned as t-!-Araf"5 linkage. The resonances at 
d108.9 and d109.2, correlating to protons at d5.2 and d5.12 were assigned as 2-#-Araf"3 
and 2-#-Araf"5 linkage, respectively. Spin systems (d111.1 and d5.06 ppm) assigned to 




wild-type C. glutamicum-AG. The 13C resonance at d109.4 ppm, which correlates to a 
proton at d5.05 ppm was designated as the 5,6-!-Galf linkage. The well separated spin 
systems for 5-!-Galf (d110.6, d5.18 ppm) and 6-!-Galf (d111.4, d4.98) were visible in 
both wild type and C. glutamicum!aftA!emb-‘AG’ spectra. Overall, NMR analysis 
suggests that, as compared to wild-type AG, the ‘AG’ of the double mutant is lacking 




















Figure 3 Glycosyl compositional analysis of cell walls (mAGP) of C. glutamicum and 
C. glutamicum!aftA!emb. Samples of purified cell walls were hydrolysed with 2 M 
trifluoroacetic acid, reduced with sodium borohydride and per-O-acetylated resulting in 
alditol acetates. Subsequently, samples were examined by gas chromatography as 








Figure 4 Two-dimensional NMR spectra of base solubilised AG from C. glutamicum 
and C. glutamicum!aftA!emb. Structural characterisation of wild type C. glutamicum-
AG (A) and C. glutamicum!aftA!emb-AG (B). 1H, 13C HSQC NMR spectra were acquired 




4.3.3 Lipoglycan analysis of C. glutamicum and C. glutamicum!aftA!emb 
To date, only four ArafT - AftC, AftD, AftE and EmbC - have been demonstrated to play 
a role in LAM assembly of Mycobacterium (Goude et al., 2008, Skovierova et al., 2009, 
Birch et al., 2010, Mishra et al., 2012). Therefore, we wanted to examine the potential 
role of AftA and Emb in LAM biosynthesis. Extracted lipoglycans from wild type C. 
glutamicum and C. glutamicum!aftA!emb were analysed quantitatively by labelling 
cultures with [14C]-glucose and loading equal amounts of radioactive lipoglycans to a 15 
% SDS-PAGE. Extracts from both strains showed presence of [14C]-LAM, -LM and -
PIMs with no significant difference between the two samples.  
 
Figure 5 SDS-PAGE analysis of lipoglycans extracted from C. glutamicum and C. 
glutamicum!aftA!emb. Bacterial cells were refluxed with 50 % ethanol to extract crude 
lipoglycans. Samples were then subjected to hot phenol treatment and dialysed against 
water to yield pure lipoglycan fraction from both C. glutamicum and C. 
glutamicum!aftA!emb. Equivalent aliquots (20,000 cpm) from each strain were analysed 

























4.3.4 In vitro arabinofuranosyltransferase activity with extracts of C. glutamicum, 
C. glutamicum!aftA, C. glutamicum!emb, C. glutamicum!aftB!aftD and C. 
glutamicum!aftA!emb 
 




Initial attempts to develop an in vitro assay using purified recombinant Emb from C. 
glutamicum have thus far proved unsuccessful. As an alternative, to catalyse ArafT 
activity in the presence of exogenous neoglycolipid acceptors, MJ-13-77 and MJ-14-01 
(Figure 6), was assessed using membrane preparations from C. glutamicum, C. 
glutamicum!aftA, C. glutamicum!emb, C. glutamicum!aftB!aftD and C. 
glutamicum!aftA!emb. The cell free assay format was based on previously established 
ArafT assays (Seidel et al., 2007, Birch et al., 2008) and was designed to directly 
examine whether Emb enzyme from C. glutamicum acts as an (1"5) ArafT and transfers 
Araf residue to the primed galactan chain. Three pentasaccharide products (A, B and C) 
were synthesised in the presence of synthetic acceptors, when assayed with wild type C. 




result of #(1"5) Araf linkages added to the MJ-13-77 and MJ-14-01 acceptors, 
respectively. Whereas B pentasaccharide was possibly synthesised by adding either 
#(1"2) or #(1"3)Araf linkage to MJ-13-77. Addition of EMB at concentrations of up 
to 1 mg/ml to the reaction mixture, resulted in an inhibition of A and C product 
formation, suggesting that the enzyme(s) adding Araf residue onto the acceptors are EMB 
sensitive, such as Emb. A comparable experiment was repeated using C. 
glutamicum!aftA membranes and neoglycolipid acceptors, MJ-13-77 and MJ-14-01, 
where a similar profile to that of wild-type C. glutamicum was observed (Figure 7B). 
Hence, demonstrating that AftA ArafT is highly unlikely to be involved in addition of 
Araf residue to either synthetic acceptor. Another experiment utilising C. 
glutamicum!emb membranes and synthetic acceptors was performed where both A and C 
products were not formed (Figure 7C), suggesting that the deleted enzyme Emb is indeed 
responsible for the generation of these two products. Interestingly, C. glutamicum!emb 
strain was still able to produce product B utilising MJ-13-77. Addition of EMB to the 
reaction mixture did not inhibit the synthesis of product B, therefore, implying that ArafT 
adding the Araf residue to the MJ-13-77 is EMB insensitive. An in vitro experiment was 
completed using C. glutamicum!aftB!aftD membranes where only A and C products 
were synthesised (Figure 7D). The data clearly show that AftB or AftD possessing 
#(1"2) and #(1"3) ArafT activity, respectively, are most likely to be responsible for 
the formation of product B. Finally, an in vitro ArafT assay was repeated employing C. 
glutamicum!aftA!emb membranes leading to formation of a single product B. This is 





Figure 7 Arabinofuranosyltransferase activity assay utilising MJ-13-77 and MJ-14-
01 neoglycolipid acceptors and membranes prepared from C. glutamicum (A), C. 
glutamicum!aftA (B), C. glutamicum!emb (C), C. glutamicum!aftB!aftD (D), C. 
glutamicum!aftA!emb (E). The representative diagram is (F). 
Arabinofuranosyltransferase activity was determined using synthetic acceptors in a cell-
free assay with and without ethambutol (1mg/ml). The products of the assay were 
subjected to TLC using silica gel plates (5735 silica gel 60F254, Merck) in 
isopropanol/acetic acid/water (8/1/1, v/v/v) with the reaction products visualised by either 
autoradiography using Kodak BioMax MR films or phosphorimaging using Molecular 




4.3.5 Characterisation of arabinosyltransferase reactions products 
Products A, B and C, synthesised using synthetic acceptors MJ-13-77 and MJ-14-01, 
membranes from wild-type C. glutamicum, and in some cases EMB were excised from a 
preparative TLC plate, per-O-methylated and subjected to matrix-assisted laser 
desorption/ionisation-time-of-flight mass spectrometry (MALDI-TOF MS). To rule out 
co-chromatography of both the starting material and product even after separation by the 
TLC, both MJ-13-77 and MJ-14-01 acceptors were also analysed and served as a marker 
for any remaining unreacted acceptor (Figure 8A-B). All three samples containing A, B 
and C products have provided similar molecular ion profiles (Figure 8 C-E). Molecular 
ions of m/z 1099.5 were observed and corresponded to the formed pentasaccharide 
[Gal3Ara2-C8H17+Na]+(Figure 8C-E) containing newly added Araf-(1-?). Ions for 
unreacted MJ-13-77 and MJ-14-01 of m/z 939.5 [Gal3Ara1-C8H17+Na]+ were also 
detected. In addition, all samples including spectra of acceptors contained molecular ions 
of m/z 969.5, suggesting a possible permethylation artefact. Overall, MALDI-TOF MS 
analysis confirms the addition of a single Araf residue to MJ-13-77 and MJ-14-01 
resulting in products A, B and C with composition Gal3Ara2-C8H17. 
In order to define the branching pattern of the generated oligomers, the respective ions 
were subjected to MALDI-TOF MS/MS analysis. The fragmentation patterns of synthetic 
acceptors and arabinan oligomers have been validated previously (Lee et al., 2006, Zhang 
et al., 2007, Shi et al., 2008). The original Gal3Ara1-C8H17 acceptors provided the series 
of ions: O,3A, 2,4A, C, E, G, O,2X and 1,4X (Figure 9A), consistent with expected linkages 
and cleavages (Figure 9B-C). In the case of product A and B, both provided similar 




that in both cases Araf residue have been added to either Araf or Gaf residue at the non-
reducing end of MJ-13-77 acceptor. Lack of arabinosylation at the C-2 of the Araf residue 
of MJ-13-77 is supported by the absence of ions 2,4A and O,2X of m/z 125 and 981, 
respectively. In addition, the Y ion of m/z 765, coupled with ions at m/z 285, 327 and 
863, locate the Araf residue at either C-3 or C-5 of the Araf unit of the acceptor in both 
product A and product B. However, ions (m/z 97 and 1025) that would indicate if the 
residue was attached to the C-3 were not exclusive to both spectra, whereas ions (m/z 
257, 865) that would locate the residue specifically to C-5 were not detected most likely 
due to low abundance. In contrast, for the product C (Figure 11), the Y, O,3A and 2,4A ions 
at m/z 335, 665 and 693, respectively, indicated the newly attached Araf residue linked to 
either Galf or Araf residue at the non-reducing end of the MJ-14-01 acceptor, whereas the 
ion of m/z 375 clearly places the Araf residue to the #(1"5) linked Araf of the acceptor. 
More importantly, the O,3A, O,2X, E and G ions with m/z of 257, 301, 343 and 863, 







Figure 8 MALDI-TOF MS analysis of acceptors and enzymatic products. Both MJ-13-
77 (A) and MJ-14-01 (B) were dried, per-O-methylated and subjected to MALDI-TOF MS. 
(C-E) Products formed utilising Gal3Ara1-C8H17 synthetic acceptors and wild-type C. 






Figure 9 MALDI-TOF MS/MS analysis of per-O-methylated MJ-13-77 and MJ-14-
01 acceptors. A The fragmentation pattern and adopted nomenclature of 
oligosaccharides. MS/MS spectra related to the expected cleavages and linkages of 
synthetic acceptors MJ-13-77 (B) and MJ-14-01 (C). 


















































































Figure 10 MALDI-TOF MS/MS analysis of per-O-methylated product A (A) and 
product (B). The added Araf residue is depicted in red, whereas cleavages and linkages 





















































































Figure 11 MALDI-TOF MS/MS analysis of per-O-methylated product C. The added 
Araf residue is depicted in red, whereas cleavages and linkages that are diagnostic for 
determining the structure are depicted in blue. 
 
4.4 Discussion 
The mAGP complex is a key cell wall component of the Corynebacterianeae, which is 
essential for the growth and viability of M. tuberculosis. This highly complex structure is 
rich in lipids and sugars that act as a low permeability barrier and contribute to resistance 
to common antibiotics. It is therefore not surprising that potent anti-TB drugs target the 
biosynthesis of mAGP, including EMB and INH that inhibit the biosynthesis of AG and 
mycolic acids, respectively. Nevertheless, cases of drug resistant TB pose a challenge to 
treatments offered by the chemotherapy, therefore, increasing the need to discover novel 
drug targets and develop new therapeutic agents against mycobacterial infections. Our 








































remains somewhat incomplete. For instance, the catalytic mechanisms of how these 
ArafTs synthesise the bulk of arabinan containing #(1"5), #(1"3) and #(1"2) 
glycosidic linkages in mycobacteria and corynebacteria remain unknown. Structural and 
functional information of these enzymes would aid the further exploitation of ArafTs as 
potential drug targets to inhibit the crucial mAGP complex in M. tuberculosis. 
In this study, we have characterised a C. glutamicum!aftA!emb mutant. Analysis of its 
cell wall revealed AG containing only the galactan domain with no arabinose (Figure 4). 
In addition, the double deletion of afta and emb also led to an increase in non-covalently 
linked TDCMs and TMCMs and a loss of covalently bound cell wall mycolates 
indicating the loss of mycolylation sites in AG (Figure 2). Individual disruptions of aftA 
and emb in C. glutamicum obtained previously led to analogous effects – complete 
absence of AG arabinan and a highly truncated AG with only terminal Araf residues, 
respectively (Alderwick et al., 2005, Alderwick et al., 2006). In contrast, individual 
deletions of embA and embB in M. smegmatis (Escuyer et al., 2001) resulted in highly 
arabinosylated AG with alterations present only in Ara6 motif. Since previous attempts to 
construct a double deletion of embA and embB in M. smegmatis were unsuccessful, it is 
tempting to speculate that EmbA or EmbB may compensate for each other in the 
individual knockouts in M. smegmatis. 
In addition, we examined the potential role of AftA and Emb enzymes in LAM 
biosynthesis by isolating lipoglycans (PIMs, LM and LAM) from both wild type C. 
glutamicum and C. glutamicum!aftA!emb strains. Since individual inactivation of either 
AftA or Emb led to significant arabinan loss in AG, deletion of both ArafTs were 




extractions from both wild type and double mutant strains showed similar profiles with 
no significant difference (Figure 5), implying that neither AftA, nor Emb play a role in 
the synthesis of LM/LAM in C. glutamicum. Nevertheless, the LAM structure is less 
elaborate in C. glutamicum than compared to M. smegmatis or M. tuberculosis (Mishra, 
2011), therefore, it is possible that AftA may still contribute to biosynthesis of LM/LAM 
in Mycobacterium. Previous studies demonstrated that disrupting the synthesis of the only 
arabinose donor in AG - DPA - through inactivation of UbiA led to a total loss of 
arabinose (Alderwick et al., 2005). However, C. glutamicum::ubiA mutant still produced 
variants of LAM containing Araf residues, indicating the presence of yet uncharacterised 
arabinose sugar donor and putative ArafTs that employ it (Tatituri et al., 2007). Notably, 
AftE has been characterised as an ArafT, which attaches singular Araf residues onto the 
LAM intermediate in C. glutamicum (Mishra et al., 2012). Deletion of C. glutamicum 
AftE resulted in a truncated LAM structure with complete absence of arabinose, but 
extended mannosylation. One could argue that AftE may employ the uncharacterised 
Araf donor for the biosynthesis of the arabinan domain in LAM in C. glutamicum. 
Although, previously described ArafTs including Emb proteins (Escuyer et al., 2001, 
Alderwick et al., 2005), AftA (Alderwick et al., 2006), AftB (Seidel et al., 2007), AftC 
(Birch et al., 2008) and AftD (Skovierova et al., 2009) share certain functional 
relationship, these enzymes are distinct ArafTs with their own individual features. A 
classic example is the sensitivity of Emb proteins from Mycobacterium species and Emb 
from C. glutamicum towards EMB, but insensitivity of other ArafTs including AftA, 
AftB and AftC towards the same drug. The number of ArafTs involved in the assembly of 




AG suggests at least six different ArafTs that are involved in its synthesis. Since Emb 
proteins are the targets of EMB, a number of studies attempted to characterise them. 
Escuyer et al. (2001) constructed individual EmbA and EmbB mutants in M. smegmatis 
that possessed reduced levels of the disaccharide ß-D-Araf-(1"2)-#-D-Araf in AG 
resulting in a terminal non-reducing Ara4 motif instead of the usual Ara6. It was 
concluded that EmbA and EmbB are responsible for the 3,5 branching in AG and the 
synthesis of a distinct disaccharide !-D-Araf-(1"2)-#-D-Araf (Escuyer et al., 2001). 
However, taking into account the identification of AftB, AftC and AftD ArafTs, 
development of in vitro studies in combination with mutants and with structural and 
mutational studies, has promoted the view that EmbA and EmB possess #(1"5) ArafT 
activity. 
In this study, we show that Emb from C. glutamicum acts as #(1"5) ArafTs as 
demonstrated through the use of in vitro cell free assays in conjunction with C. 
glutamicum mutant strains. Specifically, we show that incubation of membranes prepared 
from wild type C. glutamicum with pRpp (an indirect donor of Araf residues that is 
converted to DPA in situ) and !-D-Galf-(1"6)-[#-D-Araf-(1"5)]-!-D-Galf-(1"5)-!-D-
Galf (MJ-13-77) neoglycolipid acceptor resulted in the synthesis of products A and B 
(Gal3Ara2-C8H17) (Figure 7). Further characterisation of the products by mass 
spectrometry established that the acceptor was extended by addition of Araf to #-D-Araf-
(1"5) at either C-3 or C-5 resulting in a further #(1"5) extension (Figure 10). Although 
the precise attachment site of the Araf residue was not determined by mass spectrometry, 
the exploitation of the Emb target EMB and C. glutamicum mutant strains assisted in 




reaction mixtures containing wild type C. glutamicum membranes inhibited the formation 
of product A, thus suggesting that the enzyme adding Araf residue onto the acceptor is 
EMB sensitive, such as Emb. In contrast, the generation of pentasaccharide B was 
observed even in the presence of EMB, indicating that the ArafTs in action is EMB 
insensitive, for example, AftA, AftB, AftC or AftD (Figure 7). In addition, reaction 
mixtures containing membranes lacking Emb activity did not produce product A, 
indicating that the deleted enzyme Emb ArafT is indeed responsible for its formation. In 
vitro assay employing C. glutamicum!aftB!aftD membranes and !-D-Galf-(1"6)-[#-D-
Araf-(1"5)]-!-D-Galf-(1"5)-!-D-Galf (MJ-13-77) synthetic acceptor did not form 
product B implying that either AftB or AftD is responsible for addition of Araf to the 
acceptor. However, considering TLC and MS analysis together, it is clear that 
pentasaccharide A is formed due to #(1"5) activity of Emb, whereas pentasaccharide B 
is generated by AftD acting as an #(1"3) ArafT. Finally, formation of product C was 
only identified in cell free assays containing membranes with Emb enzymatic acitivity, 
p[14C]Rpp and !-D-Galf-(1"6)-[#-D-Araf-(1"5)]-!-D-Galf-(1"5)-!-D-Galf (MJ-14-
01) (Figure 7). Further analysis by mass spectrometry confirmed that addition of Araf to 
the MJ-14-01 neoglycolipid acceptor is attached at the position C-5 (Figure 11). 
Therefore, establishing for the first time that Emb from C. glutamicum acts as #(1"5) 
ArafT. 
The discovery of Emb from C. glutamicum as #(1"5) ArafT has shed the light on the 
key ArafT involved in the synthesis of AG, which may contribute to a more detailed 




future will be to define the precise role of Emb enzymes from Mycobacterium species as 
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5   Conclusions and Future work!
The threat from the rising emergence of drug resistant TB cases worldwide has renewed 
interest and improved funding into research of the pathogenicity of its causative agent, M. 
tuberculosis. Improved chemotherapeutic treatments and novel drugs that would shorten 
the duration of TB therapy, would encourage patients to complete their drug regimens 
and perhaps reduce the trend of drug resistant TB cases. However, the development of 
new and effective drugs requires a better understanding of the pathogen itself. The cell 
envelope of M. tuberculosis is unique and vital for its persistence and virulence due to the 
characteristic cell envelope structures, such as AG, LAM and mycolic acids. For many 
years, proteins involved in the biosynthesis of these cell wall components have been 
attractive targets for the development of potential anti-TB drugs. The majority of these 
enzymes are essential for the growth of M. tuberculosis and more importantly lack 
homologues in the mammalian systems, thus forming a focal point for drug discovery. 
This thesis has focused on characterising genes and their encoded proteins involved in 
vital AG and LAM biosynthetic processes with the view of discovering new drug targets. 
Networks of interacting proteins mediate pathways of biological processes varying from 
signal transduction to disease pathogenesis and drug resistance (Cui et al., 2009, Wang et 
al., 2010, Lee et al., 2012). Formation of large multi-protein complexes in bacteria is not 
uncommon and has been fairly well described in E. coli. Bacterial cell division depends 
on the formation, positioning and contraction of the Z-ring, which in E. coli is composed 
of at least ten different proteins, and includes FtsZ, FtsA, FtsB, FtsI, FtsK, FtsL, FtsN and 
FtsQ (Buddelmeijer and Beckwith, 2004, Wadenpohl and Bramkamp, 2010, Robichon et 




accessory proteins (ZapA, ZapB, ZapC, ZapD and ZapE) have been shown to contribute 
to the formation of the Z-ring (Galli and Gerdes, 2010, Hale et al., 2011, Durand-Heredia 
et al., 2012). These proteins, acting as a large multi-protein complex, which drive cell 
membrane invagination, inward growth of the cell wall, and, ultimately promote 
separation of the progenitor cell into two independent daughter cells. However, only very 
few studies have been conducted to examine protein-protein interactions of enzymes 
involved in mycobacterial cell wall biosynthesis (Zheng et al., 2011, Larrouy-Maumus et 
al., 2012"! Veyron-Churlet et al., 2004, Veyron-Churlet et al., 2005). In the second 
chapter, we employed in vitro pull-down assays and in vivo BACTH system to elucidate 
the protein-protein interaction network involved in the C. glutamicum major cell wall 
component AG. We have identified twenty-four putative homotypic and heterotypic 
protein interactions. Our studies demonstrated that WecA and WbbL, proteins that are 
responsible for the formation of the AG linker unit, interact with decaprenyl-5-
phosphoribose synthase UbiA. In addition, WecA and UbiA show evidence for physical 
interaction between AftB and AftC proteins. Formation of protein complexes was also 
observed between AftB and the priming enzyme AftA, branching enzyme AftC and 
arabinan elongation enzyme Emb. Finally, a number of proteins involved in AG 
biosynthesis were shown to form either dimers or multimers. Our findings demonstrated 
that enzymes involved in C. glutamicum cell wall assembly and precursor formation form 
sophisticated multi-protein complexes in order to maintain the efficiency and fidelity of 
AG polymerisation. These findings provide a useful recourse for understanding the 
biosynthesis and function of the corynebacterial cell wall, as well as providing putative 




In the third chapter we explored the potential role of AftA and AftB in the biosynthesis of 
LM/LAM in M. smegmatis using CESTET and analysing the cellular composition of the 
mutants. We also examined full-length AftA and AftB membrane proteins and their C-
termini in order to biochemically characterise them. As previously reported by Shi et al 
(2008), we confirmed that AftA is essential to M. smegmatis viability and growth.  
Depletion of AftA in the M. smegmatis!aftA::pMV306-aftA strain resulted in a clear 
lysed cell culture. However, an often drawback of CESTET was observed, where 
conditional mutant strains acquire mutations in the acetamide protmoter region causing 
continues production of the protein of interest, thus rescuing the cell from death. Since 
such persisters mask the effects of the AftA depletion, a careful selection from generated 
transductants has to be performed in order to segregate true aftA conditional mutants in 
M. smegmatis. In order to acquire knowledge on the key ArafT conserved within 
Corynebacterineae, we expressed and purified the hydrophilic C-terminal domain of 
AftA from M. tuberculosis. Attempts to stabilise the recombinant protein employing 
thermostability screening led to sufficient amount of AftACT, which was subsequently 
used for crystallisation screens. In addition, we have employed a recently reported 
SMALP method to solubilise and purify full-length AftA from C. glutamicum. Utilising 
techniques, such as AUC and CD, we have demonstrated that AftA within SMALP is 
properly folded and stable. Ligand binding employing various lengths of synthetic 
acceptors resembling the galactan chain indicated that AftA has a markedly stronger 
affinity for longer acceptors.  
Similarly to AftA, in the third chapter we have demonstrated that aftB is an essential gene 
in M. smegmatis. Lipid analysis from the AftB depleted cells demonstrated an increase in 




of mycobacterial MAMES, suggesting a cell wall defect. SDS-PAGE and sugar analyses 
of lipoglycans extracted from both parental and conditional mutant strains did not exhibit 
significant difference between each other, however a monoclonal antibody F30-5 
generated against hexa-arabinan motif of LAM no longer recognised LAM extracted 
from the aftB mutant, thus suggesting a loss of terminal !(1"2) Araf residues. 
Subsequent NMR or glycosidic linkage analysis is required to identify the precise 
changes of LAM structure resulted upon depletion of AftB. Expression of the full length 
AftB and its hydrophilic C-terminal domain from M. tuberculosis and C. glutamicum 
were also examined, however, this did not yield any soluble recombinant proteins and 
therefore were not pursued further. 
In chapter four, we aimed to characterise the target of front-line drug EMB in C. 
glutamicum - Emb ArafT. For that purpose, we constructed and examined effects of an 
aftA and emb double deletion on AG biosynthesis. Cell wall analysis revealed a complete 
absence of arabinose resulting in a truncated cell wall containing only galactan 
accompanied with the loss of cell wall bound mycolates. In addition, we explored the 
potential role of AftA and Emb enzymes in C. glutamicum LAM biosynthesis, since 
individual inactivation of either C. glutamicum aftA or emb resulted in a significant 
arabinan loss in AG (Alderwick et al., 2005, Alderwick et al., 2006). However, 
lipoglycan extractions from both wild type and aftA and emb double deletion showed 
similar profiles of no significant differences, indicating that both enzymes are not 
involved in LAM biosynthesis in C. glutamicum. Finally, by employing a cell free assay 
using C. glutamicum, C. glutamicum!aftA, C. glutamicum!emb, C. 
glutamicum!aftB!aftD, C. glutamicum!aftA!emb strains, neoglycolipid acceptors that 




that the transfer of Araf residue from DPA to the primed galactan in C. glutamicum is 
catalysed by Emb ArafT with !(1"5) activity. The findings obtained in the fourth 
chapter has shed the light on the key Emb ArafT responsible for the elongation of 
arabinan domain of AG and the target of EMB in C. glutamicum. A clearer knowledge of 
structure and function of ArafTs is key for the further exploitation of putative inhibitors 
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6   General Materials and Methods 
6.1 Chemicals and reagents 
All chemicals, solvents and restriction enzymes were purchased from Sigma-Aldrich 
(UK), Bio-Rad (USA), Thermo Fischer Scientific (USA) or New England BioLabs 
(USA) unless otherwise stated, and were of highest reagent grade.  
6.2 Culture media preparations 
6.2.1 Luria-Bertani broth 
25 g of Luria-Bertani (LB) powder (10 g/l tryptone, 5 g/l yeast extract and 10 g/l sodium 
chloride; DifcoTM) was dissolved in 1 l of deionised water and sterilised by autoclaving at 
121 ˚C for 15 minutes.  
6.2.2 Luria-Bertani agar 
37 g of LB agar powder (10 g/l tryptone, 5 g/l yeast extract, 10 g/l sodium chloride and 
15 g/l agar; DifcoTM) was dissolved in 1 l of deionised water and sterilised by autoclaving 
at 121 ˚C for 15 minutes.  
6.2.3 Brain Heart Infusion broth 
37 g of Brain Heart Infusion (BHI) powder (5 g/l beef heart, 12.5 g/l calf brains, 2.5 g/l 
disodium hydrogen phosphate, 2 g/l glucose, 10 g/l peptone and 5 g/l sodium chloride; 
DifcoTM) was dissolved in 1 l of deionised water and sterilised by autoclaving at 121 ˚C 
for 15 minutes.  
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6.2.4 Brain Heart Infusion agar 
37 g of BHI agar powder (5 g/l beef heart, 12.5 g/l calf brains, 2.5 g/l disodium hydrogen 
phosphate, 2 g/l glucose, 10 g/l peptone, 5 g/l sodium chloride and 15 g/l agar; DifcoTM) 
was dissolved in 1 l of deionised water and sterilised by autoclaving at 121 ˚C for 15 
minutes.  
6.2.5 Tryptic soy broth 
30 g of Tryptic soy broth (TSB) powder (17 g/l casein peptone, 2.5 g/l dipotassium 
hydrogen phosphate, 2.5 g/l glucose, 5 g/l sodium chloride, 3 g/l soya peptone; DifcoTM) 
was dissolved in 1 l of deionised water and sterilised by autoclaving at 121 ˚C for 15 
minutes.  
6.2.6 Tryptic soy agar 
40 g of Tryptic soy agar (TSA) powder (15 g/l casein peptone, 5 g/l sodium chloride, 5 
g/l soya peptone and 15 g/l agar; DifcoTM) was dissolved in 1 l of deionised water and 
sterilised by autoclaving at 121 ˚C for 15 minutes.  
6.2.7 7H9 basal agar 
4.7 g of 7H9 powder (0.5 g/l ammonium sulphate, 2.5g/l disodium phosphate, 1 g/l 
monopotassium phosphate, 0.1 g/l sodium chloride, 0.05 g/l magnesium sulphate, 0.0005 
g/l calcium chloride, 0.001 g/l zinc sulphate, 0.001 g/l copper sulphate, 0.04 g/l ferric 
ammonium citrate, 0.5 g/l glutamic acid, 0.001 g/l pyridoxine and 0.0005 g biotin; 
DifcoTM), 15 g/l of agar, and 2.5 ml of glycerol was dissolved in 1 l of deionised water 
and sterilised by autoclaving at 121 ˚C for 15 minutes.  
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6.2.8 7H9 soft agar 
4.7 g of 7H9 powder (0.5 g/l ammonium sulphate, 2.5g/l disodium phosphate, 1 g/l 
monopotassium phosphate, 0.1 g/l sodium chloride, 0.05 g/l magnesium sulphate, 0.0005 
g/l calcium chloride, 0.001 g/l zinc sulphate, 0.001 g/l copper sulphate, 0.04 g/l ferric 
ammonium citrate, 0.5 g/l glutamic acid, 0.001 g/l pyridoxine and 0.0005 g biotin; 
DifcoTM), 7.5 g/l bacto agar, and 2.5 ml glycerol was dissolved in 1 l of deionised water 
and sterilised by autoclaving at 121 ˚C for 15 minutes.  
6.2.9 MacConkey agar 
40 g of MacConkey agar powder (17 g/l pancreatic digest of gelatin, 3 g/l peptones, 10 
g/l lactose, 1.5 g/l bile salts, 5 g/l sodium chloride, 13.5 g/l agar, 0.03 g/l neutral red and 1 
mg/l crystal violet; DifcoTM) was dissolved in 1 l of deionised water and sterilised by 
autoclaving at 121 ˚C for 15 minutes.  
6.2.10 CGXII minimal media  
CGXII minimal media was prepared by mixing 20 g of ammonium sulphate, 5 g of urea, 
1 g of potassium dihydrogen phosphate, 1 g of dipotassium hydrogen phosphate, 0.25 g 
of magnesium sulphate hepta hydrate, 42 g of MOPS (3-[N-Morpholino] propanesulfonic 
acid) in 800 mL of deionised water. The media was supplemented with 1 mL of trace 
elements solution (1 g of ferric sulphate heptahydrate, 1 g of manganese sulphate 
monohydrate, 0.1 g of zinc sulphate heptahydrate, 0.02 g of copper sulphate, 0.002 g of 
nickel chloride hexahydrate prepared in 90 mL deionised water, adjusted to pH 1 using 
concentrated hydrochloric acid), 1 mL calcium chloride solution (1 g in 100 mL 
deionised water), 50 µL biotin solution (10 mg in 100 mL deionised water), 8 mL 
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protocatechuate (0.3 g in 8 mL deionised water). The prepared salt media was adjusted to 
pH 7.0 using sodium hydroxide and its final volume adjusted to 920 mL. Media was filter 
sterilised and the 0.2-0.4 % carbon source of choice was added to CGXII medium just 
before use. 
6.2.11 M63 minimal media  
15.6 g of M63 minimal media powder (2 g/l ammonium sulphate, 13.6 g/l monobasic 
potassium phosphate, 0.5 mg/l ferrous sulphate heptahydrate; Amresco) was dissolved in 
1 l of deionised water, pH adjusted to 7.0 using potassium hydroxide and media sterilised 
by autoclaving at 121 ˚C for 15 minutes. After sterilisation, 1 ml of vitamin B1 (5 mg/ml) 
and the 0.2-0.4 % carbon source was added to the media just before use. 
6.2.12 M63 minimal agar  
15.6 g of M63 minimal media powder (2 g/l ammonium sulphate, 13.6 g/l monobasic 
potassium phosphate, 0.5 mg/l ferrous sulphate heptahydrate; Amresco) and 15 g/l of 
agar was dissolved in 1 l of deionised water, pH adjusted to 7.0 with potassium hydroxide 
and media sterilised by autoclaving at 121 ˚C for 15 minutes. After sterilisation, 1 ml of 
vitamin B1 (5 mg/ml) and the 0.2-0.4 % carbon source was added to the media just 
before use. 
6.2.13 Sauton’s minimal media 
Sauton’s minimal media was prepared by mixing 0.5 g of dipotassium phosphate, 0.5 g of 
magnesium sulphate, 4 g of asparagine, 0.05 g of ferric ammonium citrate, 60 ml of 
glycerol and 2 g of citric acid in 1 l of deionised water. After the pH was adjusted to 7.2, 
the media was sterilised by autoclaving at 121 ˚C for 15 minutes. The prepared salt media 
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was supplemented with 1 % (w/v) zinc sulphate and 5 % Triton WR-1339. 
6.2.14 Minimal media for M. smegmatis 
Minimal media for the growth of M. smegmatis was prepared by mixing 1.5 g of 
potassium phosphate, 1 g of ammonium chloride, 0.2 g of magnesium sulphate, 20 mg of 
calcium chloride, 1.2 mg of ferric ammonium citrate, 0.85 g of sodium chloride and 8.99 
g of disodium phosphate in 1 l of deionised water and sterilised by autoclaving at 121 ˚C 
for 15 minutes. The 0.2-0.4 % carbon source was added to the media just before use. 
6.2.15 Minimal agar for M. smegmatis 
Minimal agar for the growth of M. smegmatis was prepared by mixing 1.5 g of potassium 
phosphate, 1 g of ammonium chloride, 0.2 g of magnesium sulphate, 20 mg of calcium 
chloride, 1.2 mg of ferric ammonium citrate, 0.85 g of sodium chloride, 8.99 g of 
disodium phosphate and 15 g of agar in 1 l of deionised water and sterilised by 
autoclaving at 121 ˚C for 15 minutes. The 0.2-0.4 % carbon source was added to the 
media just before use. 
6.3 Bacterial strains and growth conditions 
6.3.1 General bacterial strains and growth conditions used in this thesis 
M. smegmatis mc2155 strains were grown in TSB or minimal media (Chang et al., 2009) 
supplemented with 0.05 % Tween-80 (Sigma Aldrich) at 37 °C. Strains of C. glutamicum 
ATCC 13032 were grown on rich BHI or the salt medium CGXII at 30 °C. Samples for 
lipid analysis, lipoglycan extractions and membrane preparations were prepared by 
harvesting cells at an OD600 of 10-15 followed by subsequent washing using phosphate 
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buffered saline. Cell pellets were stored at -20 °C until further use. E. coli TOP10 
(Invitrogen) strain used for plasmid propagation and E. coli strains used for protein 
overexpression including BL21 (F- ompT hsdSB(rB- mB-) gal dcm (DE3), C43 (F– ompT 
gal dcm hsdSB(rB- mB-)(DE3)), Rosetta pLysS (F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pLysSRARE (CamR)), and Tuner (F- ompT hsdSB(rB- mB-) gal dcm lacY1(DE3)) were 
grown in LB media at 37 °C. The pLysS plasmid encoding T7 phage lysozyme (an 
inhibitor for T7 polymerase) in E. coli Rosetta cells was retained with chloramphenicol 
(25 µg/ml). The concentrations of supplements used were 25 µg/ml of kanamycin, 50 
µg/ml of ampicillin, 100 µg/ml of hygromycin, and 0.2 % of acetamide with M. 
smegmatis and C. glutamicum; and 50 µg/ml of kanamycin, 100 µg/ml of ampicillin, 150 
µg/ml of hygromycin with E. coli.  
6.3.2 Bacterial strains and growth conditions used for BACTH 
All cloning steps were performed in E. coli XL1-Blue cells (Invitrogen). XL1-Blue strain 
has a high level of LacI repressor expression, which is not encoded in pKT25, pKNT25, 
pUT18 and pUT18c plasmids and, therefore, might prevent accumulation of mutations 
during cloning procedure if the hybrid protein is toxic to E. coli cells. The E. coli cya- 
strain BTH101 ((F-, cya-99, araD139, galE15, galK16, rpsL1 (Strr), hsdR2, mcrA1, 
mcrB1) was used for the bacterial two-hybrid screen (Euromedex). Plasmids were 
maintained with ampicillin (100 µg/ml) or kanamycin (50 µg/ml). LB agar reporter plates 
contained streptomycin (100 µg/ml), ampicillin (100 µg/ml), kanamycin (50 µg/ml), 5-
bromo-4-chloro-3-indolyl-!-D-galactopyranoside (X-gal; 40 µg/ml) and isopropyl !-D-1-
thiogalactopyranoside (IPTG; 0.5 mM). MacConkey plates (DifcoTM) contained 
streptomycin (100 µg/ml), ampicillin (100 µg/ml), kanamycin (50 µg/ml), IPTG (0.5 
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mM) and maltose (1%). M63 minimal media plates (Battesti et al., 2012) were 
supplemented with streptomycin (50 µg/ml), ampicillin (50 µg/ml), kanamycin (25 
µg/ml), X-gal (40 µg/ml), IPTG (0.5 mM) and maltose (0.2%).  
6.4 Antibiotics and supplements 
Table 1 Antibiotics and supplements used in this thesis. 
Additives Concentration Storage 
Acetamide  20 % at 4 ˚C, in water 
Ampicillin 100 mg/ml at -20 ˚C, in water 
Chloramphenicol 30 mg/ml at -20 ˚C, in ethanol 
Hygromycin B 50 mg/ml at 4 ˚C, in PBS, protect from 
light 
Kanamycin  50 mg/ml at -20 ˚C, in water 
Nalidixic acid 30 mg/ml at -20 ˚C, in ethanol 
Streptomycin 100 mg/ml at -20 ˚C, in water 
Glucose 20 % at 4 ˚C, in water 
Maltose 20 % at 4 ˚C, in water 





1 M at -20 ˚C, in water 
ONPG (o-nitrophenol-! -
galactoside) 
4 mg/ml at -20 ˚C, in PM2 media, 




20 mg/ml at -20 ˚C, in dimethyl 
formamide, protect from light 
 
!
6.5 Molecular biology techniques 
6.5.1 Polymerase chain reaction  
Phusion DNA polymerase (New England BioLabs) have been employed in all 
polymerase chain reactions (PCR). Four different reaction mixtures, presented in Table 2, 
have been exploited to optimise DNA amplification. A temperature gradient PCR was 




Table 2 PCR mixtures used in this thesis.  
Components Concentration Mix 1 (!l) Mix 2 (!l) Mix 3 (!l) Mix 4 (!l) 
Forward primer 100 pmol/"l 0.08  0.08  0.08  0.08  
Reverse primer 100 pmol/"l 0.08  0.08  0.08  0.08  
template DNA 10 ng/"l 0.4  0.4  0.4  0.4  
dNTP 25 mM 0.4  0.4  0.4  0.4  
5 x GC buffer  4  4  4  4  
DNA polymerase 10 U/ml 0.2  0.2  0.2  0.2  
MgSO4 50 mM - - 0.4  0.4  
DMSO 100 % - 1  - 1  
H2O - 14.84  13.84  14.44  13.44  
Total - 20  20  20  20  
 
Table 3 PCR cycling conditions. 
PCR stage Temperature Time Cycles 
Initial denaturation 98 ˚C 30 sec 1 
Denaturation 98 ˚C 10 sec 35 
Annealing 60-75 ˚C 60 sec 35 
Extension 72 ˚C 60 sec/kb 35 
Final extension 72 ˚C 10 min 1 
Hold 4 ˚C # - 
!
6.5.2 DNA gel electrophoresis 
DNA fragments were separated employing agarose gel electrophoresis. Samples were 
mixed with DNA loading dye (6 x stock: 2.5 % Ficoll 400, 11 mM EDTA, 3.3 mM Tris-
HCl, 0.017% SDS and 0.015 % bromophenol blue) and loaded onto 0.8-1 % agarose gel 
prepared using agarose powder (Bioline) and TAE buffer (50 x stock: 242 g Tris-base, 
57.1 ml acetate and 100 ml 0.5 M EDTA). The loaded gel is run at 120–140 V, 400 mA 
for 45 minutes. DNA is visualised by ethidium bromide stain and analysed under UV 
light employing Bio-Rad GelDoc XR System. 
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6.5.3 DNA purification 
DNA bands of interest were excised from the agarose gel and purified employing 
QIAquick Gel Extraction kit (Qiagen). Briefly, excised agarose fragments were dissolved 
in the provided QG buffer and subjected to a spin column with a silica membrane that 
binds DNA. Impurities such as salts, agarose and ethidium bromide are removed by 
several washing steps, whereas the pure DNA is eluted with deionised water.  
6.5.4 DNA digestion 
Plasmid DNA, PCR products or genomic DNA were single or double digested using a 
reaction mixture presented in Table 4. Reaction mixtures were incubated at 37 °C for 1-4 
hours. After digestion, digestion enzymes were heat inactivated by incubating samples at 
65 °C for 5 minutes. 
Table 4 General reaction mixture of DNA digestion used in this thesis. 
Component Concentration Volume (!l) 
DNA 0.1-0.2 "g/"l 10  
Digestion buffer 10 x 2  
Digestion enzyme(s) 50 U/"l 1  
BSA 10 x 2  
Water - 5  
Total - 20  
 
6.5.5 DNA ligation 
Digested DNA fragments with compatible ends were ligated using a reaction mixture 
presented in X and incubated at 37 °C for 10 minutes. After digestion, T4 DNA ligase 
was heat inactivated by incubating samples at 65 °C for 5 minutes. 
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Table 5 General reaction mixture of DNA ligation used in this thesis. 
Component Concentration Volume (!l) 
Insert DNA 0.020 pmol/"l 3  
Vector DNA 0.020 pmol/"l 1  
T4 DNA ligase 400000 U/ml 1  
10 x T4 DNA ligase buffer 10 x 2  
Water - 5  
Total - 20  
!
6.5.6 Plasmid DNA extraction 
Plasmid DNA purification was performed employing QIAprep Spin Miniprep Kit 
(Qiagen). E. coli cells harbouring plasmid of interest were cultivated in 5 ml of LB media 
with appropriate antibiotics at 37 °C with shaking overnight. Cells were harvested, 
resuspended in 250 µl of P1 buffer and transferred to a 1.5 ml eppendorf. Cell contents 
were released by addition of 250 µl of P2 lysis buffer and neutralised by 350 µl of N3. 
Subsequently, samples were centrifuged for 15 minutes at 13,000 g and the recovered 
supernatant containing the DNA subjected to QIAprep spin column. Sample was 
centrifuged for 30 seconds at 3,000 g and the flow-through discarded. Column was 
washed with 750 µl of PE wash buffer before eluting the plasmid DNA with 30-50 µl of 
EB buffer or deionised water. 
6.5.7 Preparation of competent E. coli cells 
A single colony of E. coli was inoculated into 5 ml LB medium and incubated at 37 °C 
with shaking overnight. The pre-culture was then used to inoculate 250 ml LB medium 
with 20 mM MgSO4. Cells were grown to OD600 of 0.4-0.6 and then harvested by 
centrifugation at 4,500 g for 5 minutes at 4 °C. Cell pellets were gently resuspended in 
0.4 volume of ice-cold TFB1 (30 mM potassium acetate, 10 mM CaCl2, 50 mM MnCl2, 
100 mM RbCl, 15 % glycerol, filter-sterilised and stored at 4 °C) and resuspended cells 
Chapter 6 
 194!
were incubated on ice for 5 minutes. Cells were harvested by centrifugation as described 
previously and were then gently resuspended in 1/25 of the volume of ice-cold TFB2 (10 
mM MOPS pH 6.5, 75 mM CaCl2, 10 mM RbCl, 15 % glycerol, filter-sterilised and 
stored at 4 °C). Cells were incubated on ice for 15-60 minutes, shock-frozen and stored as 
50 µl aliquots at -80 °C. 
6.5.8 Preparation of competent C. glutamicum cells 
A single colony of C. glutamicum was inoculated into 5 ml BHI medium and incubated at 
30 °C with shaking overnight. The pre-culture was then used to inoculate 100 ml BHI 
medium and cultivated at 30 °C with shaking until an OD600 reached 1.75. Cells were 
harvested by centrifugation at 4,500 g for 10 minutes at 4 °C. Cell pellets were gently 
resuspended in 20 ml of ice-cold TG buffer (1 mM Tris-HCl pH 7.5, 12 g 87 % glycerol 
per 100 ml deionised water, filter-sterilised and stored at 4 °C). Cells were harvested by 
centrifugation at 4,500 g for 10 minutes at 4 °C and washed twice more in TG buffer. 
Cell pellet was washed once in ice-cold 10 % glycerol solution and resuspended to a final 
volume of 2 ml of 10 % glycerol. Aliquots of 100 µl were dispensed, shock-frozen and 
stored at -80 °C.   
6.5.9 Preparation of competent M. smegmatis cells 
A single colony of M. smegmatis was inoculated into 5 ml TSB medium supplemented 
with 0.05 % Tween-80 and incubated at 37 °C with shaking overnight. The pre-culture 
was then used to inoculate 50 ml TSB medium with Tween-80 and cultivated at 37 °C 
with shaking until an OD600 reached 0.8. Cells were harvested by centrifugation at 4,500 
g for 10 minutes at 4 °C, washed thrice in ice-cold 10 % glycerol and resuspended in 1/10 
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of the volume 10 % glycerol. Aliquots of 50 µl were dispensed, shock-frozen and stored 
at -80 °C.   
6.5.10 Transformation of E. coli competent cells 
Competent E. coli cells (50 µl) were thawed on ice and 50 -100 ng of plasmid DNA was 
added to the cells. The mixture was transferred into 1.5 ml eppendorf tube and incubated 
at 4 °C for 30 minutes. Transformation was induced by a heat shock at 42 °C for 30 
seconds. LB medium (500 µl) was added to the sample, cells were allowed to recover at 
37 °C for 1 hour and 20-100 µl aliquots were plated onto LB agar plates supplemented 
with appropriate antibiotics and plates incubated at 37 °C for 12 hours. 
6.5.11 Transformation of C. glutamicum competent cells 
Competent C. glutamicum cells (50 µl) and 5 µg of plasmid DNA were transferred to a 
sterile electroporation cuvette (2 mm) and 0.8 ml of ice-cold 10 % glycerol solution was 
carefully laid over the cells. Electroporation was performed using Electroporator 2510 at 
25 µF, 2500 V. BHI media was added to the sample (4 ml) followed by a heat shock at 46 
°C for 6 minutes. Cells were allowed to recover at 30 °C for 1 hour, harvested by 
centrifugation and resuspended in 400 µl of BHI media. Aliquots (100 µl) were plated 
onto BHI agar plates supplemented with appropriate antibiotics and plates incubated at 30 
°C for 48 hours. 
6.5.12 Electroporation of M. smegmatis competent cells 
Competent M. smegmatis cells (100 µl) were thawed on ice and 5 µg of plasmid DNA 
was added to the cells. The mixture was transferred into an electroporation cuvette (1 
mm) and electroporated using Electroporator 2510 at 25 µF, 2500 V. Cells were 
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transferred into a culture tube, combined with 800 µl TSB media and allowed to recover 
at 37 °C for 4 hours. Cell aliquots (50-100 µl) were plated onto TSB agar plates 
supplemented with appropriate antibiotics and plates incubated at 37 °C for 48-60 hours. 
6.5.13 Membrane fraction preparation  
Cells were resuspended in buffer containing 50 mM MOPS pH 7.9, 5 mM !- 
mercaptoethanol and 10 mM MgCl2 buffer. Cell slurry was sonicated (MSE Soniprep 
150, 12 micron amplitude, 60 seconds ON, 90 seconds OFF, for 10 cycles), centrifuged at 
27,000 g for 20 minutes at 4 °C, and the resulting supernatant re-centrifuged at 100,000 x 
g for 90 minutes at 4 °C to isolate cell membranes.  
6.5.14 Extraction and analysis of cell wall associated lipids  
Cells (10 ml) were grown to an early exponential growth phase (OD600 of 0.6), labelled 
with [1, 2-14C]-acetate 1 µCi/ml and incubated for further 6 hours at 30 °C with shaking. 
Labelled cells were harvested, washed twice in phosphate buffered saline and dried. The 
pellets were extracted using 2 ml of chloroform/methanol/water (10:10:3, v/v/v) for 4 
hours at 50 °C. The organic extracts were combined with 1.75 ml of chloroform and 0.75 
ml of water, mixed, and the two layers separated by centrifugation. The lower organic 
phase was recovered, washed twice with 2 ml of chloroform/methanol/water (3:47:48, 
v/v/v), dried and resuspended in 200 µl of chloroform/methanol/water (10:10:3, v/v/v). 
An aliquot was subjected to TLC analysis, using silica gel plates (5554 silica gel 60F254, 
Merck) developed in chloroform/methanol/water (60:16:2, v/v/v) and [14C]-labelled lipids 
were visualised by autoradiography using Kodak BioMax MR films. Analysis of cold cell 
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wall associated lipids was performed in a similar fashion and visualised using 
molybdophosphoric acid (5 % in ethanol; w/v), followed by heating at 100 °C. 
6.5.15 Extraction and analysis of cell wall bound lipids  
Cells were grown, labelled with [1, 2-14C]-acetate and harvested as described above 
(Materials and Methods 6.5.14). The pellets were extracted using 2 ml of 
chloroform/methanol/water (10:10:3, v/v/v) for 4 hours at 50 °C, and bound lipids from 
the delipitated extracts were released by addition of 2 ml of 5 % (v/v) tetra-butyl 
ammonium hydroxide (TBAH), followed by a 12 hour incubation at 100 °C. After 
cooling, water (2 ml), dichloromethane (4 ml) and methyl iodide were added and mixed 
thoroughly for 30 minutes. The organic phase was recovered following centrifugation, 
washed three times using water (4 ml), dried and resuspended in diethyl-ether (4 ml). 
After centrifugation, the clear supernatant was dried and resuspended in dichloromethane 
(100 µl). An aliquot was subjected to the TLC (5554 silica gel 60F254, Merck), developed 
in petroleum ether/acetone (95:5, v/v) and [14C]-labelled lipids visualised by 
autoradiography using Kodak BioMax MR films. Analysis of cold cell wall associated 
lipids was performed in a similar fashion and visualised using molybdophosphoric acid (5 
% in ethanol; w/v), followed by heating at 100 °C. 
6.5.16 Purification of mAGP complex  
Cells (10 g) were resuspended in phosphate buffered saline containing 2 % Triton X-100 
and lysed by sonication (MSE Soniprep 150, 12 micron amplitude, 60 seconds ON, 90 
seconds OFF, for a total of 10 cycles). The cell slurry was centrifuged at 26,000 g for 30 
minutes at 4 °C. The pelleted debris was extracted three times with 2 % SDS in 
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phosphate buffered saline at 95 °C and washed subsequently with excessive amount of 
water. The pellet was washed three times in 80% (v/v) acetone in water, and 100% 
acetone, and finally dried to yield a highly purified cell wall preparation. 
6.5.17 Acid hydrolysis and alditol acetate derivatisation 
The mAGP preparations (5-10 mg) were hydrolysed in 250 µl of 2 M trifluoroacetic acid 
at 120 °C for 2 hours. After cooling, samples were dried under compressed nitrogen and 
sugar residues reduced using 50 µl of sodium borohydride solution (10 mg/ml re-
suspended in ethanol : 1 M ammonium hydroxide, 1:1). Alditols were per-O-acetylated 
using 100 µl of acetic anhydride at 100 °C for 1 hour. Samples were cooled, 100 µl of 
toluene added to the sample and dried. The resultant alditol acetates were particulated 
between water (2 ml) and chloroform (2 ml). The organic phase containing the alditol 
acetates were transferred to a new glass tube, dried under compressed nitrogen and 
further analysed by gas chromatography. 
6.5.18 Gas chromatography analysis 
GC analysis was performed using a CE Instruments ThermoQuest Trace GC 2000. 
Samples were injected in the splitless mode. The column used was a DB225 (Supelco) ID 
0.10 mm, length 10 m and df 0.05 µm. The oven was programmed to hold at an 
isothermal temperature of 275 °C for a run time of 15 minutes. Data was collected and 
analysed using Xcaliber (v.1.2) software. 
6.5.19 Extraction and purification of lipoglycans 
Cells (10 ml) were cultivated as described above (General Materials and Methods 6.3.1), 
labelled with [1, 2-14C]-glucose (1 µCi/ml) and incubated for further 12 hours at 37 °C 
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with shaking. The labelled cells were harvested and washed twice in phosphate buffered 
saline. Pellet was resuspended in 4 ml of 50 % ethanol in water (v/v) and the mixture was 
refluxed at 85 °C for 6 hours. The supernatant was recovered by centrifugation and 
transferred to a fresh tube. The extraction process was repeated five times, the supernatant 
fractions were pooled and dried. Crude lipoglycans were subjected to 90 % phenol 
treatment (w/v in phosphate buffered saline) at 65 °C for 1 hour. After cooling, the 
sample was centrifuged and the upper aqueous layer recovered and dialysed against water 
(MWCO 3,500 kDa). An equal amount of radioactivity was subjected to 15 % SDS-
PAGE and [14C]-labelled purified lipoglycans were visualised by autoradiography using 
Kodak BioMax MR films.  
6.5.20 Acid hydrolysis of LAM for sugar analysis 
LAM samples from wild type M. smegmatis and M. smegmatis!aftB::pMV306-aftB were 
hydrolysed using 400 µl of 2 M trifluoroacetic acid at 120 °C for 1 hour. Mixtures were 
dried under a stream of nitrogen to remove acid, residue resuspended in water (2 ml) and 
washed in chloroform (2 ml). The upper aqueous phase was recovered by centrifugation 
and dried. Samples were loaded onto HPTLC-Cellulose TLC (Merck) and developed 
thrice in formic acid/water/tert-butanol/methyl ethyl ketone (3:3:8:6, v/v/v/v). The [14C]-




6.6 Protein biochemistry techniques 
6.6.1 SDS-PAGE analysis 
Mini-PROTEAN TGX pre-cast gels (Bio-Rad) were used for protein electrophoresis. 
Protein samples were mixed 1:1 with the loading dye (0.125 M Tris-HCl pH 6.8, 20 % 
glycerol, 4 % SDS and 10 % !-mercaptoethanol) and boiled at 95 °C for 10 minutes and 
approximately 10-20 µg of protein was loaded in each well of the pre-cast gel. 
Electrophoresis was run at 300 mV and 25 mA and 300 mV and 45 mA for one and two 
gels, respectively. Protein bands were visualised by staining the gel for 30 minutes using 
Instant Blue (Expedeon). 
6.6.2 Western blot analysis 
Gels were processed for Western blot analysis. Briefly, protein transfer to nitrocellulose 
membrane (Bio-Rad) was carried out using the Mini Trans-blot electrophoretic transfer 
cell (Bio-Rad). The nitrocellulose membranes were probed with monoclonal penta-His 
antibody (1:1000, QIAGEN) and subsequently incubated with secondary anti-mouse 
antibody (1:20000, GE Healthcare) for His6-tag detection. Protein bands were visualised 
using SIGMA FAST™ BCIP/NBT (5-Bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium; 1 tablet per 10 ml of dH2O) system. For detection of T25 or T18 domains, 
nitrocellulose membranes were probed with either Cya (3D1) monoclonal (SantaCruz), or 
Cya (b-300) polyclonal antibodies (SantaCruz) (1:1,300) and subsequently incubated 
with either goat anti-mouse or goat anti-rabbit antibodies (1:25,000), respectively, and 
developed with chemiluminescence reagents (SantaCruz).  
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6.6.3 Protein expression and purification  
Recombinant cells harbouring the construct of interest were used to inoculate an 
overnight culture of 5 ml media supplemented with appropriate antibiotic(s). This pre-
culture was then used to inoculate 1 l of media supplemented with appropriate antibiotics 
and incubated at 30 ºC (C. glutamicum) or 37 ºC (E. coli) with shaking until an OD600 of 
0.5-0.8. IPTG was then added to a final concentration of 0.1-1 mM and growth continued 
for additional 4 hours at 30 ºC/37 ºC or 12 hours at 16 ºC with shaking. Cells were 
harvested by centrifugation, washed with phosphate buffered saline, and cell pellets 
frozen until further use. Cell pellets were thawed and resuspended in lysis buffer (50 mM 
KH2PO4 pH 7.9, 300 mM NaCl, 20 % glycerol and 20 mM imidazole) containing 
protease inhibitor pellet (Roche). Cells were sonicated at a pulse rate of 60 seconds ON, 
90 seconds OFF for a total of 10 cycles (MSE Soniprep 150, 12 micron amplitude) and 
centrifuged at 27,000 g for 30 minutes at 4 ºC. The supernatant was collected and passed 
over a 1 ml HiTrap Ni2+-NTA agarose column (GE Healthcare), which was previously 
equilibrated with lysis buffer. Protein elution occurred via a stepwise gradient of 50-
2,000 mM imidazole in 50 mM KH2PO4 pH 7.9, 300 mM NaCl. Pure protein fractions 
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